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ABSTRACT 
Myeloid-derived suppressor cells (MDSC), emerging during tumor growth or chronic 
inflammation play a critical role in regulating T cell function. However, mechanisms governing 
the generation of these cells remain unclear, and need to be further defined. Using a DSS-
induced colitis and recovery model, we characterized the dynamic changes within myeloid 
compartments and the emergence of MDSC during active and resolution phases of inflammation. 
We show that the immature myeloid compartment expands in bone marrow (BM) specifically at 
the resolution phase of inflammation during colitis transition to recovery. Additionally, we found 
enhanced levels of IL-17 in the serum of colitis mice tightly correlates with expansion of the 
IMC compartment, and is likely the factor responsible for expansion of these cells. Our study 
also determined that the expanded population of myeloid cells underwent a functional 
reprogramming event. In particular, two major functional changes occurred when colitic mice 
were allowed to recover: 1) CD11b+Gr-1+ myeloid cells in bone marrow and spleen acquired T 
cell suppressive functions, and 2) acquired the ability to enter into circulation from BM, 
confirming previously reported characteristics of MDSC. Additionally, we determined that 
acquired migratory capability in the low density myeloid cells isolated from resolution time 
points was due to enhanced surface expression of chemokine receptor CXCR2. Furthermore, we 
determined that after mobilization of MDSC from the bone marrow, these cells collected in the T 
cell-rich spleens, where they effectively functioned to suppress T cell proliferation. Through 
these acquired functions, our study determines a protective role for MDSC during the recovery 
phase of post-acute inflammation during persistent DSS-induced colitis. 
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1 INTRODUCTION 
1.1   The Inflammatory Response 
 Inflammation is the immune system’s protective response to any disruption of tissue 
homeostasis, and serves as the first line of host defense against invading pathogens [1]. The 
immune system uses the inflammatory process to detect and eliminate “foreign” cells. The 
inflammatory process of the immune system serves as the first level of protection against harmful 
agents to the host. The terms “foreign” and “alien” refer to many potential sources of danger for 
the host, including invading pathogens (bacteria, fungi, toxins), foreign cells (transplanted, 
incompatible tissue), and abnormal cells (tumor, apoptotic, and necrotic cells) [1]. The immune 
system has many methods of detecting and eliminating these threatening stimuli; the primary 
method of removal of most for these threats is the inflammatory response. 
 Inflammation is described by five hallmark characteristics: heat, swelling, redness, pain, and 
in extreme cases, loss of function. These characteristics are all consequences of increased blood 
vessel permeability, which allows for the robust infiltration of circulating inflammatory 
leukocytes into the tissue. These leukocytes, primarily monocytes and neutrophils, are the first 
effector cells that respond to the initial detection of danger signals. Once in the tissue, these cells 
remove sources of tissue damage and pathogens [1]. Functional deficiency in any of the cells that 
are responsible for coordinating the inflammatory response has profound consequences on the 
host. For example, loss of function in neutrophil-mediated digestion of pathogen leads to chronic 
granulomatous disease, characterized by the formation of pus-filled abscesses, and inability to 
remove pathogens [2]. Decreased inflammatory function often leads to increased susceptibility to 
infection for the host, while disorders that increase activity of the inflammatory response have 
similar detrimental outcomes for the host. One example of this type of inflammatory 
  2 
dysregulation is represented by a wide variety of diseases, including rheumatoid arthritis [3], 
inflammatory bowel disease [4], and atherosclerosis [5]. There are three major goals of the 
inflammatory response: 1) The recognition and removal of pathogen and other sources of 
threatening stimuli, 2) removal of the damaged and “alien” cells within the tissue, and 3) the 
initiation of the tissue repair process, which is responsible for terminating the inflammatory 
program and returning the tissue to homeostasis [1].  Beginning first in the locally insulted 
tissues, the inflammatory response gradually expands to include systemic signaling molecules that 
result in the robust influx of effector innate and adaptive immune cells [3]. 
1.2 Initiation of Inflammation, Cytokine Signaling, and Immune Cell Recruitment  
The first step in the inflammatory response is the recognition of the source of tissue 
damage. These sources include two distinct types. The first type of tissue injury is referred to as 
sterile injury because the tissue’s protective barrier layer remains intact [6]; therefore no pathogen 
is able to enter the wound. Sources of insult in the sterile injury include necrotic and apoptotic 
cells, and are typically inflicted by trauma [6]. The second type of injury occurs when a protective 
barrier, such as the skin, is breached, which allows entry of pathogen into the wound. In the case 
of non-sterile injury, pathogens are recognized by the resident immune cells, including 
macrophages and dendritic cells [1].  These cells have unique cell-surface pathogen recognition 
receptors (PRRs), which recognize non-specific conserved pathogen-associated molecular 
patterns (PAMPs), including bacterial peptides lipopolysaccharide and flagellin, and viral DNA 
and RNA antigens [7]. Once the pathogens have been recognized, an immune response is 
mounted with the purpose of removing any sources of tissue damage and/or pathogen, and 
commences the tissue repair process [3]. The following describes in detail how the inflammatory 
response accomplishes these goals.  
  3 
1.2.1 Early Inflammatory Response 
 The immediate initiation of the inflammatory response functions primarily through 
activation of innate immune cells, including macrophages, dendritic cells, and neutrophils, which 
are responsible for rapid, broad identification and clearance of pathogen [1, 3, 6]. Upon 
recognition of PAMPs through PRRs, the immune cells undergo activation of signal transduction 
pathways [6]. Consequences of these activation events result in the dynamic alteration of many 
cell functions, including modification of transcriptional programs. After local tissue resident 
immune cells recognize the sources of tissue insult they undergo transcriptional activation of the 
inflammatory program for the purpose of recruiting leukocytes to the site of insult [7]. The 
alteration of the transcriptional programs leads to generation of pro-inflammatory mediators 
including  
 
Figure 1-1 The early inflammatory response.  
Generated using “Blood and Immunology” licensed under CC BY 3.0. 
 
chemokines, cytokines, and lipid mediators, which are then secreted into the local environment 
and diffuse into circulation [8]. The generation of secreted chemokines acts as a gradient to direct 
the infiltrating leukocytes into the tissue.  Some of the cytokines produced by the tissue immune 
cells, such as IL-1β and TNFα, function to induce changes in the endothelium, such as enhanced 
expression of adhesion molecules and loosening of the junctions between adjoining cells, thereby 
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increasing vascular permeability, which helps facilitate extravasation of circulating leukocytes [1, 
7].  
 
Figure 1-2 Rolling adhesion and diapedesis.  
Generated using “Blood and Immunology” licensed under CC BY 3.0 
 
 Meanwhile, naive myeloid leukocytes circulate in the bloodstream waiting to sense 
inflammatory signals that will trigger activation. Soluble cytokines produced primarily by 
immune cells in the local insulted tissue bind to extracellular receptors on the circulating 
monocytes and polymorphonuclear leukocytes (PMN) to induce powerful changes (Fig. 1-2). 
These changes can be characterized as a series of processes known as rolling adhesion and 
diapedesis [9]. First, the leukocytes increase L-selectin and VLA-1 surface molecules to leave the 
sweeping flow of the blood stream and begin tethering to the endothelial walls. Next, the 
leukocytes increase their presentation of more adhesion molecule, including p-selectin 
glycoprotein ligand-1 (PSGL-1). These molecules begin the process of rolling adhesion, a 
transient process of weak adhesion and dissociation with counter-receptors on the endothelium, 
that helps the leukocytes bind the endothelium more steadily and further decreases the speed of 
the circulating cells (Fig. 1-2). After the leukocyte rolling begins to slow down, the cells become 
activated by the locally diffused cytokines and chemokines emanating from the area of insult [9]. 
Inflammatory 
Stimulus 
Blood Vessel 
Endothelial Cell 
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Circulating PMN 
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The binding of cytokines and chemokines to their leukocyte receptors induces signaling cascades 
within the leukocytes that leads to activation of the leukocyte surface integrins, in a process 
known as “inside-out” signaling [1, 9]. 
 Leukocytes use activated integrins to form tighter associations with the endothelial counter-
receptors, further enhancing the binding avidity between the leukocytes and the endothelium. It is 
important to note that the endothelium at the site of insult has undergone several complimentary 
changes as a results of inflammatory cytokine and chemokine secretion that will help the 
leukocytes identify the area of interest and facilitate extravasation from the circulation into the 
tissues, such as increased vascular permeability and increased expression of surface adhesion 
molecules (ICAM, PECAM) [9]. Once tight adhesion is established, the leukocytes begin the 
process of extravasation from the endothelium. To do this, the leukocytes must use the chemokine 
gradient as a directional guide to crawl along the endothelial lumenal surface. The myeloid cells 
use the CD11b/CD18 integrin pair to interact with ICAM-1 on the endothelial surface to facilitate 
movement toward areas of concentrated chemokines, usually found near the endothelial cell 
borders. It is here that the leukocytes will undergo transmigration or diapedesis across the 
endothelium to reach the insulted tissues [9]. Once the cellular junctions are reached, the 
leukocytes flatten against the endothelium and extend a cytoskeletal protrusion between the cell 
junctions. The leukocytes then use a PECAM to pull themselves through the meeting cells. Once 
the leukocytes reach the basement membrane, PMN must undergo degranulation to release 
proteolytic enzymes, including gelatinase and collagenase to digest the basement membrane [10]. 
Upon entering the tissue, the leukocytes use the chemokine gradient (primarily IL-8) to migrate 
toward the injury site [10]. 
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1.3 Mechanisms of Pathogen Elimination 
Upon entry into the insulted tissue, PMN undergo further sequential degranulation steps 
necessary for the destruction of microbial pathogens present at the wound site. During this phase, 
the PMN are fully activated and quickly mobilize microbiocidal factors into the tissue including 
many proteases, complement proteins, and defensins via release of intracellular granules. PMN 
also produce high quantities of hydroxy radicals H2O2 and O2- in an effort to kill microbes present 
within the wound by producing an environment rich in oxidative stressors [10, 11]. These 
molecules are primarily meant to induce DNA breakage and protein and lipid modifications in 
invading pathogens; however, because the secretion of these reactive pro-oxidant species is non-
specific, DNA damage and signaling molecule modification accumulates in the host tissue as well 
[11]. 
1.3.1 Oxidative Stress 
Although intended only to cause harm to present pathogens, reactive oxygen and nitrogen 
species secreted during the influx of leukocytes function in a non-specific way, and can also cause 
harm to the host tissue. This process is known as oxidative stress, and describes the accumulation 
of pro-oxidant molecules in the inflamed tissue [6, 12]. These molecules are powerful reductants, 
meaning they donate electrons to other molecules in the environment. Pro-oxidants can be 
grouped as radical pro-oxidants or non-radical pro-oxidants [12]. The radical group of these 
reactive oxygen and nitrogen species possess an unpaired electron in their outermost electron 
shell making them highly volatile, and very reactive. The non-radical group of pro-oxidant 
reactive oxygen species do not possess such an unpaired electron; however, these compounds are 
highly reactive and have a tendency to donate electrons to other molecules in order to reduce their 
energy state [12]. Consequences of this electron donation event include three major types of 
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oxidative damage: 1) lipid peroxidation, 2) protein modifications, and 3) DNA damage [12]. 
Lipid peroxidation is the process by which free radicals react with lipids in the plasma membrane 
resulting in the production of more reactive peroxide products and membrane degradation [12]. 
While this consequence of oxidative stress is indeed harmful to the host, the second and third 
outcomes of oxidative damage are directly transformative; meaning the modifications of signaling 
proteins and direct DNA damage are capable of transforming healthy tissue cells into neoplastic 
pre-tumor cells [13]. Protein modifications due to oxidative damage come in a variety of different 
versions, including cross-linking, misfolding, and peptide fragmentation. These types of 
modifications often result in functional changes in the proteins [12]. Cellular DNA damage is the 
third target of oxidative damage, and can result in the accumulation of gene mutations within the 
cell. If these gene mutations occur in oncogenes or tumor suppressor genes, the cell may be able 
to escape cell cycle regulation and become a neoplasm. For these reasons, inflammation-induced 
oxidative stress is defined as a powerful inducer of cancer [13]. 
1.3.2 Microbiocidal Agents & PMN Degranulation 
In addition to producing large quantities of reactive oxygen and nitrogen species, the 
influx of leukocytes to the area of insult also induces release of many more specific molecules 
that help to rid the system of invading pathogen, and restore the tissue to homeostasis. In addition 
to production of oxidative stressors, the innate immune system functions through an additional 
two pathogen elimination strategies: 1) the complement system, and 2) PMN degranulation 
events. Both of these approaches to pathogen elimination are more specific than the alternative 
oxidative stress induction pathway, and are somewhat less harmful to the host [10]. Although 
complement is an essential mechanism of eliminating pathogen from the wounded tissue, it is not 
the focus of our study, therefore for the purposes of this discussion, PMN degranulation and direct 
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phagocytosis of pathogen will be the primary focus. Indeed, complement system and PMN 
degranulation are more specific than widespread production of detrimental reactive oxygen and 
nitrogen species, these pathways are general enough to be effective against a wide spectrum of 
pathogens without inducing damage to the host tissue. These molecules are secreted specifically 
for the elimination of microorganisms either by direct puncture of the cells, destruction of  key 
biological molecules, and by direct labeling for destruction by immune cells. The following is a 
detailed description of how pathogen elimination is accomplished in a more specific manner than 
respiratory burst. 
1.3.2.1 Primary (azurophil) granules 
Primary granules are first to be released during migration into the site of inflammation. 
These granules, also called azurophilic granules contain many microbiocidal agents that function 
differently to eliminate a wide range of pathogens [10]. MPO is one such enzyme secreted from 
primary granules that functions to produce many antimicrobial compounds from the peroxide 
generated during respiratory burst [2, 10]. Like most antimicrobial molecules, MPO is produced 
in myeloid leukocytes, primarily neutrophils, and are sequestered in primary granules [2]. Upon 
immune activation, leukocytes undergo the process of degranulation, which results in release of 
MPO into the extracellular space, or during phagocytosis, primary granules can fuse with the 
phagocytosis vesicle [12]. This fusion results in the total destruction of the pathogen within the 
phagosome. The MPO enzyme functions as a potent antimicrobial enzyme by producing 
hypohalous acids, predominantly hypochlorus acid from the reactants H2O2 and chloride ions 
present in the periphery [2]. The MPO enzyme works in conjunction with the NADPH oxidase 
complex, as the NADPH oxidase enzymes produce the peroxide reactants that are used in the 
MPO reaction (Fig. 1-2). Due to the highly reactive nature of the hypochlorus acid, excess 
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degranulation of myeloid leukocytes during periods of inflammatory overstimulation results 
serious pathological conditions; many of which are due to increases in oxidative stress [14]. 
Conversely, lack of the MPO enzyme, or defects in MPO enzyme function does not typically 
present any characteristic immunodeficiency as seen in NADPH oxidase enzyme defects [14]. 
This is due to the redundant nature of the microbiocidal agents present in leukocyte granules [12]. 
Primary granules also contain a large quantity of the α-defensin proteins. These small peptides are 
cationic in nature and have potent microbiocidal functions through creation of large pore-forming 
transmembrane complexes within the pathogenic cells [10]. This group of proteins also includes 
bactericidal/permeability-increasing protein (BPI). Additionally, α-defensins function as 
chemoattractants for innate immunes cells, including monocytes and macrophages as well as 
adaptive immune T cells. The third major component of azurophilic granules is the serprocidins. 
Standing for serine proteases with microbiocidal activity, this group of proteins includes cathepsin 
G, elastase, and proteinase-3, all of which possess proteolytic function on extracellular matrix 
proteins [10]. The function of these proteases is to facilitate digestion of the basement membrane 
to allow the migration of activated PMN into the tissue. The release of azurophilic granules must 
be tightly regulated to reduce the amount of unnecessary tissue digestion, as this can lead to 
degradation of tissue structure and function. For this reason, many anti-serprocidin proteins are 
secreted into the plasma constitutively, as a method of restraining excess ECM damage by 
proteases [10]. 
1.3.2.2 Secondary (specific) and tertiary granules 
The second and third types of neutrophil granules are secondary (or specific) and tertiary, 
which primarily contain microbiocidal substances and digestive enzymes. These granules are 
peroxidase negative, meaning they do not produce peroxide as a major antimicrobial substance. 
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They do, however, produce large amounts of lactoferrin, hCAP-18, lipocalin-2/neutrophil 
gelatinase-associated lipocalin (LCN2/NGAL), and lysozyme [10, 15]. These molecules are 
potent antimicrobial proteins that target a wide variety of microbial pathogens through multiple 
mechanisms. The most common function of these antimicrobial proteins is to sequester precious 
limited metals from bacterial uptake [16]. Tertiary granules contain mostly digestive enzymes that 
function to digest the basement membrane and extracellular matrix to facilitate migration of PMN 
through the tissue [10]. Because of the harmful nature of these enzymes, it is imperative for their 
release to be stringently controlled, as dysregulation of this system leads to extreme 
consequences, particularly tissue damage, within the host. 
1.3.2.3 Monocyte recruitment and differentiation 
Initially, monocytes entering the site of tissue injury function similarly to activated PMN, 
secreting proteolytic enzymes and rapidly taking up pathogen via phagocytosis through PRRs; 
however, unlike PMN, recruited monocytes undergo further differentiation into macrophages and 
dendritic cells after reaching the wound site [1]. This differentiation is mediated by cytokines, 
chemokines, growth factors, and other secreted molecules in the local wound microenvironment. 
Because monocytes are the first responders of the immune system during inflammation, and 
initially establish a non-specific response to inflammation, they use this differentiation 
opportunity to transform themselves into more wound type-specific sentinels [5]. From a single 
population of monocytes develops a highly plastic spectrum of professional antigen presenting 
cells (macrophages and dendritic cells) capable of recognizing and phagocytizing a wide variety 
of targets. The utility of this transformation lies in the ability for the innate immune system to 
communicate with the adaptive immune system about antigens that have entered the body [5]. 
This system, bridging the innate immune system with the adaptive immune system, allows the 
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host to become educated about encountered pathogens, helping to initiate a sustained, life-long 
immunity to regularly contacted antigens such as bacteria and viruses, and is responsible for 
inducing tolerance to regularly-encountered, non-pathogenic antigens [3]. 
1.4 Removal of Target Cells Via Phagocytosis 
Phagocytosis is the process of direct uptake of antigenic targets primarily by professional 
phagocytes, including dendritic cells, macrophages, and PMN. The phagocytic targets can be 
pathogenic or commensal microbes (alive or dead), alien cells, and misplaced or damaged host 
cells. Depending on the target cell being taken up, this process can stimulate the activation of the 
inflammatory response, or can function as a method of inducing immune tolerance. Phagocytosis 
is an absolutely essential process for sampling antigen, and maintaining the appropriate immune 
response within the tissues, and significantly contributes to maintenance of homeostasis. 
1.4.1 Phagocytosis 
As previously stated, the first and second major functions of the inflammatory response 
are the removal of pathogen and damaged tissue cells from the insulted tissue. Phagocytosis is the 
process used to accomplish these tasks. Removal dead and dying cells, and pathogens from the 
tissue are eliminated from the tissue by professional phagocytic cells, such as macrophages, 
neutrophils, dendritic cells, and B cells, however other, non-professional phagocytic cells can 
undergo changes that allow them to perform phagocytosis [17]. The process of phagocytosis 
involves three steps: 1) sensing target cells, 2) determining whether the target is labeled for 
destruction, and 3) engulfment of the target [17, 18]. Sensing of the phagocytic target is carried 
out using chemoattractant gradients. These can be cytokines or chemokines, or as in the case of 
pathogens, can be microbial PAMPs [6, 17]. The second step in phagocytosis is to determine 
whether the target cell is labeled for destruction. Many tags, or labels can be used to induce 
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activation of phagocytosis of the target cells, and these tags are collectively referred to as pro-
phagocytic “eat me” signals [17]. “Eat me” signals include a wide variety of pro-phagocytic 
molecules, including exposure of PS by apoptotic cells, complement proteins, and antibody tags. 
Conversely, a range of anti-phagocytic “don’t eat me” signals can also be displayed on cells, 
which work to oppose the activation signaling of the “eat me” signals [18]. These cellular 
indicators include markers that define cellular health, such as MHC molecules and CD47 [18]. 
Upon contact with a potential target, the phagocyte searches the cell for these pro- and anti-
phagocytic molecules using counter receptors. In most cases, both pro- and anti-phagocytic 
signals are received by the phagocyte; however, the prevailing signal determines the outcome of 
the phagocytosis event. If pro-phagocytosis signals overpower the anti-phagocytic signals, then 
activation of phagocytosis is achieved, and the target will be taken up by the phagocytic cells. If 
anti-phagocytosis signals prevail, then the target cell will not be removed from the tissue by the 
phagocyte. Therefore, target cells maintain the delicate balance of expression of phagocytic 
signals, and have some control over their ability to either survive in the tissue, or to be removed 
[17]. The third step of phagocytosis is the actual act of target engulfment by the phagocyte. This 
is highly controlled process that involves the activation of cytoskeletal rearrangement and 
coordination of engulfment and digestion machinery [19]. 
1.4.1.1 Necrosis vs. apoptosis 
 Removal of damaged cells is dependent on detection of damage-associated molecular 
patterns, or DAMPs. These DAMPs are specific to the type of cell death occurring within the 
tissue. Two major types of cell death processes can be observed in the eukaryotic tissue: necrosis 
and apoptosis. Necrosis, which is best described as “unplanned” cellular death [19]. This type of 
cell death typically results from cellular injury, and is a far messier process than apoptosis, or 
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“programmed” cell death, which is an extremely tightly coordinated and controlled process [19]. 
During necrosis, the cells have been suddenly damaged, and do not undergo the clean, self-
contained process of tidy cell death, as occurs in apoptosis. For this reason, necrosis is referred to 
as passive cell death, and apoptosis is described as active cell death.  
  
Figure 1-3 Necrosis versus apoptosis.  
Generated using “Intracellular Components” licensed under CC BY 3.0 
 
 Apoptosis occurs when the cell has sensed inducible death signals, lack of resources, or 
intracellular pathogen, and progresses through a series of tightly regulated protein cleavage 
cascades using the caspase proteases [19]. Once activated, the caspases promote internal 
destruction of cellular components, including cellular proteins. Additionally, release of 
intracellular calcium from the mitochondria induces changes to the plasma membrane, including 
exposure of inner leaflet phosphatidyl serine (PS) to the extracellular environment [18]. PS is a 
pro-apoptotic marker that signals the act of cell death to patrolling professional phagocytes, thus 
marking the cell for removal. Unlike necrosis, apoptosis is a unique, tidy method of controlling 
exposure of self-antigen, which can go on to cause autoimmune disease through activation of B 
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cells (Fig. 1-3). Because the intracellular contents of the apoptotic cell remain sequestered within 
the plasma membrane of the dying cell, until uptake via phagocytosis, risk for inducing an 
autoimmune reaction remains low. This prevents any self cellular antigens from leaking out into 
the extracellular space, where they can be taken up by patrolling B cells [18]. Limiting the 
activation self-reactive B and T cells is crucial to avoiding autoimmunity in the host. Necrosis, on 
the other hand, is not the preferred method of cell death, as it does not guarantee the sequestration 
of self antigen within the plasma membrane, and can therefore, induce the activation of 
autoimmunity [17]. 
1.5 Progression to the Adaptive Immune Response 
During the innate immune response, many foreign antigens are taken up through the 
phagocytosis pathway. Dendritic cells and macrophages are the two major populations of innate 
phagocytes that present antigens during inflammation [18]. Of these two populations of 
phagocytes, macrophages primarily function as transducers of inflammation, whereby the 
phagocytosis pathway stimulates these cells to produce cytokines that work to recruit other 
leukocytes to the area [6]. Unlike macrophages, dendritic cells are antigen presenting cells whose 
primary purpose is to bridge communication between the innate and adaptive components of the 
immune system. In other words, they collect and process antigen with the express purpose of 
presenting the antigen to adaptive immune cells [18]. This process educates adaptive immune 
cells and initiates the adaptive immune response, involving activation of lymphocyte-derived 
cells, such as T cells, B cells, and NK cells, which coordinate development of the memory 
response, and development of T cell-mediated immunity. 
As tissue resident dendritic cells take up antigens through the phagocytic pathway, they 
become activated, a process which induces maturation of dendritic cells (Fig. 1-4). The process of 
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activating maturation in DCs is characterized by the changes in morphology of the cells, 
upregulation of antigen presenting machinery, and increased cellular mobilization [20]. First, 
antigen-loaded MHC molecules become upregulated on the cell surface. Correspondingly, DCs 
undergo transcriptional upregulation of T cell co-stimulatory molecules, including CD40, CD80, 
and CD86 [21, 22]. Coordination of actin polymerization induces changes to the DC cytoskeleton 
to increase production of dendrites. These dendrite protrusions extend out from the smooth cell 
surface and serve to increase the surface area of the plasma membrane [23]. Additionally, DCs 
augment the expression of chemokine receptor CCR7, which allows them to migrate into local T 
cell rich lymphoid tissues, where they present the antigens to T cells. [22] 
 
Figure 1-4 Dendritic cell maturation.  
Generated using “Blood and Immunology” licensed under CC BY 3.0 
 
Following maturation and migration of DCs into lymphoid tissue, such as the lymph nodes, 
antigen presentation commences. The major consequence of antigen presentation is activation of 
T cells. Briefly, this process takes place between antigen-loaded MHC molecules displayed on the 
surfaces of DCs, and matching, antigen-specific T cell receptors expressed on the naïve T cells 
present in the lymphoid organs [24]. Additionally, many co-receptors are utilized to strengthen 
the signal produced upon binding of MHC to the TCR. This process is collectively referred to as 
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formation of the immunological synapse [24, 25]. It is important to distinguish the MHCI-
restricted antigen pathway from the MHCII-restricted antigen pathway. Although MHCI and 
MHCII are both similar molecules that function to present antigens to TCRs, MHCI molecules 
generally present endogenous peptide antigens, whereas MHCII molecules generally present 
exogenous peptide antigen. The type of MHC molecule that is most relevant in for responding to 
non-sterile injury is the MHCII molecule because DCs are primarily concerned with removal of 
exogenous pathogen [24]. Therefore, the following discussion will focus mainly on the 
MHCII:TCR immunological complex formation; however, activation of T cells via the 
endogenous MHCI presentation pathway is absolutely essential for recognition of aberrant tissue 
cells, and is used as then primary mechanism for recognition and removal of tumor cells. 
1.6 Formation of the Immunological Synapse 
Although a necessary component of T cell activation, ligation of the TCR with antigen-
loaded MHC molecules is not sufficient for sustaining substantial T cell activation or 
proliferation. It is through the formation of the immune synapse that sufficient activation of the T 
cell is achieved [25]. The immunological synapse centers around the initial TCR:MHC complex, 
and forms a “bull’s eye” shaped protein cluster around the complex (Fig. 1-5). On the T cell side 
of the assembly, the TCR complex is positioned at the very center of the synapse [26]. Following 
activation, this receptor complex becomes surrounded by costimulatory receptors, including CD4 
or CD8, and CD28. The costimulatory molecule CD28 binds it’s counter receptor CD80 (also 
termed B7) on the antigen presenting cell, which results in the activation of many intracellular 
signaling pathways, including JNK kinase, Cdc42, and PI3K. Activation of these signaling 
molecules results in enhanced transcription of cytokines, restructuring of the cytoskeleton, and 
stimulation of growth and proliferation signals within the T cell [25]. The costimulatory 
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molecules function to ensure the activation and proliferation signals persist, and result in the 
proliferation and maturation of antigen-responsive T cells. 
 
Figure 1-5 Formation of the immunological synapse.  
Generated using “Receptors and Channels” licensed under CC BY 3.0 
 
The immunological synapse is also comprised of co-inhibitory molecules. Perhaps the most 
significant, well-characterized pair of co-inhibitory molecules within the immunological synapse 
are CTLA-4 and PD-1 [27]. These two molecules induce T cell exhaustion upon ligation to their 
counter receptors CD80/CD86 and PDL-1, respectively. These inhibitory receptors function to 
limit the activation of T cells during the adaptive immune response in order to avoid any 
undesired chronic activation of the immune response during inflammation by inducing T cell 
exhaustion [27]. TIGIT, another representative of the IgSF family of co-inhibitory molecules, 
induces inhibition of T cell proliferation, NK cell activation, and promotes the secretion of IL-10 
at the expense of IL-12 in lymphocytes upon ligation with any of its three counter receptors 
CD155, CD112, and CD113 [27]. Like many inhibitory IgSF receptors, TIGIT carries out this 
inhibition through the phosphorylation of its intracellular ITIM domains [27]. Induction of the 
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adaptive immune response is an incredibly important process, which ensures the defense of the 
host from infection, and allows for clearance of damaged, or unhealthy cells from the tissue; 
however, equally as important is the ability to reduce the adaptive immune response when the 
source of inflammation is removed. All of these co-inhibitory receptors play a vital role in 
inhibiting the immune response via induction of T cell exhaustion [27]. As will be discussed later, 
under certain conditions, these non-pathogenic co-inhibitory molecules can become the dominant 
species within the immunological synapse, resulting in the inappropriate inhibition of the adaptive 
immune response, and defining a pathogenic role for these receptors. 
1.7 Late Inflammatory Response and Wound Healing 
Although onset of the inflammatory response is crucial for the elimination of pathogen and 
damaged tissue, the resolution of this process is equally as important for the maintenance of tissue 
homeostasis. In fact, if this hostile environment is allowed to persist, the tissue becomes the 
source of chronic wounding, leading to a state of constant inflammation. Fortunately, the 
recruitment of leukocytes into the tissue functions through a self-limiting process that initiates the 
third function of the inflammatory response: the tissue repair process. Leukocytes orchestrate the 
wound healing program via secretion of signaling molecules and growth factors that stimulate 
tissue growth, proliferation, and angiogenesis. It is also very important that this tissue repair 
response is terminated quickly, as prolonged, unresolved tissue repair programming can lead to 
tissue fibrosis, and in extreme cases, leads to the creation of an immunosuppressive environment 
which can help neoplastic cells escape the anti-tumor immune response. 
1.7.1 Late Inflammatory Phase 
 The first step in resolution of inflammation is to stop the recruitment of circulating 
leukocytes into the injured tissue [3]. Persistence of leukocyte recruitment only functions to 
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further promote the inflammatory response and create a more detrimental environment for the 
host tissue. Under these circumstances, the wounded tissue cannot begin to recover from the 
damage inflicted by the initial insult and the active PMN. Therefore upon entry into the tissue, the 
leukocytes begin a self-limiting feedback mechanism of lipid mediator secretion [28-30]. By 
generating large quantities of protectins and resolvins through lipid mediator class switching, 
inflammatory leukocytes (primarily PMN and macrophages) limit their own recruitment into the 
tissues (Fig. 1-6). Through binding of GPCR receptors on immune cells, resolvins block the 
transmigration of circulating monocytes and PMN into the wound [28]. Specifically, resolvin E1 
directly antagonizes the BLT1 GPCR on PMN, a receptor that is activated upon binding of its 
agonist leukotriene B4. This antagonism results in the inactivation of NF-kB transcription factor 
pathways in migrating PMN, thereby turning off the activity of the prevailing inflammatory 
leukotriene pathways [30]. Resolvin E1 also functions to increase MAPK signaling activity in 
monocytes, and reduces dendritic cell migration and pro-inflammatory cytokine production 
through activation of the ChemR23 receptor [30]. Protectin D1 serves a similar purpose to curb 
inflammation and promote the initiation of wound healing. Protectin D1 inhibits recruitment of 
leukocytes, decreases TNFα and IFNγ production, and aids in the induction of T cell apoptosis at 
the wound site [30, 31]. All of these mechanisms help to reduce the influx of inflammatory cells, 
and help reduce the production of pro-inflammatory mediators by resident inflammatory cells. It 
is clear from this information that the initiation of the inflammatory response also induces the 
termination signals required to limit the tissue damage induced by the acute inflammatory 
response [29].  
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Figure 1-6 Late inflammatory phase.  
Generated using “Tissues” licensed under CC BY 3.0 
 
As the inflammatory response progresses, initially inflammatory leukocytes build up in 
the wound site and continue their differentiation and phenotypic changes into more specialized 
effector cells, such as macrophages and dendritic cells [3]. As a result, these cells add to the wave 
of secreted factors building up in the wound microenvironment. Some of these factors, such as 
TGF-β, EGF, FGF, and collagenase are very important for beginning the transition to the tissue 
reparative wound healing program [32]. These secreted factors function to establish a shift in the 
tissue microenvironment away from the proinflammatory milieu and toward the tissue repair-
supportive setting. These factors induce the microenvironment to promote cell proliferation, 
angiogenesis, and ECM remodeling to return the tissue to its previous, undisrupted function. At 
this late stage of inflammation, cytokines and chemokines function to recruit lymphocytes, mainly 
T cells to the wound site, and promote transition to the adaptive immune phase of wound healing, 
which promotes memory and tolerance functions of the immune response [3]. 
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1.7.2 Stages of Wound Healing 
1.7.2.1 Fibroblast proliferation and migration 
 The initial response to wounding also induces the deposition of granulation tissue, which 
serves as a plug that prevents infiltration of microbes and acts to tether the edges of the wound 
together to prevent tearing of the tissue (Fig. 1-6). Granulation tissue is composed mainly of 
extracellular matrix components such as collagen. Generation of the granulation tissue is carried 
out by fibroblasts. Following the decrease in the immediate inflammatory response, and 
establishment of the granulation tissue, fibroblasts at the wound site undergo extreme 
proliferation, and migrate into the wound as a result of increased secretion of growth factors [33]. 
Specifically, PDGF, EGF, and FGF function to enhance proliferation, and TGF-β and PDGF act 
as chemoattractants to aid in recruitment of the newly proliferated fibroblasts into the wound [32, 
33]. Once in the wound, the fibroblasts continue to proliferate and begin to produce large 
quantities of extracellular matrix components including fibronectin and collagen, which helps 
establish tissue repair [33].  
1.7.2.2 Angiogenesis 
 Another consequence of growth factor secretion is the stimulation of new blood vessel 
growth, a process known as angiogenesis, within the wound. This process is key to reestablishing 
the blood supply to the injured tissue. Growth factors FGF, VEGF, PDGF, TGF-α and β act on 
remaining endothelial within the wound to promote their proliferation. In turn, new blood vessels 
are formed within the wound site, which helps the tissue return to its uninjured state [33]. 
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1.7.2.3 Remodeling 
Concurrent with the restoration of blood flow to the wound site during angiogenesis, the 
final step of the wound healing process is the remodeling stage [33]. This process involves 
secretion of proteolytic enzymes by PMN, fibroblasts, and tissue macrophages that digest the 
newly deposited ECM, as well as redeposition of collagen and fibronectin within the wound [32, 
33]. Many of the same growth factors necessary for the other stages of wound healing are also 
required for the remodeling stage including PDGF, FGF and TGF-β. 
1.7.3 Changes in Microenvironment During Wound Healing 
Although inhibiting the influx of inflammatory leukocytes is a very important, necessary 
step in the resolution of inflammation, it is not only the absence of inflammation that defines the 
wound healing program, but other characteristic changes to the tissue microenvironment. As 
changes in the microenvironment are known to have profound effects on the functions of effector 
immune cells and the processes they carry out, it is important to discuss the cells that are 
responsible for inciting the changes within the tissue microenvironment, and how shifting the 
microenvironment toward pro- or anti-inflammatory conditions regulates the functions of nearby 
immune cells. 
1.7.3.1 M1 vs M2 polarized macrophages 
 One example of these characteristic microenvironmental changes is the polarization of 
recruited inflammatory monocytes to the alternatively activated M2 phenotype, instead of the 
classically activated proinflammatory M1 phenotype [3]. The major consequence of M2 
polarization is the transcriptional downregulation of inflammatory mediators such as TNFα, IL-
1β, IL-12, and IL-8 [34]. The loss of these proinflammatory cytokines also contributes to the 
switching of the microenvironment towards a tissue repair permissive state. Macrophage 
  23 
polarization is crucial for tuning the tissue microenvironment away from the inflammatory state 
and toward the wound healing. Many different cell types respond to cues via secreted factors 
within the local environment, and macrophages are the primary sources of such factors. M1, or 
“classically activated” macrophages, are termed thus because they respond directly to pathogen-
associated molecular patterns (PAMPs), or to local tissue response [34]. As a result of danger 
signal detection, these cells undergo transcriptional alterations, resulting in increased expression 
or proinflammatory cytokines. As discussion previously, this action sets off the recruitment of 
inflammatory effector cells (monocytes and PMN) into the tissue, and the inflammatory response 
progresses through until resolution of the insult. Conversely, M2, or “alternatively activated”  
 
Figure 1-7 Macrophage polarization.  
Generated using “Blood and Immunology” licensed under CC BY 3.0 
 
macrophages are polarized under very different conditions from M1; the polarization of M2 
macrophages is carried out via signaling through tissue repair cytokines, specifically IL-4 and IL-
13 [34] (Fig. 1-7). These characteristic anti-inflammatory cytokines induce transcriptional 
changes within the macrophages, thus promoting production of tissue repair supporting 
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molecules, including cytokines, growth and angiogenic factors. These transcriptional changes 
support the tissue repair process, and also function to further inhibit the inflammatory immune 
response. Furthermore, a second consequence of M2 polarization is the transcriptional 
downregulation of inflammatory mediators such as TNFα, IL-1β, IL-12, and IL-8 [34].  
 M2 macrophages transform the microenvironment to support tissue repair through a number 
of mechanisms. The first is that they secrete massive amounts of IL-4, which results in conversion 
of any non-activated tissue macrophages to M2 polarization [5]. IL-4 secretion induces a positive 
feedback system, whereby the initial production of IL-4 induces alternative polarization of M1 
macrophages toward the M2 phenotype. This polarization event converts any present 
macrophages to the M2 tissue repair phenotype [5, 34]. Consequences of upregulated IL-4 
secretion also include further polarization of M2 cells, and inhibition of pro-inflammatory 
cytokine expression [5]. Furthermore, IL-4 is a powerful stimulator of fibroblast functions, 
including proliferation and collagen deposition. Consequences of excess IL-4 production include 
the accumulation of fibrotic lesions due to hyperstimulation of the tissue repair process [35]. IL-4 
has also been shown to induce the production of other anti-inflammatory cytokine including IL-10 
[5]. This second mechanism of M2 macrophage-induced tissue repair uses a subtype of M2 
macrophages, termed “deactivated” macrophages, which exclusively secrete large amounts of IL-
10 and TGF- β [34]. These two anti-inflammatory cytokines further attenuate any expression of 
inflammatory mediators by the tissue and/or immune cells [5]. IL-10 expression also stimulates 
the activation of the STAT3 transcription factor, which increases the expression of factors that 
further drive the tissue repair process [36]. Additionally, IL-10 reduces NF-κB activity [37], 
which further reduces the expression of pro-inflammatory cytokines and results in the reduction 
of MHC molecules in antigen presenting cells [38]. 
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One consequence of increased IL-10 and TGF-β secretion is the tuning of activated T cells 
toward the immunomodulatory phenotype [6]. These cells are known as regulatory T cells, or 
Tregs, which promote tissue repair through inhibition of localized immune effector cells. As 
mentioned previously, Treg cells work to induce immunomodulation directly through decreasing 
CD4+ helper T cell function, and indirectly by secreting cytokines, which contribute to 
maintaining the skewed polarization of immune cells toward immunosuppressive phenotypes 
within the microenvironment [38]. Tregs use many co-inhibitory molecules within the 
immunological synapse to induce T cell exhaustion pathways in helper T cells. Specifically, Treg 
cells use the PD1-PDL-1 and CTLA4-B7 interactions to induce inhibition of helper T cell 
activity. This directly inhibits the activity and proliferation of activated helper T cells within the 
tissue repair microenvironment [27]. Treg cells also secrete high quantities of immunosuppressive 
cytokines, IL-10 and TGF-β, which further promote the polarization of infiltrating immune cells 
toward immunosuppressive Treg and M2 phenotypes [38]. Collectively, these cytokines condition 
the tissue repair microenvironment to inhibit the inflammatory response and support the wound 
healing response. In addition to tissue repair cytokine accumulation, the tissue repair-supporting 
microenvironment is also rich in angiogenic and growth factors, which work to drive the 
proliferation and migration of fibroblasts for the generation of new tissue [33]. These factors 
facilitate the production of new tissue cells, as well as promote the establishment of new blood 
vessels via stimulation of angiogenesis. The process of tissue repair also induces deposition of 
extracellular matrix components such as collagen, and activates proteases that coordinate 
remodeling of the tissue and the extracellular matrix. These pathways all work in concert to 
restore the tissue to homeostasis [33]. 
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1.8 Dynamic Regulation of Hematopoiesis 
The process of inflammation is not restricted to the local tissue environment, but intimately 
associated with the production of responsive immune cells in the distal bone marrow. This 
function allows the immune system to specifically adapt production of immune cells in order to 
appropriately respond to the type of insult that is present in the tissue. Hematopoiesis is the 
process of forming the cellular components of the blood [39]. This process occurs in the bone 
marrow, and follows a hierarchical flow of development and cellular differentiation. Several stem 
cell subtypes and progenitor cells undergo proliferation and fate commitment steps to produce the 
terminal effector cells of both myeloid and lymphoid lineages, which go on to perform the 
necessary functions of the immune system [39]. Tight regulation of hematopoiesis is critical in 
controlling the immune response, and any dysfunction of this system can result in disruptions to 
immune function. For example, overstimulation of the inflammatory process can result in extreme 
production of inflammatory leukocytes, and deficiency in hematopoiesis can result in extreme 
neutropenia and increased susceptibility to infection [40]. Regulation of hematopoietic 
development is critical to maintaining the population of inflammatory effector cells, and multiple 
levels of regulation exist to maintain dynamic flexibility of the process of hematopoiesis. Two 
major levels of regulation are of note: 1) basal maintenance or steady-state, and 2) emergency, or 
demand-adapted hematopoiesis [40]. 
1.8.1 Hematopoiesis Process 
 Hematopoiesis is a tightly regulated process that involves several proliferation and 
commitment steps that are arranged in a hierarchical pattern (Fig. 1-8). The hierarchy begins with 
the hematopoietic stem cells (HSC), which are multipotent, self-renewing stem cells that give rise 
to all of the cells of the blood system. Due to the short-lived, terminally differentiated nature of 
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hematopoietic effector cells, HSC undergo many rounds of self-renewal and differentiation events 
to keep up with the constant loss, and subsequent replacement demand of effector cells [41]. 
Therefore, by replenishing the pool of HSC, the sources of all hematopoietic progenitors is 
replenished resulting in the constant supply of new effector cells to replace the outgoing 
hematopoietic cells. The next level of differentiation involves a certain subset of HSC from the 
self-renewing pool to differentiate into the two major progenitor lineages: The common lymphoid 
progenitors and the common myeloid progenitors. Like the HSC they are derived from, these two 
progenitor cell types retain their multipotent differentiation ability, but lose self-renewal 
capability [39]. This loss of self-renewal function highlights the importance of maintaining the 
pool of HSC, as HSC are the sole source of all the terminally differentiated hematopoietic effector 
cells. Without the HSC population, the entire population of effector immune cells, and 
components of the blood system collapses [41]. 
The multipotent common lymphoid progenitor cells are distinguished by the dramatic 
upregulation of the ikaros gene; a zinc-finger transcription protein that helps program the fate of 
the HSC into lymphoid-like cells. Mice deficient in ikaros do not produce thymic dendritic cells, 
B cells, NK cells, γδ T cells, and display dysfunctional αβ T cells [42]. In addition to impairments 
of the lymphoid arm of hematopoiesis, ikaros null mice also display a dramatic reduction in the 
number of mature PMN within the bone marrow compartment, indicating that ikaros also plays an 
important role in granulopoiesis [42]. In parallel, other cells from the HSC pool may alternatively 
undergo transcriptional enhancement of transcription factor PU.1 [43]. This event commits the 
cells to a myeloid progenitor fate. Following irreversible commitment of HSC to either the 
lymphoid, or myeloid progenitor fate, cells undergo a number of transcriptional programming 
changes that further differentiate them into oligopotent progenitors. Although still capable of 
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differentiating into all the cell types of the blood system, oligopotent progenitor cells are no 
longer able to revert to multipotent progenitors, and are committed to producing either lymphoid 
or myeloid subsets of terminally differentiated effector cells. 
 
Figure 1-8  Hematopoiesis process. 
Hierarchy of hematopoiesis. Self-renewing multipotent hematopoietic stem cells undergo several rounds of differentiation to 
become lineage-restricted progenitor cells, eventually producing all the effector components of the blood system. HSC, 
hematopoietic stem cell; MMP, multipotent progenitor; CMP, common myeloid progenitor (CD11b+ population of BM cells); GP, 
granulocyte progenitor; MP, monocyte progenitor; MkP, megakaryocyte progenitor; EP, erythrocyte progenitor; Eosin, eosinophil; 
Baso, Basophil; PMN, polymorphonuclear leukocytes; MΦ, macrophage; DC, dendritic cell; RBC, red blood cell; CLP, common 
lymphoid progenitor; TNK, T cell-natural killer cell progenitor; T, T cell; NK, natural killer cell; B cell. 
 
Once formed, oligopotent progenitor cells from both the common lymphoid and common 
myeloid progenitor pools that continue to diverge transcriptionally, and thus develop into 
different types of cells [39, 43]. The next stage of differentiation results in the generation of 
lineage restricted progenitors [43]. These cells form the final level of precursor cells before final 
differentiation is achieved; the lymphoid progenitors go on to develop into B, T, and NK cells, 
while the myeloid progenitors produce monocytes, and granulocytes [39]. Of particular note, the 
development of the effector cells from the common myeloid progenitors is carefully orchestrated 
through a series of cytokine signals, which induce transcriptional alterations within the cells, 
silencing genes that contribute to oligopotency, and activating genes that contribute to specific 
effector functions of the particular cell type [39]. Monocytes can further differentiate into 
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macrophages and dendritic cells, and granulocytes develop into three major types of granulocytic 
cells: basophils, eosinophils, and neutrophils. As with the early stages of hematopoiesis, 
development of these terminally differentiated cells occurs through cytokine-induced 
transcriptional regulation [39]. It has been determined that bone marrow resident macrophages are 
responsible for regulating this process of hematopoiesis, at least in part through production and 
secretion of cytokines and growth factors [44]. 
1.8.1.1 Hematopoietic signaling is carried out using secreted cytokines & growth factors 
Progression of cells through the hematopoiesis process requires stimulation events that are 
carried out by secreted cytokines [39] (Fig. 1-9). Cytokines are secreted by the stroma and the 
BM resident macrophages, and bind to cytokine receptors on some or all of the progenitor cells 
found in the bone marrow to incite intracellular kinase activity to complete one of two major 
functions: 1) to promote growth and survival of progenitor cells, or 2) to induce lineage 
commitment differentiation and/or maturation [44]. These two functions together maximize the 
production of hematopoietic effector cells, and are easily adapted to the needs of the system.  
 
Figure 1-9 Cytokine-driven hematopoiesis. 
Cytokines drive hematopoiesis. Growth factors and cytokine drive progression of hematopoiesis through multiple stages of 
differentiation and lineage commitment steps. HSC, hematopoietic stem cell; CMP, common myeloid progenitor; GMP, 
granulocyte-macrophage progenitor; GP, granulocyte progenitor; MP, monocyte progenitor; PMN, polymorphonuclear leukocytes; 
Mono, monocyte; CLP, common lymphoid progenitor; TNK, T cell-natural killer cell progenitor; BCP, B cell progenitor; T, T 
cell; NK, natural killer cell; B cell. 
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Secreted factors responsible for controlling hematopoiesis fall into four major categories: 
1) interleukins (ILs), 2) interferons (IFNs), 3) colony stimulating factors (CSFs), and 
erythropoietin and thrombopoietin growth factors [39]. Each factor induces either a growth and 
proliferation signal or a differentiation/maturation event in the cell type(s) expressing the specific 
cytokine receptor(s). These receptors function as the signal transducer for the cell. Once activated 
through cytokine-receptor binding, activation of effector molecule signaling is achieved generally 
though a cascade of phosphorylation events carried out by a number of potential tyrosine kinases 
[39, 45]. The type of non-receptor tyrosine kinase that will disseminate the cytokine-induced 
activation signal cascade is determined by the type of receptor that recognizes the cytokine, and 
more specifically, the arrangement of amino acid residues that make up the intracellular domain 
of the receptor [45]. 
There are two classifications of cytokine signaling receptors, type 1 and type 2 [39] (Fig. 
1-10). Type 1 receptors are made up of two signaling chains and can be either homodimeric, or 
heterodimeric. The heterodimeric type 1 receptors can be further differentiated by their shared, or 
conserved signaling chain. Although these cytokine share a common signaling chain, specific 
cytokine-receptor interactions are carried out through a cytokine-specific α chain, that interacts 
directly with the cytokine, and subsequently recruits the conserved signaling chain. There are 
three families of shared signaling chain [39]. The first type of shared signaling chain is the gp130 
subunit. This is the common signaling protein used by IL-6 cytokine family members, including 
IL-6, LIF, and IL-11 [45]. The second type of shared cytokine receptor signaling chain is the β 
chain family. Cytokines that use this signaling chain include GM-CSF, IL-3, and IL-5 [45]. The 
third shared receptor chain family is the γ chain. Many cytokines use this type of signaling, 
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including IL-2, IL-4, IL-7, IL-9, IL-13, IL-15, and IL-21 [45]. Although type 1 cytokines signal 
using various shared chain peptides, and the consequence of each cytokine signal is different, the 
general mechanism of signal transduction is conserved in all type 1 receptors. The accepted model 
for type 1 cytokine signaling is that the cytokines first bind the specific cytokine receptor subunit 
(termed the α subunit) with high affinity [45]. Binding of the cytokine induces a conformational 
change in the intracellular domain of the α receptor chain, which induces oligomerization, or 
recruitment of the shared chain (gp130, β, or γ) [45]. Only then can activation of the signal 
pathway occur. Not unlike the type 1 receptors, type 2, or single chain receptors often follow a 
similar pattern of activation; however, single chain receptors may form homodimers after 
cytokine binding to propagate the signal, instead of using a shared signaling receptor. 
Additionally, type 2 cytokine receptors possess all the necessary domains for recruiting non-
receptor tyrosine kinases that will disseminate the signal [45]. Examples of type 2 cytokine 
receptors include IFNs and the IL-10 family [46].  
1.8.1.2 Dissemination of cytokine signaling is mediated by non-receptor tyrosine kinases 
Although receptor binding is the first level of cytokine signaling, and receptor expression 
determines the ability of the cell to respond to cytokines and other growth factors, this is simply 
the first step of the signaling cascade. Membrane-bound receptors are responsible for transmitting 
the signal of cytokine binding into the cell, where non-receptor tyrosine kinases (RTKs) function 
to activate the cellular machinery, thus inducing the changes to the cell that result in either 
enhanced growth, survival, and proliferation, or in changes to the transcriptional program [45]. 
There are many families of non-RTKs that carry out the intracellular cytokine signaling cascades. 
The type of non-RTK responsible for disseminating the cytokine signal is highly dependent on the  
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Figure 1-10 Cytokine signaling families. 
 
type of receptor that receives the initial stimulus, and the domains that are phosphorylated upon 
binding of the external cytokine stimulus [45]. There are a number of domains that are conserved 
in the intracellular signaling domains of cytokine receptors chains, and recognized by downstream 
signaling proteins. The first, perhaps most common type of intracellular receptor domain is the 
SRC homology type 2 (SH2) domain [45]. This conserved sequence of amino acids is present in 
nearly every cytokine receptor signaling subunit, and, once phosphorylated, this domain functions 
as a docking site for non-RTKs that also possess SH2 domains, including Janus kinases (Jaks), 
Src family kinases, feline sarcoma virus kinase (Fes/Fps), Tec/Btk, and Syk family kinases [45]. 
Although each of these kinase families have different signaling pathway targets, they all have a 
conserved method of disseminating the cytokine signal, that is that all become phosphorylated 
after docking to the activated receptor via the SH2 domains, and are then able to “pass the 
phosphorylation” to the next target molecules. These phosphorylation cascades modulate the 
GM-CSF IL-3 IL-5 
β β β 
GM-CSFRα IL-3Rα IL-5Rα 
G-CSF IL-6 IL-11 
gp130 gp130 gp130 
G-CSFRα IL-6Rα IL-11α 
IL-4 IL-13 
γ γ γ 
IL-2 
β IL-2Rα IL-4Rα IL-4Rα 
IFN IL-10 
IFNR1 IFNR2 
IL-10R2 
IL-10R1 
Type 1 β chain Type 1 gp130 chain 
Type 1 γ chain Type 2 
  33 
target protein in either a positive, or negative manner, thereby activating or inhibiting the function 
of the target protein [39, 45].  
It is important to note that although each cytokine receptor functions through a different 
mechanism of activation, and use different non-RTKs to activate signaling cascades, many of 
these pathways converge at the effector molecule level [45]. The advantage to using different 
methods of signaling is that each pathway is subject to individual methods of regulation, therefore 
bestowing flexibility of regulation of each cytokine signaling pathway. 
1.8.1.3 Cytokine signaling directs hematopoiesis 
It would be impossible to discuss the entire list of possible cytokine signaling pathways 
identified during hematopoiesis; however, because later discussions will address the importance 
of regulating myelopoiesis, three major cytokine signaling pathways that are critical to 
myelopoiesis will be presented here. The first major type of SH-2 mediate signaling pathway 
occurs through the activation of Jak kinases [45]. These kinases, as in most signaling models, 
binds to the phospho-tyrosine residues in the SH2 domains of either type 1 or type 2 receptors 
(including IL-6) [46]. Once bound, individual Jak monomers phosphorylate each other in a trans 
manner, and recruit monomers of the signal transducer and activator of transcription (STAT) 
proteins to dock at the SH2 domain. Once STATs bind, they are also phosphorylated, which 
allows for the dimerization of the phospho-STATs, and translocation of this complex to the 
nucleus, where it acts as a transcription factor to drive differentiation of the cell [46]. The 
Jak/STAT mechanism is highly variable, as each protein family consists of multiple members, 
and varying the combinations of Jaks and STATs alters the specific gene targets that ultimately 
become transcribed as a result of the pathway activation. The second and third major types of 
SH2-mediated signaling pathways involve the activation of the small GTPases. Most families of 
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tyrosine kinases are capable of activating guanine nucleotide exchange factors, which regulate 
activity of small GTPase effector proteins. In these signaling pathway methods, tyrosine kinases 
either directly activate guanine nucleotide exchange factors, or adaptor proteins first, which is 
followed by the rapid activation of small GTPases, including Rac, Cdc42, and Grb2 [45]. These 
activated proteins can go on to complex with scaffolding proteins, or effector molecules. 
Typically, this is where cytokine activation pathways converge, in many cases resulting in 
activation of mitogen-activated protein kinase (MAPK), or other transcription factors that go on 
to regulate gene expression or cell growth and proliferation [45].  
1.8.2 Steady-State Hematopoiesis 
Steady-state hematopoiesis refers to the generation and maintenance of hematopoietic 
cells during a state of relative homeostasis. In other words, steady-state hematopoiesis occurs 
continuously within the body of the host that is not under a “stressed” condition (i.e. no active 
inflammation, infection, or trauma) [44]. Conversely, emergency, or demand-adapted 
hematopoiesis occurs during times of stress, including systemic inflammation and infection [40, 
44]. This concept will be addressed in more detail in the following section. Steady-state 
hematopoiesis is the process of continuously replenishing terminally differentiated hematopoietic 
cells from both the lymphoid and myeloid lineages by stimulating the self-renewal of the 
multipotent HSC population, which results in a “trickle-down” effect for the increased production 
of the progenitors and the terminally differentiated effector cells. During steady-state 
hematopoiesis resident BM macrophages, stromal, and endothelial cells are responsible for 
secreting the necessary cytokines for maintaining pools of hematopoietic effector cells [44]. 
Furthermore, BM macrophages provide secreted factors that drive the differentiation of stem cells 
to lineage-committed progenitors, and eventually effector cells. In addition to maintaining the 
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generation of effector cells, BM macrophages also control the mobilization of effector cells into 
the periphery through maintaining appropriate expression of tethering molecules, which serve to 
keep effector cells sequestered in the bone marrow until it appropriate for them to be released, 
such as a period of infection or wide-scale tissue damage [40]. For example, tethering, or 
anchorage of effector leukocytes in the bone marrow occurs through binding of the CXCR4 
chemokine receptor on the leukocytes to the CXCL12 chemokine, which is highly expressed in 
the bone marrow [40]. Upon stimulation of leukocytes with G-CSF, a cytokine potently 
upregulated during periods of infection and inflammation, leukocytes reduce their expression of 
CXCR4, and thus, as the tethering molecule expression decreases, the interaction between the 
tether and anchor is also reduced, releasing the effector cells into circulation [40, 44]. 
Macrophages can also regulate the egress of mature effector cells from the bone marrow by 
directly increasing G-CSF production, thereby promoting egress of mature leukocytes into 
circulation for immediate response to insult [44]. 
1.8.3 Demand-Adapted Hematopoiesis 
Unlike steady-state hematopoiesis, emergency, also known as demand-adapted 
hematopoiesis, occurs when there is a harmful stimulus detected by the immune system, or 
directly by the resident BM macrophages, or the HSC themselves [40]. During a systemic 
infection, pathogen recognition receptors (PRRs), including toll-like receptors, present on innate 
immune cells and HSC detect the presence of pathogen-associated molecular patterns (PAMPs), 
such as flagellin, LPS, or peptidoglycan. This detection results in the  
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Figure 1-11 Emergency hematopoiesis.  
Emergency hematopoiesis. HSC, hematopoietic stem cell; CMP, common myeloid progenitor; GMP, granulocyte-macrophage 
progenitor; GP, granulocyte progenitor; IMC, immature myeloid cells (heterogeneous group of immature monocytes and immature 
granulocytes); MP, monocyte progenitor; CLP, common lymphoid progenitor. During emergency hematopoiesis IMC population 
expands, and acquire migratory function. Production of myeloid cells increases as production of lymphoid cells decreases. 
Generated using “Blood and Immunology” licensed under CC BY 3.0. 
 
production of inflammatory mediators [40]. If the pathogen stimulus is detected directly by PRRs 
present on HSC, the HSC undergo a process of rapid self-renewal in anticipation of the need for 
replenishing neutrophils that will be mobilized to the site of infection. This evolutionary response 
mechanism allows the HSC to sense the threat, anticipate the need for augmented generation of 
immune cells, and response accordingly by directly initiating the self-renewal process, thereby 
replenishing the pool of multipotent cells that will resupply the effector immune cells [40]. 
Furthermore, the production of lymphocyte cells becomes reduced during emergency 
hematopoiesis, demonstrating yet again that hematopoiesis is an extremely adaptable process 
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capable of mounting a tailored response to the specific nature of the insult. As in the steady state, 
demand-adapted hematopoiesis is also controlled by resident BM macrophages [44]. As the pool 
of self-renewing HSC proliferates in response to threatening stimuli, BM macrophages secrete 
cytokines that induce differentiation of newly formed HSC, so as the pool of progenitor cells 
increases, the cells are bathed in differentiation-inducing cytokines [44]. This system allows for 
rapid production of effector cells, while remaining dynamically adaptive to the particular insult 
(Fig. 1-11). The ability to sense and quickly adapt to the changing inflammatory needs of the host 
is a crucial system for maintaining the leukocytes effector cell populations for the response to 
inflammatory stimuli. In addition to increasing the pools of available leukocyte progenitors, 
cytokines produced during demand-adapted hematopoiesis also mediate cell release mechanisms 
[40, 44]. Therefore, cytokines secreted by BM macrophages during demand-adapted 
hematopoiesis not only stimulate cell production, but they also stimulate the migration of 
leukocytes into circulation. 
1.9 The Importance of Cytokine Signaling in Inflammation 
Cytokines are important immunoregulators that coordinate both the onset and resolution of 
the inflammatory response. As small, secreted molecules, cytokines function as the primary 
method of communication between cells of the immune system; however communication is not 
their only function [7]. These secreted factors are often effector molecules that result in regulation 
of function in their target cells. This functional regulation occurs at many levels, including both 
transcriptional and post-translational modifications. Thus, cytokines act as effector response 
molecules that control cellular function via a multitude of methods. 
1.9.1 Coordinating the Inflammatory Response 
 Proinflammatory cytokines specifically control the onset of the inflammatory response. The 
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three most notable inflammatory cytokines involved in inflammation are IL-1β, TNFα, and IL-6 
[7]. These cytokines work together to mount the innate immune response during tissue injury. IL-
1β is primarily secreted by monocytes, macrophages, and non-immune endothelial cells and 
fibroblasts during wounding [32]. IL-1β is secreted as a consequence of pathogen-associated 
molecular patterns being recognized by the pathogen recognition receptors present on the surface 
of tissue resident macrophages. IL-1β serves as a method of signal amplification in the 
inflammatory response. Through upregulation and secretion of active of IL-1β as a result of 
pathogen recognition, several other proinflammatory mediators become transcriptionally 
upregulated and the proinflammatory signal cascade is initiated [47]. The IL-1β pathway is 
critical to the host immune response as it is the first “domino” to fall in the series of inflammatory 
signals required for orchestrating the removal of pathogen from the tissue. IL-1β accomplishes its 
immunostimulatory functions by mimicking activation of toll-like receptors and signaling through 
an intracellular TIR domain to activate MAPK and NF-κB transcription factors [48]. 
 IL-1β is a key proinflammatory cytokine responsible for coordinating inflammation. In fact, 
it is so efficient at coordination inflammation, it is known to be the key factor in the generation of 
autoimmunity [47]. IL-1β is upregulated when tissue senses danger signals by many different cell 
types, including resident immune cells and fibroblasts. Once in the tissue, IL-1β drives further 
activation of the inflammatory response in many different cells types, through many different 
mechanisms. For instance, IL-1β has been shown to drive production of master regulators of 
inflammation, such as IL-6 and TNF-α, and induction of monopoiesis and granulopoiesis at the 
expense of erythropoiesis [47]. Furthermore, IL-1β drives the activation of many immune cells, 
including helper T cells, Th17 cells, macrophages, dendritic cells, NK cells, and B cells. IL-1β 
also induces changes to endothelial cells, which facilitates leukocyte infiltration, a core function 
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of the inflammatory response [1]. 
 The second key inflammatory cytokine required for mounting a successful immune 
response is TNFα [7]. This cytokine has been demonstrated as a key regulator of the 
inflammatory response, often gaining recognition for its role in chronic auntoimmune disorders, 
including inflammatory bowel disease, psoriasis, and arthritis[49]. Like IL-1β, TNFα signaling 
also results in the activation of NF-κB, MAPK, and AP-1 transcription factors to induce 
upregulation of inflammatory genes, and is also produced by macrophages following binding of 
pathogen-derived antigens to PRRs [49]. Unlike IL-1β however, following secretion of this 
cytokine, TNFα binds a unique set of receptors that signal through death domains to induce 
activation of transcription factors and their targeted genes or to induce activation of the apoptotic 
pathway [50]. 
 Like IL-1β, TNFα induces proinflammatory changes within the tissue through a number of 
different mechanisms. First, TNFα increases vascular permeability in the insulted tissue by 
increasing cyclooxygenase 2 (COX2) enzyme expression in epithelial cells. This leads to an 
increase in the production of proinflammatory lipid molecules, such as PGE2, which subsequently 
acts to induce vasodilation in the endothelium [49]. Vasodilation of the blood vessels allows for 
increased blood flow, and thus, increased leukocyte infiltration into the insulted tissue. TNFα also 
contributes to the initiation of clotting in wounded tissue through inducing expression of 
coagulation proteins [49]. At the same time, TNFα works to decreases the expression of 
anticoagulation factors. These two functions stimulate clotting at the injury site, a very important 
function of the inflammatory response. TNFα has also been shown to play a key role in septic 
shock, whereby neutralizing TNFα was shown to inhibit detrimental activities of the host immune 
system, such as stress hormone release, and organ dysfunction [49]. In addition to being a key 
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cytokine for the orchestration of the inflammatory response, TNFα is also a potent inducer of 
apoptosis [50]. It is for this reason that tumor necrosis factor α (TNFα) acquired its name; 
however, unlike its name implies, TNFα does not kill most of its target cells, but paradoxically 
promotes survival signals through induction of NF-κB [50]. 
 The third, major cytokine involved in coordinating the inflammatory response is IL-6. IL-6, 
like IL-1β and TNFα also stimulates the activation of the NF-κB pathway, resulting in the 
expression of survival signals, and inhibition of pro-apoptotic pathways within the target 
cells[51]. Additionally, IL-6 induces the activation of the STAT3 transcription factor, through the 
gp130-JAK1/2 pathway. Activation of STAT3 induces the transcriptional upregulation of many 
genes that allow the cells to survive, and resist apoptotic signals within the wound environment 
[51]. In addition to directly inducing transcription changes within its target cells, IL-6 is also a 
powerful inducer of other proinflammatory effector cytokines and chemokines that help to drive 
inflammation, such as MCP-1 [51]. IL-6 not only functions as a localized coordinator of the 
inflammatory response, but also exerts its power over peripheral tissues, such as the bone marrow, 
where this cytokine is a powerful mediator of hematopoiesis[44].  
These cytokines, in addition to many others, work in combination to produce both system 
and localized environments the promote the inflammatory response, and without these small 
molecules, cells of the innate immune response would be unable to effectively remove invading 
pathogen from the tissues, thus rendering the host susceptible to environmental contaminants and 
life-threatening infection. In contrast to proinflammatory cytokines, the anti-inflammatory 
cytokines function to limit the immune response, and to inhibit the proinflammatory cytokines 
from inducing excess tissue damage during response to infection and injury. 
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1.9.2 Orchestrating Immune Suppression 
 Because the inflammatory response results in the production of a radical, hostile 
environment in response to injury or infection, coordination of resolution of the inflammatory 
response is key to limiting excess damage to the host. Although much is known about the onset of 
inflammation, and the characteristics of the tissue repair process, the mechanisms governing 
transition from active inflammation to the resolution phase of the immune response are 
incompletely understood. The general consensus regarding the transition to the resolution phase 
of inflammation is that the wound must first inhibit the influx of inflammatory cells, and then 
must orchestrate the generation of a localized area of immune suppression [3]. Induction of the 
immunosuppressive pathways is an absolutely crucial component of the wound healing program. 
As with all mechanisms that govern homeostasis in the body, the inflammatory response has 
methods to both promote the immune response when necessary, and of course, to inhibit the 
immune response when appropriate. Many types of immune cells are used to orchestrate 
immunosuppression, therefore it can be said that immune cells have dual functionality. Immune 
cells can either enhance or inhibit the inflammatory response, through the generation of specific 
cellular subtypes. These subtypes are created through polarization events, which are primarily 
driven through cytokine signals. The immunosuppressive effector cell subtypes use many 
different methods to control the immune responses, including cell-cell contact through counter 
receptor ligation, and secretion of soluble factors, such as lipid mediators and cytokines [3]. Like 
the onset of inflammation, suppressive functions of the immune system are frequently 
orchestrated by secreted cytokines. Of all the soluble mediators that regulate inflammation, the 
three major cytokine contributors to resolution of inflammation are IL-4, IL-10, and TGF-β [35, 
38, 52]. The following section will discuss, in detail, the major functions of these 
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immunosuppressive cytokines, and their role in establishing localized immune suppression that 
supports tissue repair during inflammation resolution, as the third function of the inflammatory 
response. 
1.9.2.1 IL-10 coordinates the inhibition of active inflammation in the wound site 
 IL-10 is powerful anti-inflammatory cytokine that plays a vital role in the tissue repair 
process [38]. IL-10 is secreted by many cells in response to inflammatory stimuli[36]. This 
cytokine works through many different functions to quell the active inflammatory response in 
favor of promoting the tissue repair process. The first method in which IL-10 suppresses 
inflammation in favor of tissue repair is by limiting the production of inflammatory cytokines 
produced by various cells in the insulted tissue. IL-10 has been show to reduce the production of 
many inflammatory cytokines, including but limited to TNFα, IL-1β, IL-6, and IL-12 [38]. A 
second function of IL-10-mediated inflammation inhibition is the ability for this cytokine to 
drastically reduce the production and secretion of chemoattractants, such as IL-8 and MCP-1 [38]. 
This reduction enhances the inhibition of leukocyte recruitment process that has already been 
established by lipid mediator secretion by the infiltrating neutrophils. Thus, IL-10 helps stem the 
flood of inflammatory leukocytes into the insulted tissue, which allows for the transition of the 
tissue out of the inflammatory condition, and into the tissue repair process. Furthermore, IL-10 
conditions the microenvironment toward a tissue repair-promoting milieu, and in so doing, 
induces the skewing of macrophage and T cell polarization toward immunosuppressive M2 and 
Treg phenotypes [5]. Once polarization of these immune subtypes is induced, they continue to 
promote immunosuppressive conditioning of the microenvironment through secretion of 
immunosuppressive cytokines, including IL-4, IL-13, TGF-β, and of course, additional IL-10 
[34]. IL-10 is also a powerful inducer of STAT3, which is a major transcription factor responsible 
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for driving tissue repair processes, such as cell survival, growth and division, and angiogenesis 
[53]. Through induction of these tissue repair pathways, and by inhibiting the further 
accumulation of inflammatory cells and cytokines within the insulted tissue, IL-10 is a potent 
inhibitor of inflammation in the wound site.  
1.9.2.2 IL-4 and IL-13 coordinate tissue repair processes 
Like IL-10, IL-4 is a pleiotropic cytokine show to have a profound role in orchestrating the tissue 
repair response [54]. Secreted mainly by M2 macrophages and Th2 polarized T cells, IL-4 
functions to inhibit the inflammatory response by inhibiting the polarization of classically 
activated M1 macrophages in favor of tissue repair-supportive M2 cells [5]. Because IL-4 and IL-
13 are secreted by M2 and Th2 cells, and induce further M2 and Th2 skewing, it can be said that 
M2 and Th2 cells promote further generation of their own phenotype. Furthermore, IL-4 and IL-
13, both considered signature cytokines secreted by M2 and Th2 cells, go on to promote the 
expression of tissue repair genes, such as MMP12, EGF, and IL-10, and Arg1 [55]. MMP12, also 
known as macrophage elastase, promotes wound healing by enabling the degradation of 
extracellular matrix components to stimulate tissue remodeling after inflammatory insult. 
Epidermal growth factor (EGF) is a growth factor necessary for promoting many functions of the 
wound healing response. For example, EGF promotes the deposition of fibronectin, induces the 
synthesis of various angiogenic factors, and increases the activity of collagenase [56]. EGF uses 
these pro-repair functions to actively coordinate tissue repair and remodeling of wounded tissue. 
Furthermore, increased secretion of IL-10 works in concert with IL-4 and IL-13 to maintain the 
generation of suppressive phenotype immune cells within the injured tissue. Additionally, it has 
been shown, through the use of various tissue repair animal models, that ablation of the IL-4Rα 
chain results in impaired wound healing [35]. Not only is IL-4 able to stimulate positive effectors 
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of tissue repair, but it is also able in inhibit the proinflammatory effects of classically activated 
immune cells [55]. IL-4 potently suppresses the generation of Th1 and Th17 inflammatory 
responses by increases the activity of transcriptional repressors of IFNγ and IL-17, both cytokines 
that stimulate the inflammatory response [6]. Furthermore, IL-4 plays and indispensible role in 
limiting the inflammatory response by enhancing the production of arginase, which depletes 
arginine in the local environment [35]. Depletion of this essential amino acid potently impairs the 
activation of proliferation in responding T cells, thereby limiting the immune response in favor of 
promotion of tissue repair. Because IL-4, and its shared cytokine signaling partner IL-13, exert 
both tissue repair stimulating activities, and suppress proinflammatory immune cell activities, 
these cytokines are absolutely essential to the coordination of the tissue repair process[35]. 
1.9.2.3 TGF-β facilitates return to homeostasis 
 Transforming growth factor beta, or TGF-β is another cytokine/growth factor that is key to 
the wound healing process. TGF-β is secreted by many cells in the insulted tissue 
microenvironment, including platelets, and macrophages [52]. Its secretion occurs throughout the 
inflammatory and tissue repair processes, and coordinates many different aspects of the healing 
process. The first major goal of TGF-β is to stimulate the formation of the granulation tissue (a 
temporary layer of extracellular matrix components that acts to plug the wound to keep out 
infection) [52]. TGF-β does this by stimulating the production of connective tissue factors, 
including collagen and fibronectin [52]. At the same time, TGF-β acts to inhibit the production of 
MMP molecules that contribute to digestion of the ECM [52]. Next, TGF-β, along with other 
growth factors, acts to stimulate fibroblast proliferation and migration, and stimulates activation 
of angiogenesis to increase oxygenation to support the new tissue growth [33, 52]. As mentioned 
previously, TGF-β, in conjunction with IL-6, and IL-10 works to polarize T cells toward a 
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regulatory subset (Tregs and Th2 subsets) [6]. These cells actively secrete more TGF-β and IL-10, 
which pushes the microenvironment toward an immunosuppressive phenotype by maintaining the 
M2 polarization of the local macrophages [34]. TGF-β has been shown to have pathogenic 
functions as well. During periods of sustained tissue repair signaling, such as chronic 
inflammation and tumorigenesis, excess production TGF-β leads to generation of tissue fibrosis. 
TGF-β has also been demonstrated to support growth and development of tumors [52]. 
1.10 Inflammation is a “Double-Edged” Sword 
As previously stated, the goals of inflammation are to remove harmful stimuli from host 
tissues, in an effort to restore the area to homeostasis; however, production of antimicrobial 
substances by the inflammatory cells, although necessary, also results in many undesirable 
outcomes for the host. This harmful outcomes range from increased local tissue damage, to 
complete loss of function and development of cancer. For these reasons, it is imperative that the 
inflammatory response be tightly controlled in order to limit the tissue damage caused as a result 
of inflammation. 
1.10.1 Acute vs. Chronic Inflammation 
 There are two distinct types of inflammation: acute and chronic inflammation. It is very 
important to distinguish the characteristics of each type of inflammation, as the consequences of 
these cellular processes are vastly different. For example, acute inflammation is usually transient 
in nature, lasting from minutes to hours before undergoing resolution and tissue repair [57]. The 
primary objective of acute inflammation is to flood the insulted tissue with phagocytic 
neutrophils, which are in turn removed by tissue resident macrophages after the insult/pathogen 
has been cleared [6]. On the other hand, chronic inflammation is a prolonged process that can 
persist for years if left unattended. Chronic inflammation is also distinct from acute inflammation 
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because of the mononuclear nature of the exudate. In contrast to the exudate of acute 
inflammation, which primarily consists of polymorphonuclear leukocytes, inflammatory exudate 
from chronic inflammation is characterized as being predominantly mononuclear, including 
monocytes, macrophages and lymphocytes [6]. 
1.10.1.1 Acute inflammation 
The process of acute inflammation is characterized by the quick onset of neutrophil 
recruitment, followed by swift removal of pathogen and/or tissue insult followed by clearance of 
inflammatory leukocytes, and return to homeostasis [3]. This process is very short-lived due to 
the self-limiting nature of acute inflammation, resolving within minutes to hours following the 
initial tissue insult. Acute inflammation is quite a conspicuous phenomenon exhibiting some, if 
not all five hallmarks of inflammation: heat, redness, swelling, pain, and in extreme cases, loss of 
function. Neutrophils are the predominant cells recruited to the injury site during acute 
inflammation. Once in the tissue, neutrophils degranulate, releasing many cytotoxic factors to kill 
invading pathogen [3]. Additionally, neutrophils take up pathogens and necrotic cells by 
recognizing PAMPs and cell death molecules through initiating phagocytosis. As the tissue insult 
is eliminated, leukocytes secrete lipid mediators that work to inhibit leukocyte recruitment, and 
eventually stops the recruitment of circulating leukocytes [28]. After neutralization of the tissue 
insult, neutrophils are either phagocytized by resident macrophages or are recycled back into 
circulation [58]. Once active inflammation is neutralized, the resident tissue cells initiate the 
wound healing program as discussed above. As with the onset of inflammation, the wound 
healing program persists only as long as is necessary to restore the tissue to homeostasis. 
Although the exact mechanisms governing transition to the resolution phase of inflammation are 
not well understood, the necessity for tight regulation of inflammation and resolution is very 
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important in guarding against adverse side effects of the inflammatory response. These 
consequences of dysregulation of the inflammation resolution process can be severe, and will be 
discussed in the following section. 
1.10.1.2 Chronic inflammation 
 In contrast to acute inflammation, chronic inflammation is, as its name suggests, a more 
persistent form of inflammation, lasting from weeks to years in duration [6]. This type of 
inflammation fails to transition to the resolution phase, thus becomes a persistently active 
inflammatory condition. There are many sources that contribute to the onset of chronic 
inflammation, including persistent infection, prolonged exposure to toxins, and autoimmune 
disorders. Although many types of tissue insults may initiate the chronic inflammatory response, 
striking differences between acute and chronic inflammatory characteristics are evident. First, the 
type of leukocytes recruited to the injury site in chronic inflammation are predominantly 
mononuclear, composed of mainly monocytes, macrophages, and lymphocytes [1]. This is in 
stark contrast to the polymorphonuclear neutrophils that comprise the leukocytes exudate during 
acute inflammation. Second, the onset of the inflammatory response is markedly slower during 
chronic inflammation [6]. During acute inflammation, neutrophils are recruited, kill pathogen and 
are quickly removed by the resident macrophages, however during chronic inflammation many 
additional changes within the tissue microenvironment take place. One such change is described 
as macrophage polarization [6]. These cells, along with their monocyte precursors dominate the 
leukocyte exudate during chronic inflammation. Upon entering the tissue, monocytes can further 
differentiate into macrophages, which can then subsequently undergo further polarization steps. 
Macrophage polarization occurs through either of two pathways: classical or alternative [36]. 
During classical activation, macrophages are polarized to provide inflammatory signals either 
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through pathogen recognition or via IFNγ stimulation [5]. These classically activated 
macrophages secrete high levels of antimicrobial factors including ROS and NO [59]. 
Additionally, this polarization serves to perpetuate the inflammatory response by increasing the 
expression and secretion of pro inflammatory cytokines IL-1β, IL-12, and IL-23 [34]. The second 
type of macrophage polarization, alternative activation, is brought about via the presence of 
cytokines in the local tissue microenvironment. These cytokines are often secreted by Th2 cells, 
and function to stimulate the production of “wound healing” cytokines such as IL-10 and TGF-β, 
which serve to polarize the microenvironment toward protected phenotype. These cytokines are 
thought to play a role in coordination of wound repair and tissue resolution [34]. Alternatively 
activated macrophages also secrete growth factors that promote fibroblast proliferation, stimulates 
the generation of new tissue at the wound site [60]. In the case of chronic inflammation, 
monocytes and macrophages are constantly recruited into the insulted tissues, and continue to 
cause damage to the tissue, and eventually undergo polarization events that lead to a persistence 
of leukocytes recruitment and inflammatory mediator secretion followed by cell proliferation and 
extracellular matrix remodeling. Although presence of anti-inflammatory cytokines and growth 
factors during the dysregulation of the inflammatory response seem like they would aid in 
limiting the extent of inflammation-driven tissue damage, during chronic inflammation the tissue 
is unable to reduce the influx of leukocytes to the wound site, inhibiting the transition to the tissue 
repair program [6]. Instead of coordinating tissue repair, alternatively activated macrophages 
produces growth factors that induce a persistent wound healing program by promoting wild 
proliferation of fibroblasts and deposition of extracellular matrix components, that are then 
digested by newly recruited leukocytes and ECM remodeling enzymes. This type of perpetual, 
unresolved cycle of inflammation and wound healing leads to an prevailing immunosuppressive 
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microenvironment rich in DNA damaging ROS and NO, and an abundance of proliferation-
inducing growth factors and cytokines. Taken together, this type of environment is conducive for 
initiating and supporting tumorigenesis [1]. 
1.10.2 IL-17 Drives Chronic Inflammation 
 The proinflammatory cytokine IL-17 has been shown to drive chronic inflammation in 
many diseases, including psoriasis and rheumatoid arthritis, however has also been demonstrated 
to elicit a protective capability in colitis models. Il-17 in mainly produced by activated CD4+ 
Th17 cells. In psoriasis and rheumatoid arthritis, IL-17 perpetuates the activity of the 
inflammatory response by stimulating the production of proinflammatory cytokines, chemokines 
and growth factors. Specifically, IL-17 has been shown to drive the production of IL-6, IL-1β, 
TNFα, GM-CSF, G-CSF, IL-8 and CCL20 in a multitude of cell types. Additionally, IL-17 can 
synergize with the proinflammatory activities of TNFα and IL-1β produced from the initial 
inflammatory insult. Enhanced expression of the proinflammatory cytokines IL-6, IL-1β, and IL-8 
work to sustain the recruitment of inflammatory leukocytes, such as neutrophils and monocytes 
into the wound, where the secrete toxic compounds that destroy tissue cells. Furthermore, IL-17 
drives the enhanced expression of CCL20, which serves as the major chemokine for the 
recruitment of T cells. Accumulation of activated Th17 cells within the wound site further 
contributes to the generation of IL-17, which perpetuates chronic inflammation within the wound. 
IL-17 also stimulates enhanced expression of the growth factors GM-CSF and G-CSF. These 
growth factors drive the proliferation of new tissue within the wound, but also function as a stress 
signal. Although incompletely understood, it is possible that through enhanced production of IL-
17, induces upregulation of GM-CSF and G-CSF within the bone marrow, which drive the 
emergency hematopoiesis program.  
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1.10.3 Chronic Inflammation Increases Cancer Risk 
For some time, chronic inflammation has been closely linked to, and is now considered a 
risk factor for the development of cancer in many tissues. Research by many groups suggests that 
unresolved inflammation increases the probability of tumor formation through two general 
pathways [61]. First, chronic inflammation results in the unabated recruitment of inflammatory 
leukocytes. As previously discussed, the infiltrating leukocytes enter the tissue and secrete cell-
damaging substances. Neutrophils release superoxide radicals non-specifically into the affected 
tissue, with the intention of causing damage to the DNA of invading pathogens. Because this 
process is not directed toward pathogen in particular, but is rather a more general process, the host 
tissue is also at risk for DNA damage [61]. Any breakages in the DNA of surviving cells will be 
repaired by the DNA breakage repair enzymes; however, as a result of this process, point 
mutations are introduced into the cell’s genome. If introduced into the DNA of an oncogene, such 
as a growth factor receptor or cell cycle kinase, then these mutations can result in unchecked cell 
growth leading to the development of neoplastic cells that can grow into tumors [61, 62]. In 
addition to introducing genetic mutations in the host tissue cells, chronic inflammation also 
results in the prolonged production and secretion of proinflammatory cytokines both locally and 
systemically, which continue to promote the recruitment of damaging leukocytes [61]. 
Proinflammatory cytokines are the first step in an inhibitory feedback loop that drives the tissue 
repair process, therefore promotion of proinflammatory mediator generation also encourages the 
production of tissue repair molecules, such as growth factors and remodeling enzymes.  
The second pathway that is thought to contribute to chronic inflammation’s role in tumor 
formation is the prolonged activation of the wound healing program [61]. As mentioned 
previously, the wound healing program is initiated by the onset of inflammation, and during acute 
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inflammation is the self-limiting, terminal process of the inflammatory response. Unlike acute 
inflammation, the wound healing program during chronic inflammation begins anew following 
each new wave of inflammatory cell infiltration. This process, when tightly controlled is 
absolutely necessary to inhibit further recruitment of inflammatory leukocytes and thus, limits 
further unnecessary damage to the tissue. The wound healing process is designed to inhibit further 
inflammation and protect the inflamed environment by creating a local temporary 
immunosuppressive, proliferation supporting microenvironment [33]. During chronic 
inflammation, this activation of the tissue repair-promoting process is prolonged and sustained, 
which results in an environment rich in anti-inflammatory and proliferative growth factors [6]. 
This results in a decrease in immunosurveillance in a tissue environment that is rapidly growing 
and dividing. Taken together with the increase in the DNA mutation rates from the free radicals 
generated by the inflammatory leukocytes, chronic inflammation works to create an environment 
that is well suited to initiate and sustain neoplastic cell formation and tumor immune escape. 
In the process of chronic inflammation the inflammatory stimuli persist, which results in the 
unlimited activation of the inflammatory response. As described previously, the initiation of the 
inflammatory process also induces the activation of the tissue repair process. As part of this 
process, the tissue cells, inflammatory leukocytes, and adaptive immune cells work in concert to 
inhibit further inflammatory function, and to stimulate fibroblasts to proliferate and secrete factors 
that help to restore the tissue to homeostasis [61]. During chronic inflammation, this system is 
dysregulated, which results in what has been described as an “unhealing” or “overhealing” wound 
[60]. The “unhealing” wound is described as a region of inflammation that does not resolve to 
homeostatic conditions [60]. Dysregulation in the transition between inflammation and tissue 
repair often results in both systems being active simultaneously [61]. Activation of the early 
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inflammatory response and wound repair process is dangerous because it creates an environment 
rich in both inflammation stimulatory factors, including IL-6, IL-1β, and TNF-α, and rich in 
immunosuppressive factors, including IL-4, IL-10, and TGF-β. These “mixed signals” result in a 
wound that constantly initiates the tissue repair process, but is unable to reduce the 
proinflammatory leukocytes infiltration. Thus, immune cells are recruited to the site of 
inflammation, damage the tissue, then become transformed into cells that drive wound healing, 
including M2 and Th2 phenotype effector cells [57]. 
1.10.3.1 Wound healing environment establishes localized immunosuppression 
 In order for newly established neoplastic cells to survive, and eventually grow into a tumor 
mass, they must first escape detection and removal by the immune system. One such mechanism 
of immune escape is closely tied with the hallmark characteristics of the tissue repair response 
[60]. In order to stem the flow of inflammatory leukocytes into the site of inflammation, many 
immunosuppressive factors are secreted into the local environment. These factors include anti-
inflammatory cytokines, such as IL-10, IL-4, and TGF-β [63], and lipid mediators, including 
protectins, resolvins, and lipoxins [30]. These soluble factors have many different targets, but all 
function in concert to produce a microenvironment is protected from aggressive, proinflammatory 
cells and supports cell proliferation and return to homeostasis. One such example is the secretion 
of anti-inflammatory mediators is IL-10, which causes tissue macrophages to polarize into type 2 
macrophages [57]. These cells produce soluble factors including IL-4, IL-13, IL-10, TGF-β, 
PDGF, and VEGF that promote tissue growth and development, while also inhibiting the 
inflammatory immune response [34]. These factors have many different targets including the 
promotion of further M2 polarization, the differentiation of activated T cells into Tregs, and the 
promotion of proliferation and angiogenesis [34, 64]. Tregs decrease the proliferative ability of 
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both CD4+ and CD8+ T cells, as well as convert professional antigen presenting dendritic cells 
into T cell killing cells [65]. These mechanisms decrease the likelihood that antigen presenting 
cells will present tumor antigen to the local T cells, thus increasing the survival capability of the 
neoplastic cell. With every neoplastic cell division, the tumor will become more difficult to 
eliminate, and will exert greater influence over the immune system both locally and systemically. 
Many mechanisms supporting immune evasion exist, however chronic inflammation drastically 
increases the chances of neoplasm survival by combining increased risk of abnormal cell 
generation with immune suppressive systems in a predominantly proliferative microenvironment 
[61]. 
1.11 Inflammatory Bowel Disease 
Colitis is a prime example of a chronic inflammatory disorder that often proceeds to the 
development of cancer as a result of sustained tissue damage. Through many studies conducted in 
both animal models and in the clinical setting, it is widely acknowledged that colitis-associated 
cancer is heavily dependent on the initiation of sustained colon inflammation, and that curbing 
such inflammation is absolutely crucial to limit the incidence of colon cancer in the clinic. 
1.11.1 IBD: UC and CD 
 Affecting 1.4 million Americans each year, inflammatory bowel disease (IBD) is comprised 
of two distinct, yet related types of chronic gut inflammation: Ulcerative colitis and Chron’s 
disease[66]. While symptomatically similar, these two varieties of chronic bowel inflammation 
differ tremendously upon closer inspection. Ulcerative colitis is characterized as inflammation of 
primarily the colon, whereas Chron’s disease is typically not limited to the colon tissue, but rather 
describes inflammation of all parts of the intestinal tract [67]. Additionally, Chron’s disease 
patients can be described as having multiple areas of inflammation throughout the intestine in a 
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“patchy” pattern, while ulcerative colitis is usually a more uniform inflammation of the whole 
colon, even extending to the rectum [67]. Furthermore, ulcerative colitis generally describes 
inflammation that is limited to the colonic mucosa, whereas Chron’s disease often presents as 
transmural, spanning the entirety of the intestinal wall[67, 68]. Although not yet entirely 
elucidated, many studies have determined that host-microbial interactions play a large role in the 
presentation of inflammatory bowel disease, however these mechanisms differ with regard to the 
type of IBD. 
 Over the course of many years using both human and animal studies, researchers have 
determined that there are a number of factors that govern inflammatory states of the bowel. 
Studies have defined that the intestinal epithelium relies heavily on commensal gut microbiota for 
digestion of food, production of essential nutrients, and development of the immune system, 
primarily induction of immune tolerance [4]. These microbes, although essential to the function of 
the digestive system also play a role in the induction of inflammatory bowel disease, as 
demonstrated by experiments performed in germ-free mice. These mice do not possess gut 
microbiota, and therefore cannot be used as a model for human colitis, as they do not develop 
colitis even after treatment with established colitis-inducing chemicals such as DSS [69]. The 
types and diversity of commensal microbiota present in the intestine have been demonstrated to 
influence the inflammatory state of the bowel. For example, patients presenting with either type 
of IBD tend to lack microbiota from the phyla Bacteroidies and Firmicutes in their intestinal 
epithelium, and usually recover from IBD flare ups when these organisms are re-introduced to the 
intestine through a procedure known as fecal transplant [4]. 
 The onset of IBD has also been attributed to defects in the epithelial cell junctions leading 
to increased gut permeability [69, 70]. Goblet cells of the intestinal epithelium are responsible for 
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secreting mucus that acts as a natural barrier between the microbiota and the epithelium. In 
addition to this transient barrier, the epithelial cells function as a physical barrier between the 
microbe-exposed lumen and the antigen-responsive immune cells residing in the lamina propria. 
Tight junctions present at the apical side of the lumen-exposed epithelial cells prevent 
microorganisms, and their pathogen-associated molecular antigens (LPS, peptidoglycan, flagellin) 
from breaching the sterile lamina propria [70]. Furthermore, resident dendritic cells extend 
dendrites between the epithelial tight junctions into the lumen and uptake antigen in a process 
called “antigen sampling.” Once the antigens have been taken up by the dendritic cells, they are 
presented to the gut-associated lymphoid tissues (GALTs) [6]. This process does not however 
result in an inflammatory response, but rather works to induce tolerance of commensal microbes 
and reduces the inflammatory immune response to commensal microbiota. In contrast, if the tight 
junctions between epithelial cells become compromised, influx of pathogen-associated molecular 
antigens come in contact with resident immune cells in the lamina propria, and the inflammatory 
response begins. Although meant to inhibit the invasion of pathogen into the sterile LP, 
inflammation only serves to exacerbate the permeability of the epithelium, leading to persistence 
of the inflammatory insult [67]. 
 Genetic factors have also been shown to play a role in regulating the onset of inflammatory 
bowel disease, although genetic mechanisms of IBD are usually confined to Chron’s disease [67]. 
For this reason, Chron’s disease has a much higher degree of familial association as compared to 
ulcerative colitis [67]. Polymorphisms that govern the CD are found in a multitude of genes of 
varying function. One such gene contributing to CD is a mutation within the prostaglandin E4 
(PGE4) receptor. PGE4 is a small lipid molecule that is responsible for promoting repair of 
epithelial barrier function. In both humans and mice, mutations or complete deletion of this 
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receptor renders the host susceptible to CD [67]. Genetic deficiencies in mucin protein have also 
been identified as regulators of gut inflammation. Many other genetic polymorphisms 
contributing to IBD exist, however not all of them are directly related to maintenance of the 
epithelial barrier. Some polymorphisms alter the immune response to antigen sampling. Instead of 
producing a tolerogenic outcome, changes to the cytokine signaling network receptors such as IL-
23 and IL-12b can result in the lack of inflammatory inhibition [67]. If cells become unable to 
recognize cytokine mediators that are responsible for inhibiting the immune response, then 
accumulation of immune cells in the lamina propria indirectly results in altered barrier function 
and enhanced permeability [70] 
1.11.2 Current Treatment Strategies for IBD 
1.11.2.1 Drugs 
Many drug-centered therapies currently exist for the treatment of IBD, both CD and UC. 
These drugs range typical anti-inflammatory non-steroidal anti inflammatory drugs (NSAIDs) to 
corticosteroids, and even antifungals and anti-anaerobic antibiotics [71]. The typical progression 
of IBD treatment is to begin with aminosalicylate therapy, which are aimed at minimizing the 
inflammatory response, thus these drugs are ideal for reducing CD and UC flare ups, but should 
be noted that this category of therapeutic drug has had much more success in treating patients 
with UC [71]. Although their exact mechanism of action is unknown, many have proposed that 
aminosalicylates decrease the production of leukotrienes and IL-1 [72]. This treatment technique 
may also be combined with probiotic therapies to maintain the diversity of the gut microbiota. If 
aminosalicylate treatment is unsuccessful, additional drug-based therapies may be attempted. The 
next suggested therapy is corticosteroid therapy. This strategy targets inhibition of the 
inflammatory response in favor of tissue repair [71]. Although effective, corticosteroid treatments 
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have some significant drawbacks. Because they work to inhibit immune function, corticosteroids 
cannot be used as a maintenance therapy, and often result in unwanted side effects such as 
endocrine dysfunction, osteoporosis, and psychosis [71]. Therefore it is important that other, more 
specific types of therapies be used as a method for controlling gut inflammation. Other methods 
of treatment include drugs that limit the colonization of certain types of gut bacteria using 
antimicrobial pathways. 
1.11.2.2 Management of microbiota diversity 
 If initial treatments using drug-based therapies are unsuccessful, then more creative 
methods must be used to control the insulting gut inflammation. Recently, regulation of 
microbiota diversity has presented itself as a potential target for IBD therapy [4]. There are two 
methods that are used to control the microbiotic diversity. First, is the use of antibiotics to limit 
the many species of gut bacteria known to specifically exacerbate inflammation, and second is the 
use of probiotic suspensions to increase the population of bacteria known to drive tolerogenic 
effects within the colon environment [4, 71]. In either case, the goal is the same, to shift the 
diversity of microbial flora present in the colon to a tolerance-inducing phenotype. Additionally, 
commensal bacteria that are tolerated by the host typically help their human host with specific 
tasks, such as digestion, which, presumably is why they do not induce an inflammatory response 
in the host [4]. Additionally, maintaining the numbers of commensal microbiota helps the entire 
microbiotic system outcompete the pathogenic microorganisms. This is helpful to the human host 
because opportunistic pathogens can only exert their virulence if they are allowed to attach to the 
intestinal mucosa [4]. Maintaining high levels of non-pathogenic bacteria in the gut reduces the 
risk for attachment of pathogens because bacteria directly compete with one another for space and 
resources [4]. Clinical trials using probiotic therapy has yielded profound results for patients 
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suffering from Chron’s disease [4]. These results show a potent reduction in relapses compared to 
placebo treated patients, reducing the number of relapses from 100% to just 15% in 9 months 
[73]. This type of therapy has been less studied in ulcerative colitis patients, however clinical 
trials are in progress. Probiotic therapy is an extremely favorable method of IBD treatment due to 
its relatively low cost, ease of administration, and availability to the consumer. Often, these 
probiotics can be found in bacterially cultured foods such as yogurt and fermented foods, making 
them easily accessible to the public [73]. A new method of introducing tolerogenic microbes into 
the colon is fecal transplant. This is the process by which donor feces (containing the total 
microbiotic suspension) are transplanted into a recipient either by oral or rectal routes [71]. This 
treatment is typically reserved for patients who have stopped responding to, or are resistant to 
antibiotic and probiotic therapies. Because antibiotic treatments reduce the helpful commensal 
bacteria, as well as the pathogens, fecal transplant is often used in patients who suffer from 
Clostridium difficile infections brought on by antibiotic treatments [4]. Although in early stages of 
development, this method of microbiota management has become a promising therapeutic avenue 
to be pursued for the treatment of IBD. 
1.11.2.3 Immunomodulators to control immune response 
 Perhaps one of the most important developments made in the treatment of chronic 
inflammatory diseases is the blockade of proinflammatory cytokines. Since their initial 
application, cytokine inhibitors have become widely prescribed method of controlling 
hyperstimulation of the immune response during many chronic inflammatory disorders, including 
RA, psoriasis, and IBD [50, 74]. The major therapeutic immunomodulator group is the TNFα 
inhibitor family, which include three related, albeit subtly different therapeutic molecules. The 
first anti-TNFα molecule is Infliximab (IFX) [71, 75]. This molecule is a chimeric 
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(mouse/human) antibody that works by binding to excess TNFα, thereby neutralizing its pro-
inflammatory ability [75]. IFX has been shown to greatly reduce the occurrence of IBD symptoms 
in both UC and CD, and has also proven to limit the number of relapsing episodes in patients with 
IBD [75]. The second type of anti-TNFα biologic molecule is adalimumab (Humira) [75]. This 
human recombinant monoclonal antibody is most well known as a rheumatoid arthritis treatment, 
but has also been approved as therapeutic treatment for Chron’s disease, psoriatic arthritis, and 
plaque psoriasis [75]. Both IFX and adalimumab are capable of neutralizing both soluble and 
membrane-bound forms of TNFα, functioning to repress the proinflammatory, and apoptosis-
inducing activities TNFα exerts on its target tissues [75]. A third type of anti-TNFα antibody is 
unique due to its pegylated region. Instead of possessing the usual Fc conserved antibody region, 
which can be recognized by Fc receptors present on phagocytic cells, certolizumab pegol is a 
monoclonal antibody that instead contains a polyethylene glycol polymer attached to the antigen 
binding domains [75]. Because this antibody does not contain the Fc domain, it is effectively 
unrecognizable to the immune system, which increases its viability within the tissue. Collectively, 
these anti-inflammatory, TNFα-neutralizing treatments have been extremely successful for the 
treatment of Chron’s disease and ulcerative colitis.  
 As IL-17 is the major proinflammatory cytokine upregulated during both Chron’s disease 
and ulcerative colitis, blockade of IL-17 has been developed and investigated as a treatment for 
IBD [74]. Many pre-clinical experiments were carried out to determine whether blocking IL-17 
would significantly impact the severity of colitis symptoms in mice. Interestingly, blockade of IL-
17 using antibodies or small IL-17 drug inhibitors in many different colitis models was either 
ineffective or even worsened the disease activity in colitic animals [74]. Similarly, clinical trials 
using IL-17 receptor antibodies secukinumab and brodalumab proved ineffective at reducing 
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disease activity in these patients, even to the point of aggravating the colitis symptoms in Chron’s 
disease patients. The small chemicals vidofludimus and tofacitinib, however, proved effective at 
limiting colitis symptoms in both UC and CD [74]. These data suggest that although IL-17 
undoubtedly plays a role in regulating the inflammatory response during colitis, blockade of IL-
17 is not enough to inhibit the disease activity in IBD patients, and that the role of IL-17 in colitis, 
and other chronic inflammatory conditions is incompletely understood. 
1.11.2.4 Future of IBD treatment 
 Many of the factors that are responsible for inducing, and sustaining the inflammatory 
response during colitis are currently unknown. More studies are being conducted to determine the 
role of IL-17 in the inflammatory response, and seek to understand why blockade of this 
important inflammatory regulator does not inhibit the immune response in a clinical setting. 
Additionally, it is important to strive for improvement within the current anti-inflammatory 
biologics, specifically anti-TNF-α therapies, as reducing activity of such master regulators of the 
inflammatory response can often lead to undesirable side effects, including susceptibility to 
infection as certain types of cancer [50]. By adding to the information the scientific community 
understands about the mechanisms that govern colitis, and the dysregulation of the inflammatory 
immune response, we can hope to improve the efficacy of anti-inflammatory immune therapies 
[76].  
1.11.3 Animal Models of IBD 
1.11.3.1 Introduction to various models 
Since the identification of inflammatory bowel disease, and the recent increase in disease 
prevalence, predominantly in western society, many models of ulcerative colitis and Chron’s 
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disease have been generated using a wide variety of animal species [77]. The most commonly 
used being the rat and mouse models. Additionally, each animal model has been generate to 
mimic the specific pathophysiological presentations of either ulcerative colitis or Chron’s disease. 
Many approaches have been taken to induce colitis in these models, and accordingly, each model 
presents advantages and drawbacks. These model approaches include various methods of colitis 
induction including chemical, microbial, and transgenic manipulation of the model animals to 
establish the specific characteristics of inflammatory bowel disease to be studied [77]. The 
following discussion will explore the characteristics, advantages, and drawbacks of several 
commonly used colitis models, and will discuss how each model is tailored to specifically 
investigate the mechanisms of disease progression and treatment strategies for both types of 
inflammatory bowel disease. 
1.11.3.2 Chemical inducers of colitis 
 Many chemicals are able to induce colitis symptoms in mice and rats, such as oxazolone, 
acetic acid, and TNBS; however, many of these chemicals must be administered rectally and 
therefore present difficulty of use to the researcher [77]. Therefore, this portion of the 
introduction will focus solely on the chemical DSS, which is administered orally, and will be used 
as the basis of our experimental model. 
1.11.3.3 Dextran sulfate sodium (DSS) 
Among the most commonly used methods of chemically induced colitis is DSS, which is 
typically administered orally in mice and rats. These sulfated sugar chain molecule acts like a 
detergent in the colon, inducing chemical injury in the epithelium of the intestinal mucosa, 
thereby facilitating introduction of microbial pathogen into the lamina propria of the colon. Due 
to the prevalence of antigen-detecting resident immune cells in the sterile environment of the 
  62 
lamina propria, the inflammatory response is quick to follow epithelial injury [77]. This response 
is characterized by markedly enhanced production of inflammatory mediators such as IL-1β, 
TNFα, IL-6, and IL-8 [69], which results in recruitment of circulating inflammatory monocytes, 
macrophages, and most predominantly PMN. This model can be used as a method of assessing 
both acute and chronic colitis; however, chronic colitis induction requires multiple rounds of DSS 
administration, or continuous, low dose administration [77, 78]. Characteristics of DSS-induced 
colitis include rapid weight loss, loss of colon epithelial tissue, crypt architecture disruption, 
bloody stool, and increased fecal lipocalin [79]. The DSS colitis model is a rapid, and effective 
method of colitis induction, and is self-limiting. Once the DSS is removed, the inflammatory 
response abates quickly in favor of tissue recovery [77]. Colitis-associated disease characteristics 
are easily measured, and most of them do not require euthanasia of the animals. This presents a 
significant advantage because it reduces the expense of the study and allows this model to not 
only be applied to studies of active inflammation during colitis, but can also be used to address 
periods of colitis recovery. DSS is routinely administered in the drinking water, and because of 
the nature of preparation and administration is an easy model to work with when assessing colitis. 
The DSS model of colitis is also advantageous due to the ease of dosage control [78]. Although 
DSS administration is a preferred method of inducing colitis in mice and rats due primarily to 
ease of use, there are significant drawbacks to consider when selecting a colitis model. The first 
disadvantage to the DSS model system is the large variability in susceptibility and disease 
progression between test subjects. Additionally, sex of the animals is also cause for consideration 
with use of DSS, as male mice are more susceptible to colitis-associated pathophysiology in this 
model [77]. Strain of the animals used can also greatly impact the results of a DSS-induced colitis 
study due to the mechanism of action of DSS-induced colitis. Mice that exhibit alterations to their 
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innate and/or adaptive immune cells may have delayed colitis onset, and in come cases may 
render the animals resistant to colitis [78]. Additional factors that pose disadvantages to the DSS-
induced colitis model concern the effectiveness of the DSS itself. The DSS chemical differs 
widely among manufacturers, as well as between lots/batches. The variations in chemical 
formulations available also range in purity and size of the DSS molecules [78]. The facility that 
houses the experimental animals also impacts the susceptibility and severity of the colitis model. 
For example, the specific commensal and pathogenic microorganisms that are present within the 
animal housing facility can greatly impact the results of the colitis study, and can influence the 
severity and presentation of the colitis [77]. Another drawback of the DSS colitis model is 
expense. DSS is a more expensive method of inducing colitis than other chemical methods. It is 
for these reasons that other colitis models have been developed for examining colitis mechanisms. 
1.11.3.4 Microbial pathogen inducers of colitis 
 In addition to chemical inducers of colitis, many models of colitis use bacteria to directly 
induce inflammation of the colon. Some bacteria that are capable of directly inducing colitis are 
Salmonella typhimurium, S. dublin and adherent-invasive E. coli [77]. Because these methods do 
not use chemical means to disrupt the colonic epithelium, some researchers argue that these 
techniques result in colitis that more closely resembles the probable onset of human colitis. 
However, these systems use gavage administration methods, and often lead to complications such 
as septicemia in the experimental animals [77]. 
1.11.3.5 Transgenic and knockout mice as inducers of colitis 
 In addition to both chemically- and microbial-induced methods of experimental colitis, 
several transgenic and knockout mice models have also been established to assess the 
mechanisms underlying the onset and maintenance of colitis in vivo. Two examples of these 
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animal models are the IL-2 and IL-10 knockout strains of mice. Both of these strains of mice 
spontaneously develop colitis [77]. Interestingly, for these mice to develop colitis, both of these 
experimental model animals must be housed in the presence of commensal bacteria, as germ-free 
mice do not develop colitis symptoms, highlighting the importance of the microbiotic component 
during colitis [77]. Because animals used in these models are genetically modified to have 
specific immune cell deficiencies, they are typically used for more targeted studies of the immune 
system during inflammation, and therefore will not be used as the basis for our study. 
1.11.3.6 Justification for DSS-induced model choice 
 In this particular study, we found that using the DSS model of colitis was the most 
appropriate choice for examining the inflammatory mechanisms of wound healing during colitis. 
In addition to its ease of delivery (drinking water), DSS-induced colitis offers many other 
attractive advantages. First, this model mimics ulcerative colitis that can be reversed upon 
elimination of the DSS administration. Because this study examines the role of tissue repair in the 
generation of MDSC, recovery from colitic inflammation is a necessary attribute the model. The 
DSS colitis model also offers ease of inflammatory phenotype measurement. In this study we 
endeavored to establish a timeline of inflammation and tissue repair, therefore it was a 
requirement that the model used in our study would yield easily quantifiable symptoms of disease 
progression and severity. The DSS method of colitis induction produces observable symptoms of 
inflammation, that can be traced over time, such as body weight loss, stool consistency, blood in 
feces, colon tissue loss, and fecal lipocalin levels. Furthermore, because DSS-induced colitis is 
established using a highly controllable method of chemical administration, this model will afford 
us the ability to establish a recovery period, and thus allow us to trace the inflammation recovery 
process, an impossible task for other models of colitis. It is for these reasons that the DSS-induced 
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model of colitis was chosen for our study. 
1.12 Lipocalins as Diagnostic Markers of Inflammation 
 Lipocalins are small lipophilic proteins secreted by bone marrow-derived cells and luminal 
epithelial cells. Members of the lipocalin family are typically very small proteins composed of 
eight strands of anti-parallel β-barrels, surrounding a core pocket of hydrophobic amino acid side 
chains [80]. This hydrophobic core can be either very selective for substrate, or very promiscuous, 
binding to many lipophilic molecules, including prostaglandins, fatty acids, retinoids, and 
cholesterol-based hormone/steroid-like molecules [80]. Members of this family of proteins have a 
wide variety of functions, including lipophilic molecule transport, immunomodulation, and 
regulation of cell senescence. Lipocalins are capable of forming large secreted macromolecular 
complexes, and are often secreted as covalent complexes with other proteins [80]. The underlying 
mechanism for this covalent linkage between molecules is not entirely understood, however 
studies using lipocalin 2 (NGAL) and matrix metalloproteinase 9 (MMP-9) suggest a regulatory 
role for the lipocalin, which has been found to limit the gelatinase function of MMP-9 when in 
complex. Lipocalins can therefore, be thought of as multifunctional secreted proteins; at their 
core, lipocalins primarily function as transporters of hydrophobic molecules, but also play 
additional roles in modulating cell function [80]. 
 Neutrophil gelatinase-associated lipocalin is one member of the lipocalin family. This 
protein, also called NGAL and lipocalin, is 25 kDa in size, and forms various associations with 
itself, and other secreted proteins, and has been demonstrated as a useful clinical marker of 
inflammation [16]. Originally isolated as a covalently bound protein to matrix metalloproteinase 9 
(MMP-9), human NGAL has since acquired many other names including, uterocalin, and 
oncogene 24p3. This 25kDa protein was found to exist as a monomer, a homodimer, and as a 
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heterodimer in complex with MMP-9. Soon after identification of the human protein NGAL, the 
murine homologue was discovered. Possessing 62% sequence homology, LCN2 is considered the 
murine form of NGAL, and also forms these dimeric associations in mice.  
 NGAL protein, and its murine homologue LCN-2, are primarily expressed in bone marrow-
derived cells, specifically neutrophils, and are inducible in epithelial cells of luminal tissues. In 
neutrophils, NGAL/LCN-2 are generated and packaged into specific granules [81]. This 
packaging indicates that neutrophils tightly regulate the secretion of these molecules, only when 
the neutrophils become activated by some inflammatory stimulus (i.e. transmigration into 
inflamed tissues). Additionally, only epithelial cells that are constantly exposed to 
microorganisms secrete NGAL/LCN-2, and unlike neutrophils, these cells constitutively secrete 
basal levels of NGAL/LCN-2 into the microbe-exposed lumen.  One known function of lipocalins 
is to bind small, hydrophobic peptides shed by bacterial or fungal pathogens [81]. These 
hydrophobic molecules have been identified as siderophores: small, bacterially produces iron-
scavenging molecules. The ability for NGAL/LCN2 to act as a sponge for these bacterial survive 
molecules illustrates an antimicrobial function for this protein [15]. 
 In recent studies, additional functions have been proposed for NGAL/LCN2. Perhaps most 
obviously, NGAL/LCN2 has been shown to be markedly upregulated during persistent infections, 
such as sepsis, chronic inflammation, and cancer [16]. In contrast to the tightly regulated and 
limited release of NGAL/LCN2 from inflammatory PMN during acute inflammation, this 
enhanced production of NGAL/LCN2 during persistent inflammation and infection is attributed to 
induced expression primarily in the luminal epithelium via stimulation by inflammatory 
cytokines, specifically the IL-1, and IL-17 cytokine families [16, 81]. Stimulation of epithelial 
cells with IL-1β results in activation of the TIR domains within the IL-1 receptor, resulting in 
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activation of downstream transcription factor NF-κB, which leads to enhanced transcription of 
lcn2 [16]. In addition to activation of transcription via IL-1β, induction of NGAL/LCN2 
transcription in epithelial cells can be accomplished at later stages of inflammation by IL-17 [16]. 
Although the IL-17 receptor complex lacks a true TIR domain, it does possess a similar signaling 
domain SEFIR. Activation of the IL-17 receptor similarly initiates activation of NF-κB the SEFIR 
domain, which increases transcription of lcn2 [16]. IL-17 also stimulates the activation of C/EBPβ 
and δ through activation of the CBAD domain on IL-17RC [82]. Activation of C/EBP molecules 
results in two contrasting functions. At early IL-17 stimulation time points, C/EBPβ becomes 
activated, travels to the nucleus, and robustly enhances lcn2; however, in later IL-17 stimulation 
time points, C/EBPβ becomes hyperphosphorylated by ERK and GSK3β, resulting in 
sequestration in the cytosol [83]. This pathway appears to function as a method of feedback 
inhibition to limit the transcription of lcn2 and thereby limiting the amount of secreted 
NGAL/LCN2. 
 It is important that NGAL/LCN2 expression and secretion be regulated in epithelial cells, as 
this protein is a potent immunomodulator [16]. In addition to being a sink for collection of metal 
scavenging molecules, NGAL/LCN2 functions to limit the immune response by inhibiting 
secretion of proinflammatory cytokine from M1 macrophages and by transforming classically 
activated M1 macrophages into immunomodulatory M2-like “deactivated” macrophages [84]. A 
study performed by Zhang et al. in 2008 demonstrated that treatment of classically activated 
macrophages with LCN2 and LPS resulted in a complete inhibition of production of inflammatory 
factors IL-1β, IL-6, MCP-1, TNFα, GM-CSF, and iNOS 20 hours post LPS stimulation [85]. 
These data demonstrate a powerful anti-inflammatory tissue protective function for NGAL/LCN2 
during inflammation. In addition to this staggering finding, Warszawska et al. have since 
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demonstrated that LCN2 is highly expressed in “deactivated” macrophages-a subtype of 
alternatively activated macrophages [84]. In addition to this finding, the authors also reported a 
new function of LCN2, the induction of “deactivated” macrophage polarization. Upon treatment 
of bone marrow-derived WT or Lcn2 -/- macrophages with classically activating stimuli (S. 
pneumoniae), Lcn2 -/- macrophages produced significantly more proinflammatory cytokines 
including, KC, TNFα, and IL-6 than the WT macrophages. Furthermore, the authors reported 
increased expression of IL-10 in these “deactivated” macrophages [84]. This data suggests that 
LCN2 plays a role in skewing the polarization of macrophages toward an immunosuppressive, 
tissue repair-supporting, protective phenotype. These data taken together support the hypothesis 
that NGAL/LCN2 has multiple functions in governing the immune response. The first function is 
to inhibit the growth of microorganisms by limiting their access to freely available iron [16]. The 
second function is to protect the host from the detrimental effects of the sustained inflammatory 
response during an infection [84]. 
Enhanced NGAL/LCN2 expression has also been observed in cancer patients, and has even 
been proposed as a potential diagnostic marker[16]. Increased expression of LCN2 has been 
documented in many cancer presentations including, prostate, breast, ovarian, brain, lungs, liver, 
stomach, and pancreatic cancers[16]. In addition to being widely expressed by tumor tissue, 
LCN2 may play a tumor-supportive role during cancer progression. Like other 
immunomodulatory systems, many hypothesize that LCN2 may become coopted by neoplastic 
cells to support growth and serve to generate an environment that is protected from 
immunosurveillance [81, 86, 87]. In support of this theory, LCN2 overexpression studies in breast 
cancer models have demonstrated that LCN2 induces transformation of neoplastic cells to a more 
aggressive phenotype, which is characterized by the loss of contact inhibition and progression to 
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the epithelial-mesenchymal transition (EMT) [16]. This allows the neoplastic cells to invade and 
metastasize to other tissues [87]. Studies performed in colon cancer models corroborate the theory 
that high expression of LCN2 contributes to the invasiveness of neoplastic cells, and that levels of 
LCN2 expression correspond well with the clinical stage of tumor diagnosis [88] The type of 
molecular complex LCN2 forms also seems to determine its function in tumor progression. For 
example, in glioblastoma brain cancer patients, high levels of secreted LCN2 are found almost 
exclusively complexed with MMP-9, which serves as a faithful biomarker for measuring the 
severity of disease [89]. 
 The idea that NGAL/LCN2 is a good biomarker candidate for measuring disease 
progression is not limited to cancer. This protein has also been used as a diagnostic marker for 
sepsis and chronic inflammation, particularly colitis [15, 79] Although LCN2 can be used as a 
non-invasive biomarker in clinical application settings, it is perhaps most frequently used as a 
criterion for assessing disease progression in animal models of inflammation such as 
inflammatory bowel disease. In contrast to other methods of assessing disease progression, 
measurement of fecal LCN2 is a more sensitive, quantitative test for determining colitis-
associated inflammation in animals [79]. Traditional inflammation assessment methods are often 
more subjective, or are based on vague disease activity index scoring criteria such as body weight 
and stool consistency. Other criteria for assessing disease activity often involve collection of body 
tissues, which requires sacrifice of the animal in order to determine the full scope of the disease 
activity. Another advantage to testing of LCN2 in body fluids is that it is a less invasive 
technique, and does not require sacrifice of the animal. Additionally, this means that animals may 
be monitored as “repeated measures” subjects. The advantage to using this method in animal 
models is that one can observe the disease progression of a single animal over time, and this 
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allows the researcher to determine the disease state of the animal in real time, without having to 
sacrifice an animal only to determine that the predicted disease activity index is contrary to the 
disease activity index determined by terminal necropsy. LCN2 is also an incredibly stable 
molecule [79], making it an ideal candidate for simple ex vivo quantification. LCN2 is a reliable 
marker of disease which presents in most body fluids, as it is inducibly expressed and secreted by 
luminal epithelia, thus LCN2 can be measured in a multitude of body fluids, including feces, 
urine, and sputum. Because of these traits, LCN2 is an ideal candidate for use as a biomarker for 
several human and animal model pathologies. 
1.13 Cancer 
1.13.1 Overview of Cancer and Tumorigenesis 
 Because the process of tissue repair and the onset of cancer share many defining 
characteristics, and it has long been established that chronic, unresolved inflammation contributes 
to the generation of tumors, it is our goal to understand how the transition from active 
inflammation to the resolution phase and tissue repair process coincides with the initiation of 
tumorigenesis. The following section will discuss the hallmark characteristics that describe cancer 
cells. By outlining the changes seen during tumor generation, we hope to further define 
similarities between tumorigenesis and the changes that occur during the transition to the 
resolution of inflammation.  
 Cancer is a broad term used to describe a number of diseases caused by the dysregulation of 
cell division. This disruption of tightly regulated cell division can occur in virtually any tissue in 
the human body, and results in the rapid, unchecked proliferation of cells that results in an 
abnormal growth of tissue known as a neoplasm [13]. The neoplastic mass of cells is often 
referred to as a tumor. Cancer affects millions of people worldwide each year, and eradication of 
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this group of diseases has been the focus of many research foundations, including the National 
Cancer Institute at the NIH. Improvements to current treatments for cancer have been 
forthcoming; however, because of the diverse nature of this group of diseases, no one treatment 
strategy can be expected to be effective for all cancer types. Thus, researchers must strive to 
understand the more complicated underlying mechanisms of these diseases to bring about an end 
to their dominance.  
 Cancer has, thus far, been described using six hallmarks: 1) sustaining proliferative 
signaling, 2) evasion of growth suppressors, 3) resistance of cell death programs, 4) enabling 
replication immortality, 5) induction of angiogenesis, and 6) activation of invasion and metastatic 
signals [13]. Each one of these hallmarks contributes to the ability of the neoplastic mass to grow, 
divide, and perhaps most importantly, resist detection and clearance by the host’s immune system. 
Transformation of healthy cells into neoplastic unregulated dividing cells is often twofold. That is 
to say the DNA must often be damaged in at least two distinct places: a proto-oncogene and a 
tumor suppressor gene [13]. This process often begins when the cell undergoes a DNA breakage 
event, resulting in repair of the DNA, perhaps incorrect repair of the DNA sequence. This first 
mutation is usually a “gain-of-function” point mutation within the proto-oncogene and is 
necessary to promote the growth signals within the effected cell [13]. These mutations are often in 
proteins that participate in growth factor receptor signaling cascades, such as Ras and Wnt [90]. 
These proto-oncogenes must be mutated in such a way that they are constitutively active, and 
therefore support unregulated cell growth and proliferation. Although a powerful type of 
mutation, the enhanced activity of the proto-oncogenes is usually not enough to transform the cell 
into an unchecked neoplastic cell because the cell has a protective group of genes known as the 
tumor suppressor genes. These gene products function to sense dysregulated cell division and 
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inhibit the cell from progressing though further replication cycles [13]. To achieve total 
unregulated cell division, the cell requires a mutation within one of its tumor suppressor genes, 
most notably retinoblastoma (RB) and p53. This second mutation is usually a “loss-of-function” 
mutation, resulting in the loss of the detection and inhibition of unregulated cell division [13]. 
When these two types of mutations occur in the same cell, it confers a new ability on the cell: 
complete unchecked cell division, resulting in the formation of an exponentially dividing 
population of cells [90]. 
It is important to note that many of the hallmarks that characteristically define cancer also 
define the tissue repair process [60]. It is because of these similarities, that understanding the 
transition from active inflammation to the tissue repair process is critical to exposing the 
mechanisms that drive establishment of the tumor microenvironment. Although the regulation of 
inflammation is a topic frequently studied within the scientific community, investigation of the 
mechanisms governing transition from active inflammation to the tissue repair processes have 
been largely ignored in favor of investigations that focus on the onset of the inflammatory 
response. In order to understand the mechanisms by which tumor cells co-opt existing 
immunosuppressive functions of the immune response to facilitate their own growth and survival, 
more attention must be paid to the mechanisms that drive transition to the resolution phase of 
inflammation and eventually to the tissue repair process. 
1.13.2 The Six Hallmarks of Cancer 
1.13.2.1 Sustained proliferative signaling 
 Due to mutations in proto-oncogenes, cancerous cells exhibit dysregulated cell cycle 
control, which results in sustained proliferative signaling capability. The mutations that make this 
signaling possible are “gain-of function” mutations in proteins that participate in growth factor 
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signaling cascades [13]. Mutations render these proteins that drive cell division constitutively 
active. Under healthy circumstances, these proteins are subject to regulatory post-translational 
modifications that inhibit their activity, and thus the proliferative ability of the cell. Once a gain-
of-function mutation has occurred in an oncogenic protein, it becomes constitutively active, 
which often results in rendering the cell prone to unregulated cell division. This makes the 
mutated cells able to proliferate independently of the availability of resources and cell density 
signals that, under healthy conditions, modulate cell proliferation. This first type of DNA 
mutation is absolutely necessary for the production of neoplastic cells, thus sustained proliferative 
signaling is the first hallmark of cancer [13]. 
1.13.2.2 Evasion of growth suppressors 
 Although “gain-of-function” mutations are critical for the production of cancer cells, they 
are not sufficient for the total conversion of healthy cells to fully neoplastic cells. As mentioned 
previously, transformation of healthy cells to cancerous cells requires not one, but two mutation 
events. The first mutation event primes the cells for unchecked cell division, but can be overcome 
by the activation of tumor suppressor genes. Therefore mutation of the tumor suppressor genes to 
a “loss-of-function” phenotype is the second required step in cell transformation. The function of 
tumor suppressor genes is to control cell proliferation, and generally including checkpoint 
proteins including: cyclin-dependent kinase inhibitors, hormone receptors, proteins that promote 
cellular apoptosis, and DNA repair proteins [13]. Mutations in these genes render the proteins 
inactive, making them unable to participate in proliferation checkpoint regulations and DNA 
repair coordination [13]. After overcoming this final obstacle in checkpoint regulation, the newly 
transformed cells are capable of proliferating unchecked until they can be recognized and cleared 
by the immune system. 
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1.13.2.3 Resistance of cell death programs 
 The third hallmark of cancer is the ability for the cells to resist programmed cell death. 
Apoptosis is a critical pathway for regulating cell damage and overall health. Without apoptosis, 
cells lose their ability to respond to ‘danger’ signals, and gain the ability to escape removal by the 
immune system. The accumulation of mutations in oncogenes resulting from the functional loss 
of the tumor suppressor proteins results in the buildup of apoptotic stresses. In healthy cells, the 
collection of apoptotic stresses set off the apoptotic cell death cascade, ultimately resulting in the 
activation of pro-caspases 8 and 9 [13]. Activation of these molecules leads to widespread 
proteolytic activity, which signals the exposure of apoptotic signals on the outer leaflet of the cell 
membrane, and eventual uptake by phagocytes. A defining characteristic of cancer cells is that 
they evolve ways to escape succumbing to the apoptotic pathway [13]. Many proteins within the 
cell act as sensors to detect signs that the cell is in trouble: DNA damage, viral infection, killer 
lymphocyte recognition, etc. These signals function to trigger the onset of apoptosis by 
“inhibiting the inhibitor.” In other words, once the alarm is tripped and the cell senses that there is 
a problem, it enables activity of the apoptotic program, which results in a shift toward cellular 
controlled cell death [13]. The ability to escape the apoptotic pathway is an especially important 
function of tumor cell immune evasion, as many immune cells use activation of death domain-
containing receptors to trigger apoptosis as a way to eliminate tumor cells from the tissue [91].  
1.13.2.4 Enabling replication immortality 
 Neoplastic cells undergo cell replication paying no deference to the health of the cell or the 
resources available to the cell. As mentioned previously, the ability to resist cell death programs is 
partially responsible for continued cell division, however there are other pathways that, when 
corrupted, add to this division ability [13]. For example, activation of telomerase activity can 
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circumvent the onset of senescence in neoplastic cells. Through elongation of chromosomes, the 
cell can avoid signaling senescence. Similarly, apoptosis is avoided through many different 
methods. One such method is the downregulation of apoptotic death receptors in neoplastic cells 
[91]. External death receptors are triggered by immune cells, which externally recognize the 
abnormality of the neoplastic cell and attempt to induce apoptosis. The tumor cells often inhibit 
expression of death receptors to avoid immune cell-induced apoptosis. 
1.13.2.5 Induction of angiogenesis 
 Cells require a steady influx of nutrients and oxygen and a way to transport waste products 
away from themselves in order to survive and replicate. Tumor cells are no different in this 
regard, and therefore must acquire the ability to stimulate the formation of new blood vessels 
through a process termed angiogenesis [13]. Through a number of mechanisms, tumor cells are 
able to stimulate the nearby vasculature to grow new vessels and branches, which work to supply 
the tumor cells with precious nutrients, such as glucose and oxygen, and also act as a waste 
receptacle for metabolic wastes [13]. Additionally, tumor cells themselves often secrete growth 
factors, cytokine, and chemokines that drive changes in the immune system. In order to induce 
systemic changes using these secreted molecules, the tumor must recruit branches of the 
circulatory system so that the secreted molecules have an entry point into major circulation. This 
is important because it allows tumors to signal to peripheral tissues, thereby conditioning other 
tissues of the host to support tumor survival. Additionally, formation of new blood vessels 
increases the risk for tumor cell invasion and migration [13]. 
 Tumor cells induce angiogenesis by stimulating the nearby endothelial cells to proliferate 
through the secretion of growth factors. One major growth factor known to induce angiogenic 
changes in endothelial cells during cancer is vascular endothelial growth factor-A (VEGF-A) [5, 
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13]. Angiogenesis occurs early on in tumorigenesis, and is absolutely critical for the survival of 
the neoplastic cells. Bone marrow-derived cells are also responsible for contributing to growth 
factor secretion that leads to angiogenesis. Macrophages, neutrophils, and even myeloid 
progenitor cells are able to infiltrate the tumor microenvironment, where they accumulate at the 
margins between neoplastic cells and untransformed cells [5]. Here, they function to induce 
angiogenesis in previously unaffected endothelial cells, and maintain the secretion of angiogenic 
factors to sustain the angiogenic process in the vascular tissue. 
1.13.2.6 Activation of invasion and metastatic signals 
 Transformation of neoplastic to invasive tumor cells requires many cellular changes that are 
described as the epithelial-mesenchymal transition (EMT). This process is coordinated by a group 
of transcription factors that work together to facilitate the loss of contact inhibition and result in 
the ability for cancer cells to become migratory. Taken together with the ability for tumor cells to 
condition distal tissue to be immunosuppressive, acquisition of migratory capability allows tumor 
cells to establish new colonies in foreign tissue, without the risk of immediately being recognized 
and eliminated by the local immune response. 
1.13.3 Tumor Survival is Dependent on Immune Evasion 
Tumors are very strange cells, and they often express surface molecules that mark them as 
such, identifying them as aberrant cells. Surface markers that label cells as “foreign” or unhealthy 
come in many varieties [91]. The best example of cell surveillance is the carried out using the 
self-antigen presentation molecule MHCI. This protein is present on all cells, and functions to 
display peptides to surveying CD8+ T cells [92]. Mutated peptides (not present in healthy cells) 
displayed via MHCI are identified as a marker of cellular damage by the TCR on cytotoxic T 
cells, which subsequently triggers the destruction of the cell. These markers make tumor cells 
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antigenic to the immune system; however tumor cells are derived from healthy tissue cells, 
therefore they also express healthy markers of self making them somewhat tolerated by immune 
cells. Elimination of tumor cells by the immune system is entirely dependent on the signals 
received by the surveying immune cells [91]. Tumor cells typically express “foreign” markers 
which, upon ligation to counter receptors on immune cells, results in pro-apoptotic, or phagocytic 
pathways that ultimately lead to elimination of the tumor cell from the tissue; however, tumor 
cells also develop ways of concurrently enhancing markers of self that inhibit these elimination 
strategies [91]. These strategies often function by camouflaging tumor cells with healthy self cell 
markers, which allows these cells to hide within the tissue and efficiently evade clearance by 
immune cells. 
1.13.3.1 Impaired antigen presentation and tolerance 
 Survival of neoplastic cells is absolutely dependent on evasion of elimination by the 
immune system, therefore tumor cells develop many mechanisms to escape immune surveillance. 
The first method used by tumor cells to evade detection by T cells is through the downregulation 
of antigen presentation. This can be achieved through a number of mechanisms. The first is 
simple, many tumor cells decrease the surface expression of peptide-loaded MHCI molecules 
[92]. This is a very effective strategy for avoiding detection by T cells, however NK cells use 
cellular MHCI levels to determine if the cells are healthy, therefore total inhibition of MHCI is an 
ineffective method of immune escape[91]. To avoid elimination by NK cells due to lack of MHCI 
expression, tumor cells can alter the function of the peptide-loading enzymes LMP2, LMP7, TAP, 
and tapasin [91]. This mechanism of immune evasion preserves the expression of MHCI 
molecules on the tumor cell surface, so they cannot be eliminated by NK cells, but inhibits the 
self antigen presentation to T cells [91]. Another mechanism of immune escape used by tumors is 
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via the induction of tolerance. Just as in the ignorance mechanism, tumor cells often downregulate 
T cell costimulatory molecules, including B7, the counter receptor for CD28. Ligation of the TCR 
in the absence of costimulatory support induces anergy in the T cells [27]. Anergic T cells cannot 
elicit their cytotoxic functions, and are thus eliminated as a threat to the tumor cell.  
1.13.3.2 Apoptosis resistance and induction of T cell death 
 Two more methods that enable tumor cells to evade immune cell-mediated clearance are the 
ability for tumor cells to acquire resistance to apoptotic pathways, and the ability for tumor cells 
to directly induce T cell death [91]. These two mechanisms are somewhat related because these 
new abilities generally conferred through the development of changes in surface-expressed 
receptors as a function of mutations gained within the tumor cells. First, the development of 
apoptosis resistance by tumor cells is acquired by changing the levels of apoptosis-inducing 
signaling molecules on the surface of the tumor cells, primarily by members of the TNF family 
[91]. Two examples of apoptosis-inducing receptors are CD95L expressed on killer lymphocytes, 
which interacts with CD95 death receptor on target tumor cells, and the TRAIL protein expressed 
in killer lymphocytes, which targets both TRAIL-R1 and -R2 death receptors on target cells [91]. 
Under healthy circumstances, these apoptosis-inducing proteins bind to their counter receptor on 
either a T cell, or a natural killer cell, which results in downstream activation of caspase cleavage 
cascades that ultimately lead to apoptosis of the target cell. Unfortunately, as is the case with 
tumor cells, downregulation of the death-inducing surface molecules, or disruption of any part of 
the receptor signaling can lead to a loss of function in the extrinsic apoptotic pathway. Alteration 
of the apoptotic signaling pathway often leads to the apoptotic resistant phenotype observed in 
many cancer types. Other studies have reported that tumor cells often secrete soluble death 
receptors, such as CD95, which act as decoy receptors to limit the interaction of CD95L on the 
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lymphocytes with ligation of transmembrane CD95 on target cells [91]. These are some of the 
most detrimental mutations for cancer patients, as they effectively render the immune system 
incapable of clearing tumor cells through apoptosis, and limits the T cell-mediated clearance of 
tumor cells strictly to granzyme B- and perforin-mediated elimination. Furthermore, some tumor 
cell types have also demonstrated dramatic upregulation of PI-9, a protease inhibitor that 
specifically targets granzyme B and perforin [91, 93]. Thus, many mechanisms contribute to the 
evasion of immune cell-mediated apoptosis, but all mechanisms of apoptotic resistance highlight 
the necessity T cells for effective tumor clearance[91] . 
 The activation of apoptosis through CD95-CD95L ligation can be reversed, and used for the 
benefit of the tumor. In addition to being a method for resisting T cell-mediated apoptosis, tumor 
cells have also demonstrated the ability to directly induce the killing of T cells. CD95L 
expression has also been reported to be upregulated in tumor tissue as well as in immune 
privileged sites, and has been shown to profoundly increase the viability of allograft transplanted 
tissue by reducing the activity of CD95-sensitive infiltrating lymphocytes [91]. By overexpressing 
CD95L, tumor cells employ a counter-attack to the cytotoxic lymphocytes, thereby inducing 
apoptosis in the anti-tumor immune cells. CD95, however, is not the sole example of this type 
“self-defense” system used by tumors to evade clearance and prolong survival. In fact, a large 
group of these molecules have been recently termed checkpoint blockade proteins, and have been 
extensively studied as targets for drug development to promote immune clearance of tumor cells 
[94]. Perhaps the most well described, and clinically relevant set of molecules that induce T cell 
death are PDL-1 and CTLA4. PDL-1 is a transmembrane protein highly expressed by tumor cells, 
and is the ligand for PD1, or programmed death receptor 1, which is expressed on cytotoxic 
lymphocytes. Ligation of these molecules results in inhibition of T cell proliferation through 
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increased SH2 phosphatase activity within the T cells [94]. This method of inhibition is used by 
the tumor to disrupt the expansion of activated T cells, thereby preventing clearance of tumor 
cells by cytotoxic T cells. The second checkpoint blockade molecular interaction used to inhibit T 
cell-mediated clearance of tumors uses cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), an 
inhibitory receptor present on the surface of T cells [94]. CTLA4 has two binding partners: CD80 
and CD86. Interestingly, these two counter receptors also bind CD28 on T cells, and upon ligation 
between these ligands and CD28 produce a positive stimulation of T cell activation. Unlike 
CD28-CD80/86 ligation, binding of CTLA4 to CD80/86 results in potent inhibitory signaling 
within the T cells [94]. So, depending on the specific binding partner, CD80/86 molecules induce 
divergent signaling within T cells, and CTLA4 appears to outcompete CD28 for binding to the 
counter receptors. Both CTLA4 and PDL-1 have been identified as targets of immunotherapeutic 
treatment techniques, which have been hugely successful in the treatment of many cancers. In 
these therapies, antibody infusions specifically targeting the interactions between PDL-1, CTLA4, 
and their counter receptors interrupt the binding of these molecules with their counter receptors 
(expressed by tumor cells), which allows the T cells to circumvent inhibitory signaling by the 
tumors [94]. By “inhibiting the inhibitor” T cells retain their proliferation capability, which leads 
to improved clearance of tumor cells by activated T cells [94].  
1.13.3.3 Expression of immunosuppressors and immune deviation 
Tumors can also avoid immune detection by co-opting the immunosuppressive functions of 
the immune system. The first way tumor cells accomplish this task is by inducing expression of 
soluble cytokines and growth factors [91]. As discussed previously, overexpression of 
immunomodulatory cytokines, including IL-4, IL-10, and TGF-β can induce “immune deviation” 
resulting in the polarization of immune cells toward the tissue repair response [91]. Deviation 
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away from the Th1 response results in the further conversion of immune cells to the tumor 
supportive phenotypes M2 and Tregs, which contribute to the creation and maintenance of the 
immunosuppressive microenvironment surrounding the tumor cells [91]. Through increased 
expression of IL-10 and TGFβ, the tumor microenvironment becomes conditioned to drive the 
polarization of immunosuppressive immune cells subtypes, including M2 macrophages and Treg 
cells. One such subset of immunosuppressive cell types that has been powerfully associated with 
facilitating immune escape of tumor cells are the myeloid-derived suppressor cells (MDSC). 
Notably, these cells have also been observed during periods of chronic inflammation and 
persistent infection [95]. Furthermore, tumor cells have been shown to directly induce the 
generation, and recruitment of these suppressive cells, with the sole purpose of supporting their 
growth and survival [96]. Because the tumor microenvironment shares many of the same defining 
characteristics as the tissue repair process during resolution of the inflammatory response, the key 
to unlocking the initiation of immune suppression during tumorigenesis is to first define a 
mechanism for the onset of the tissue repair response. Our study will focus on the role of MDSC 
in modulating the transition from chronic inflammation to tissue repair. Understanding of the non-
pathogenic role of these immunosuppressive cells will allow the scientific community to limit 
their co-optation by tumor cells, and to increase their suppressive abilities to control unresolving 
inflammation. 
1.14 Myeloid-Derived Suppressor Play a Key Role in Immunosuppression 
1.14.1 Historical Overview and Significance of MDSC 
 Myeloid-derived suppressor cells (MDSC) were first shown to have a powerful correlation 
with tumor incidence over a hundred years ago in the early 1900s [97]. At the time these cells 
could only be characterized as myeloid in nature, and were found to be greatly expanded in the 
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circulation of cancer patients. This phenomenon was described as extramedullary hematopoiesis 
resulting in extreme neutropenia, or extreme deprivation of neutrophils [97]. That is to say, cancer 
patients presented with extremely high numbers of circulating myeloid cells, however these cells 
were not mature monocytes or neutrophils, which under healthy conditions are the prevailing 
populations of circulating myeloid cells. Although of myeloid lineage, these cells were termed 
“null” cells because they lacked distinct cell surface markers that distinguish them from other 
myeloid cells and because their primary function was unknown [97]. Recently, many functions 
have been described for these previously uncharacterized cells, such as potent suppressive and 
migratory capabilities [64]; however, MDSC remain morphologically indistinguishable from their 
non-suppressive counterparts. 
1.14.2 Nature of MDSC 
 Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of CD34+ bone 
marrow-derived cells that resemble immature monocytes and granulocytes, and share common 
acquired functions not found in their non-suppressive immature myeloid cell counterparts [98]. 
Unlike immature myeloid cells, MDSC are greatly expanded and perform additional immune 
suppressive functions during active inflammation, infection, and cancer [97]. At first glance, 
MDSC appear morphologically identical to IMC, expressing Gr-1 and CD11b surface markers, 
corresponding to the myeloid subsets of monocytes and neutrophils [97]. These cells can further 
be broken down into monocyte-like and granulocyte-like subsets; cells expressing Ly6ChighLy6G- 
surface marker pattern are defined as monocytic myeloid-derived cells, and Ly6Clow Ly6Ghigh 
surface marker pattern are defined as granulocyte myeloid-derived cells [97]. Since the initial 
discovery of MDSC, researchers have focused their attention on the role of these cells in cancer 
models. Studies using mouse tumor models have revealed the expansion of this population of  
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cells not only in the circulation, but also in the spleen, and within the tumor microenvironment; 
however it is unknown whether these cells expand outside of the bone marrow, or whether the 
Table 1-1 MDSC arise during many conditions 
 
 expansion occurs within the bone marrow, and is followed by recruitment of the cells into the 
extramedullary tissues. Other models examining autoimmunity have determined a potential role 
for MDSC [98]. Specifically, researchers using the EAE model for autoimmune encephalitis 
reported that MDSC arise from the overstimulation of the immune response, and hypothesize the 
Condition Model Observed Functions 
 Cancer 
 Breast 
Increased MDSC in peripheral 
blood correlates with poor 
prognosis 
Colon 
Melanoma 
Pancreas 
Lung 
 Persistent infection 
      Bacterial Pseudomonas aeruginosa Host protection Polymicrobial sepsis 
      Viral HIV Host protection Hepatitis C 
 Chronic inflammation 
 
IBD Host protection RA 
MS Conflicting evidence 
 Pregnancy 
 
Human/mice Protection from fetal rejection 
Transplantation 
 
Human/Rat renal allograft Protection from tissue rejection Human skin allograft 
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acquisition of immunosuppressive functions is a mechanism of control to limit excessive damage 
to the host from overstimulation of the inflammatory response [98]. As seen in table 1-1 expanded 
MDSC populations have been identified in a number of different pathological conditions, 
including cancer, sepsis, chronic inflammation, and even parasitic infections [98].  
 Since the initial identification of MDSC as potent suppressors of immune function, many 
studies have been performed to determine the precise mechanisms of immune suppression used 
by MDSC. Perhaps the most obvious method of MDSC immune regulation is the inhibition of T 
cell proliferation. Each subset of MDSC contributes to this phenomenon using multitude of 
mechanisms. Because the MDSC potently inhibit T cell proliferation and function, it is likely that 
these cells have an alternative function in tumor-bearing hosts: to promote tumor survival by 
disrupting immunosurveillance and crippling the adaptive immune response’s ability to remove 
aberrant self cells [99]. Furthermore, MDSC not only reduce T cell function, but interact with 
most immune cells to further suppress the immune response, often inducing the polarization of 
immune cells such as macrophages toward tissue repair supporting phenotypes [64, 100]. The 
specific mechanisms governing MDSC-mediated immunosuppression will be further discussed in 
the following sections, and are summarized in table 1-2. 
1.14.2.1 Monocytic MDSC-specific characteristics 
 As previously mentioned, two subpopulations of MDSC exist, the monocytic MDSC, and 
the granulocytic MDSC. Although both considered “immature” myeloid cells, each one of these 
subsets adopts its own set of cell type-specific characteristics. Specifically, the monocytic MDSC 
(M-MDSC) express surface markers consistent with immature monocyte cells, expressing a 
CD11b+, Ly6Chigh, Ly6G- phenotype [98]. Unlike their non-suppressive immature monocyte 
counterparts, M-MDSC are capable of rapidly catabolizing the amino acid L-arginine through two 
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pathways. The first is the arginase pathway, whereby the substrate L-arginine is converted into L-
ornithine and urea products via the arginase enzyme [101]. The second method of L-arginine 
depletion is through uptake by the nitric oxide synthase (iNOS) enzyme. In this process, iNOS 
breaks down L-arginine into nitric oxide (NO), a free radical molecule. Interestingly, these two 
enzymes are inducible under STAT3-mediated transcription [102]. 
1.14.2.2 Granulocytic MDSC-specific characteristics 
 The second type of MDSC most closely resemble neutrophils, and for that reason are 
termed granulocytic MDSC (G-MDSC) or PMN-MDSC [97]. These cells, like neutrophils have 
multi-lobed nuclei, and form intracellular granules. These cells also share surface molecule 
expression patterns with neutrophils, and can be described as CD11b+, Ly6C-, Ly6G+cells [98]. 
Like neutrophils, these cells express NADPH oxidase, the enzyme complex responsible for the 
production of reactive oxygen species (ROS), also know as the respiratory burst reaction [98]. 
This process is regulated by a multi-subunit complex with both membrane and cytosolic 
components. Interestingly, expression of Gp91, the primary component of the membrane-
associated respiratory burst machinery is unregulated by the STAT3 transcription factor in MDSC 
[103]. Unlike mature neutrophils, these G-MDSC do not produce vast quantities ROS, but, when 
coupled with nitric oxide release, MDSC use ROS as an effective T cell proliferation inhibitor. 
Alone, ROS secretion does not function as an effective inhibitor of T cell proliferation; however, 
used in conjunction with NO to form peroxynitrite radicals, MDSC limit the proliferative 
capability of T cells most potently [98]. 
1.14.2.3 Transcriptional regulation MDSC function 
In addition to functional studies, researchers have attempted to determine characteristic 
that define MDSC as a separate cell type from immature myeloid cells. Although many studies 
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have been carried out to identify specific cells surface markers that categorically define each 
population of MDSC, none have been identified. Therefore, researchers have relied on 
transcriptional signature changes to classify MDSC. As mentioned previously, M-MDSC express 
high levels of arginase and iNOS. While G-MDSC produce enhanced gp91, these transcriptional 
changes can be attributed to corresponding increases in upstream phosphorylated transcription 
factors STAT3 and STAT6 [98] 
1.14.2.4 The STAT5-STAT3 suppression axis in hematopoiesis 
 One hypothesis that may explain, at least in part, the mechanism development of MDSC 
during emergency hematopoiesis is supported by the observation of STAT5 activity over STAT3 
activity during steady state hematopoiesis, but not during emergency hematopoiesis [104]. During 
steady-state hematopoiesis, GM-CSF is the predominant growth factor regulating maturation and 
lineage commitment of myeloid-derived effector cells. Signaling through GM-CSF receptor 
results in potent activation of the STAT5 transcription factor, among other pathways [104]. The 
transcription factor STAT5 has been shown by researchers to be the dominant transcription 
pathway under steady-state hematopoiesis, whereby its activation potently suppresses other STAT 
activation, specifically STAT3. Cohen et al found that cells cultured in vitro under GM-CSF 
stimulation used this STAT5 dominant pathway of regulation, to produce healthy populations of 
mature myeloid-derived effector cells, including monocytes, granulocytes, and dendritic cells; all 
of which exhibited restricted proliferative capability, and did not display any suppressive 
functions [104] (Fig. 1-12). In contrast, addition of STAT3 activators, including IL-6 at the 
expense of STAT5 activation resulted in an alternative myeloid cell programming pathway. In the 
absence of STAT3 silencing by STAT5, STAT3 activation prevailed, and produced a vastly 
proliferative, lineage negative population that were able to differentiate into mature professional 
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antigen presenting dendritic cells [104]. MDSC were found to be responsive to both STAT3 and 
STAT5 programming signals; however using STAT5 knockout experiments, it was determined 
that MDSC likely arise through insufficient exposure to STAT5 stimulators, including GM-CSF, 
thereby allowing STAT3 activation to become the predominant programming transcription factor 
[104]. 
 
Figure 1-12 STAT5 suppresses STAT3 signaling. 
GM-CSF induces STAT5 signaling, which suppresses STAT3 signaling during hematopoiesis. 
1.14.2.5 Inducers of inhibitory function 
 As mentioned previously, many cytokines and growth factors induce changes in the 
transcriptional programming of immune cells. This process is carried out by activation of surface 
receptors, which function to activate downstream signaling pathways using post-translational 
modifications to their intracellular signaling domains. The most common modification utilized by 
signaling receptors is the activation phosphorylation. Members of the JAK/STAT signaling 
family, including IL-4/IL-13, IL-6, and IL-10, induce activation of signaling pathways that result 
in activation of STAT transcription factors [46]. Some of these STAT transcription factors drive 
the expression of genes that confer inhibitory function in the MDSC. For example, IL-4 induces 
the activation of STAT6, which, like STAT3 drives expression of arginase in MDSC, M2 
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macrophages, and TAMs [105]. IL-10 stimulates the activation of STAT3, which has also been 
proven to increase expression of arginase and nitric oxide synthase. IL-6 also induces changes to 
the transcriptional program via activation of STAT3 [105] 
C/EBPβ is another well-known transcription factor that has been implicated in the 
generation of MDSC [106]. In a study carried out using C/EBPβ knockout mice, it was found that 
IMC derived from tumor-bearing animals exhibited no suppressive function [106]. Many 
cytokines and growth factors have been demonstrated to use activation of C/EBPβ to confer 
suppressive function within myeloid cells. IL-10, IL-1β, IL-6, and IL-17 are all cytokines that 
have been shown to induce activation of C/EBPβ [107-109]. This transcription factor has also 
been show to regulate emergency hematopoiesis, making it a potential factor responsible for 
switching the transcriptional program away from healthy hematopoiesis and toward an adapted, 
immunosuppressive program [106]. 
1.14.3 MDSC mechanisms of immunosuppression 
 MDSC are powerful suppressors of the immune system, functioning through several 
mechanisms affecting both innate and adaptive components. MDSC cause widespread immune 
suppression in cancer and several other pathological conditions. The presence and expansion of 
these cells, since there discovery have been noted in chronic inflammation, persistent infection, 
and cancer, therefore it is no surprise that successful immunotherapy techniques seek to subvert 
the immunosuppressive mechanisms exerted by MDSC in these maladies. 
1.14.3.1 MDSC suppress T cell activity 
Both subpopulations of MDSC participate in the suppression of immune cell function, 
often coupling their different capabilities to produce a stronger suppressive phenotype than either 
subtype alone [101]. Perhaps the most profound method of immune suppression is the inhibition 
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of both T cell activation and proliferation. When in close proximity to either CD4+ or CD8+ 
MDSC exert potent inhibition of T cell function through several mechanisms [98] (Fig. 1-13). 
The first is through the depletion of L-arginine by arginase and iNOS enzymes [98]. L-arginine is 
a critical factor for T cell  
 
Figure 1-13 Mechanisms of MDSC-T cell suppression. 
Generated using “Blood and Immunology” licensed under CC BY 3.0 
 
proliferation, as it acts as a sensor of cell health within the T cell to gauge resource availability. 
When L-arginine is low, the T cell senses that there is a limit to the cellular resources, and 
subsequently downregulates proliferation machinery cyclin D3 and cyclin-dependent kinase 4  
(CDK4) [98]. This effectively inhibits T cell proliferation by keeping the T cells in the G0/G1 cell 
cycle phase. Although T cell activity and proliferation are inhibited by the rapid uptake of L-
arginine by MDSC, activation is also inhibited by the products of the nitric oxide synthase 
reaction. Once L-arginine is used as a substrate for the iNOS enzyme, production of NO can 
further suppress the activation and proliferation through inducing posttranslational nitration 
modifications on signaling molecules within the T cells [98]. Build up of NO in the 
Arg1 
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Modifications to 
TCR, IL-2R 
T cell 
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microenvironment causes T cells to decrease depression of the T cell receptor signaling 
molecules. 
CD3ζ, thereby reducing the ability for the T cells to be activated through binding of the  
Table 1-2 MDSC suppress immune cells. 
 
  Interacting Cell Type MDSC Function Consequence 
  Innate Immune Cells 
  Macrophages  é IL-10 Drives M2 polarization 
 é PGE2 Suppresses inflammatory function  
 ê IL-12 Inhibits M1 polarization 
  Dendritic Cells  é IL-10 Inhibits DC maturation 
  Adaptive Immune Cells 
  Natural Killer Cells  ê IFNγ production Limits cytotoxicity 
  Natural Killer T Cells  ê NKG2D Limits activation 
  
  T cells 
 
 
 
 ê Available arginine Cell cycle arrest 
 é RNS 
Nitration of TCR, 
costimulatory 
molecules; limits 
activation 
 é ROS 
Loss of TCRζ chain; 
limits activation 
(RNS+ROS=OONO-) 
nitrosylation of IL-2R; 
limits proliferation 
 é ADAM17 
Cleavage of L-
selectin; loss of 
trafficking 
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 é GAL9 Direct induction of apoptosis 
 é TGF-β Treg polarization 
 
counter receptor MHCI/II [98]. Since the CD3ζ chain is required for T cell activation during 
antigen presentation, downregulation of this protein results in T cells that cannot respond to 
presented antigen, thereby rendering them non-functional [110]. NO has also been shown to 
decrease the activity of the Jak3/Stat5 signaling pathway, and has demonstrated the ability to 
directly induce T cell apoptosis by stimulating release of cytochrome C from the mitochondria 
and thus, triggering the intrinsic apoptotic pathway [98]. Nitration of signaling molecules results 
in inhibition of activation-inducing phosphorylation modifications that regulate transduction of 
activation stimuli, including cytokines and other mitogens. Since IL-2 signaling and secretion are 
essential to the induction of T cell proliferation, inhibition of this signal pathway results in limited 
T cell expansion [111]. NO can also combine with superoxide and H2O2 produced using the 
respiratory burst reaction in G-MDSC to produce peroxynitrite (ONOO-) [98]. This highly 
reactive radical nitrite is capable of modifying many more signaling molecules involved in the T 
cell activation and proliferation pathways. Peroxynitrite functions as a powerful oxidizer that both 
nitrates and nitrosylates four amino acids: tryptophan, cysteine, methionine, and tyrosine; tyrosine 
being one of the most common and important substrates involved in cell signaling [98]. This 
modification of the cellular amino acids changes their chemical nature and can drastically change 
their molecular functions. In particular, addition of nitrogen groups to amino acids negatively 
impact the ability for protein signaling cascades, which can render the T cell non-functional, and 
eventually apoptotic. Therefore, high levels of peroxynitrite induce widespread protein 
modifications within T cells, rendering them unable to transduce activation and proliferation 
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signals [98]. MDSC also produce large quantities of the cleavage enzyme ADAM17. This enzyme 
reduces T cell activity by cleaving L-selectin, thereby limiting T cell trafficking to lymph nodes 
[64]. MDSC also directly induce T cell apoptosis through enhanced expression of galectin-9 
(GAL9). GAL9 interacts with TIM3 on the T cells to induce apoptosis in the T cell [64]. 
1.14.3.2 MDSC induce suppressive polarization of immune cells  
It is well known that MDSC cause a shift toward the TGFβ- rich immunosuppressive 
microenvironment [99]. One consequence of the abundant production of TGFβ is the 
development Treg cells. These cells develop under TGFβ dominant conditions, and much like the 
M1/M2 polarization paradigm, Treg cells are functionally distinct from the inflammatory Th1 and 
Th17 subtypes [35]. Treg cells secrete large amounts of IL-10, which serve to perpetuate the IL-
10 environmental dominance initiated by the MDSC-macrophage interaction [35]. These 
cytokines form a feed-forward mechanism of environmental immune suppression, polarizing 
macrophages to the M2 phenotypes, and T cells to the Treg phenotype [112]. Additionally, IL-10 
is necessary for maintaining the activity of the distinctive Treg transcription factor Foxp3 [113]. 
Tregs further compound the immunosuppressive state of the environment by reducing the 
proliferative ability of Th1 effector cells, effectively reducing antigen presentation and inducing a 
tolerogenic environment. 
 In addition to influencing the types of T cell subsets present in the tissue, MDSC also 
directly control the activity of innate immune effector cells, such as macrophages, dendritic cells, 
and natural killer cells [100]. The following sections will address the specific interactions 
between MDSC and innate effector immune cells.  
1.14.3.3 MDSC-MΦ interactions 
MDSC also regulate the immune response by interacting directly with macrophages. This 
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interaction results in alteration of macrophage cytokine production. The major overall change that 
occurs as a result of the MDSC-macrophage interactions in the tissue microenvironment is the 
shift from a highly inflammatory environment characterized by powerful expression of IL-6 and 
IL-12 to a tissue repair-supportive environment rich in IL-10, and poor in IL-12 [100]. The 
relative amounts of these two cytokines dictate whether the microenvironment will become 
immunocompetent or immunosuppressed. The IL-12 dominant environment favors NK, Th1, and 
M1 inflammatory type immune cell differentiation, while the IL-10 dominant environment results 
in the development of Treg and M2/TAM suppressive type immune cells [100].  In this process, 
MDSC work to inhibit the production of IL-12 secreted by macrophages, thus lowering the T cell 
proliferation stimulus in the tissue. This inhibitory action is achieved by direct MDSC-
macrophage contact, and is thought to occur through MDSC production and secretion of IL-10 
[100, 114]. This cell-cell contact also induces polarization of macrophages to the M2, or 
alternatively activated phenotype. There is bi-directional crosstalk that occurs during this time, 
whereby as the macrophages begin to polarize toward the M2 phenotype, they stimulate MDSC to 
produce more IL-10 creating a positive feed-forward loop [100]. This cytokine loop mechanism 
establishes a local immunosuppressive microenvironment, which results in a ripple effect that 
contributes to the alternative polarization of other immune cell types, and further exacerbating the 
changes to the microenvironment. Excess IL-10 results in the polarization of T cells toward the 
Treg subtype, and thereby decreases the development of the immunocompetent CD4+ and CD8+ T 
cells further supporting immunosuppression at the expense of immunosurveillance. 
 MDSC in the microenvironment also support the polarization of tumor-associated 
macrophages (TAMs); however, not only do MDSC promote the polarization of macrophages 
toward the TAM phenotype, but M-MDSC can further differentiate into TAMS [100]. Another 
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consequence of MDSC-macrophage crosstalk is the downregulation of MHCII expression by the 
macrophages [114]. Although not the primary antigen presenting cells, macrophage-mediated 
antigen presentation is vital to the induction of cytotoxic CD8+ T cell activation. Elimination of 
this pathway precludes activation of the Th1 and cytotoxic T cells within the local tissue 
microenvironment. 
 Chronic inflammation further intensifies the creation of an immunosuppressive environment 
via the MDSC-macrophage interaction through the secretion of IL-1β. During periods of chronic 
inflammation, large amounts of IL-1β are secreted by resident tissue macrophages [99]. 
Monocytes and MDSC are recruited into the tissue, where due to the persistence of inflammatory 
stimuli, they collect in large numbers. Following recruitment, monocytes differentiation into 
macrophages, whereupon they respond to IL-1β by secreting IL-6. The IL-6 secreted by the newly 
differentiated macrophages drives production of IL-10 by tissue MDSC. In addition to IL-6 
induced mechanisms of IL-10 upregulation, PGE2 has also been shown to drive IL-10 production 
in MDSC in the presence of macrophages [99]. IL-10 functions to shift the prevailing 
environmental conditions away from active inflammation, and toward an immunosuppressive 
state [38, 99, 114]. It is presumed that this mechanism is meant to limit the damage caused by the  
 
inflammatory response, and to push the environment into state suitable for supporting the tissue 
repair process [100]. 
1.14.3.4 MDSC-DC interactions 
MDSC also interact with other innate immune cells such as the professional antigen 
presenting dendritic cells (Fig. 1-14). These cells are myeloid-derived cells that are primarily 
responsible for antigen sampling and presentation to T cells. Dendritic cells isolated from tumor-
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bearing hosts have been demonstrated to be dysfunctional [99]. Specifically, it was found that 
MDSC inhibit the maturation of dendritic cells in the microenvironment, which prohibits their T 
cell activation function by inhibiting the antigen presentation function of the DCs. Additionally, 
MDSC inhibition of DC maturation also reduces the migratory capabilities of DC, thereby 
limiting their interactions with T cells in the lymph nodes. MDSC induce DC dysfunction through  
a multitude of processes, including hypoxia, and build up of adenosine and lactic acid. In addition 
to contributing to DC dysfunction, production of MDSC leads to decreased total production of  
 
Figure 1-14 MDSC regulate immune function.  
Generated using “Blood and Immunology” licensed under CC BY 3.0  
dendritic cells, proportionately [99, 100]. MDSC-mediated enrichment of IL-10 at the expense of 
IL-12 production further limits the mature DC population. IL-10 precludes DC maturation, 
whereas IL-12 drives DC maturation. By shifting the production of IL-12 in favor of IL-10, 
MDSC induce the accumulation of immature DCs, that are unable to present antigen to activate 
the adaptive immune response [98]. 
1.14.3.5 MDSC-NK and MDSC-NKT interactions 
MDSC have been show to suppress natural killer cell effector functions. Specifically, 
MDSC inhibit the cytotoxic effect of natural killer (NK) cells in a cell-cell contact-dependent 
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manner by limiting their ability to produce IFNγ [100]. MDSC also act to suppress NK cell 
expression of the NKG2D activation receptor. Much like in T cell activation, ligation of the 
NKG2D to it’s counter receptors (produced on target cells as an “abnormality” signal) is 
absolutely essential for activation of NK cell cytotoxic function [100]. Natural killer T cells 
(NKT) cells activities are also subject to regulation by MDSC. Two subtypes of NKT cells exist, 
type I, and type II NKT cells [115]. Type I NKT cells are primarily responsible for identification 
and elimination of harmful or aberrant cells. These cells are extremely important for the removal 
of unhealthy cells in the context of anti-tumor immunity. Conversely, type II NKT cells support 
function as tissue repair supportive cells. NKT type II cells have been most frequently studied in 
tumor models, where they have been shown to support the immunosuppressive environment 
through the secretion of IL-13 [100]. These two subsets of NKT cells and their opposing 
functions further demonstrate immune counterbalancing techniques similar to those seen in 
macrophages (M1 vs. M2) and helper T cells (Th1 vs. Th2). Therefore it is no surprise that type I 
NKT cells inhibit the collection of MDSC within the tissue, while type II NKT cells promote the 
recruitment of MDSC into the affected tissue. 
1.14.3.6 MDSC function as immunomodulators of the inflammatory response 
 Since the advent of their discovery, and notable correlation with tumor incidence and 
predicted survival outcome, perturbations of the myeloid compartment have also been described 
to a lesser degree in many other conditions, both pathogenic and non-pathogenic. In addition to 
being found in pathogenic conditions (chronic inflammation, persistent infection, and cancer), 
MDSC have also been shown to modulate the immune response during non-pathogenic conditions 
such as pregnancy, and for inducing tolerance in allograft transplantation systems [3]. 
 The role of MDSC in nonpathogenic systems has been proposed to be immunoregulatory. 
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MDSC have been proposed to be the myeloid homologous counterpart to the lymphoid Tregs, 
meaning MDSC regulate the potentially harmful functions of the inflammatory response quite 
like Tregs regulate many proinflammatory consequences of immune function. It is easy to 
understand why MDSC could be considered immunoregulatory cells because their populations are 
often expanded during overstimulation of the immune system. Examples of this include persistent 
infection and chronic inflammation. Another, perhaps more important example of a non-
pathogenic immunosuppressive role for MDSC is observed during pregnancy [116]. Expanded 
MDSC populations can be seen throughout the entire gestation period in both humans and mice 
[117]. This immunosuppressive expansion is also observed in Treg populations during pregnancy 
[117]. In the case of Tregs, to protect the allogenic fetus from rejection by the mother, a state of 
global immunosuppression is employed. It is thought that MDSC contribute to this type of 
necessary immunosuppression. Additionally, it has also been found that during pregnancy, the 
host is far more immune tolerant of cancer as found in a study by Mauti et al. that showed 
implantation of B16 melanoma in pregnant mice results in higher metastasis rates regardless of 
tumor cell types [117]. 
Pregnancy, however, is not the only example of the immune system employing 
immunosuppressive cells to induce immune tolerance that is beneficial to the host. A second 
example of this type of acquired immune tolerance is demonstrated in tissue allograft 
transplantation [118]. Here, immunosuppressive cells such as Tregs and MDSC are absolutely 
crucial for limiting allograft rejection mechanisms in transplant recipients [118]. Although both 
pregnancy and organ transplantation are both rarely encountered conditions where potent 
inhibition of inflammation is absolutely essential to induce a positive outcome in the host, these 
cells may also play a role in the regulation of the inflammatory response at the post-acute phase of 
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inflammation. It has been proposed that the non-pathogenic function of MDSC may be to help 
orchestrate the transition from chronic inflammation into the tissue repair process, the first step of 
which is to reduce inflammatory signals and functions in order to promote wound healing. 
Because MDSC only arise during inflammation that is persistent, and because MDSC exhibit 
such a powerful ability to inhibit the inflammatory functions of most immune cells, it can be said 
that these cells act as a layer of protection against inflammation-driven host tissue damage, which 
is absolutely essential for wound healing. On the other hand, activation of this wound repair 
process must be tightly regulated, as overstimulation of the tissue repair process can lead to 
unwanted pathologies, such as the generation of fibrotic tissue [36, 52]. 
1.14.4 The Functional Significance of MDSC in Suppressing Anti-Tumor Immunity 
 Since originally observing MDSC and their extreme extra medullary expansion during 
cancer in the early 1900s, more information about these interesting cells has been forthcoming. 
The functional significance of MDSC in many states has recently been addressed. Since the 
advent of their discovery, and notable correlation with tumor incidence and predicted survival 
outcome, this perturbed myeloid compartment has also been described in many other conditions, 
both pathogenic and non-pathogenic [97]. Additional studies aimed at further defining this 
perturbed population of cells have found that MDSC potently inhibit T cell proliferation, both in 
vitro and in vivo, and are even found to induce T cell apoptosis [98]. These findings, along with 
the observation that MDSC are found to be drastically increased in the circulation of cancer 
patients points to the theory that MDSC function to promote tumor survival by enhancing tumor 
immune evasion. 
 The major type of cells responsible for recognizing and eliminating tumor cells are 
cytotoxic T cells [92]. Therefore suppression of these cells by MDSC renders the immune 
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response to cancer cells insufficient, thereby allowing immune escape and further tumor cell 
survival. MDSC are the major obstacle impeding current immunotherapeutic approaches for the 
removal of tumors in the clinic [119]. Although many therapies have been developed to increase 
the efficacy of T cell-mediated tumor clearance, the exhibition of potent T cell functional 
inhibition is powerful enough to override the therapeutic activities of altered T cells in vivo. 
Furthermore, once MDSC expansion is established in the tumor-bearing host, the M-MDSC 
subtypes can further differentiate into tumor-supportive macrophages (TAMs), which then act to 
sustain the production of more MDSC [99]. Furthermore, these TAMs are polarized not only to 
protect the tumor from immune cell-mediated clearance, but to directly support the growth, 
survival, and metastatic capabilities of the altered cells. This includes production of growth and 
survival factors, and stimuli that confer loss of adhesive molecules and promote the intravasation 
of tumor cells into circulation [99]. Additionally, there is some evidence that the tumor-
supporting molecules secreted by TAMs and fibroblasts in the tumor microenvironment can 
become systemic, where they can condition other tissues to be immunosuppressed [99]. This 
conversion of healthy tissue into immunosuppressive tissue aids in the establishment of migratory 
tumor cells from the initial site of tumorigenesis into new tissue, thereby facilitating the 
generation of new metastatic tumor sites. Although T cells are the major cell type inhibited by 
MDSC, it is also important to remember that MDSC inhibit nearly every immune cell responsible 
for tumor cell clearance. In addition to this function, these cells also function to promote the 
generation of many immunosuppressive cell types, including Tregs, and suppressive macrophages 
and dendritic cells [64]. 
 One potential method of limiting the immunosuppressive capabilities of MDSC is to inhibit 
their egress from the bone marrow. Because MDSC must be in close proximity to T cells to exert 
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their suppressive functions, inhibiting the migration of MDSC into T cell-rich zones may promote 
the efficacy of T cell-mediated immunotherapeutic techniques on tumor elimination [98]. 
Unfortunately, not enough is yet understood about MDSC tethering in the bone marrow to 
develop such a therapeutic system. It is likely, however, that MDSC egress is mediated by similar 
tethering molecule interactions that control the release of mature inflammatory monocytes and 
PMN into circulation. If this hypothesis is correct, it further limits the design of therapeutic 
targets because limiting MDSC egress will likely also limit mature leukocyte recruitment to the 
periphery.  Such a system that inhibits the recruitment of mature leukocytes to the periphery is not 
ideal, posing undesirable side effects, such as the inability to respond to bacterial or fungal 
infection. Therefore it is much more desirable to limit the generation of MDSC altogether as a 
treatment strategy, because this method of MDSC inhibition is less likely to alter the generation 
and egress of mature leukocytes.  
 
Figure 1-15 CAR T cell receptors.  
Antigen-recognition domains are engineered to be covalently bound to T cell co-activation domains. Generated using “Cell 
Membrane” licensed under CC BY 3.0 
  
 MDSC are so effective at inhibiting immune cell function, that they are acknowledged as 
the primary obstacle impeding the efficacy of anti-tumor immunotherapy techniques. Many anti-
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tumor immunotherapies are tailored specifically to each patient. One such immunotherapy 
technique, known as adoptive cell transfer (ACT) uses a process that requires harvest of host-
generated T cells, introduction/education of the T cells with the specific tumor antigen, and 
reinfusion of the activated clones for the eventual T cell-mediated destruction of tumor cells 
[119]. This method has proven to be extremely effective in blood cancers, and to a lesser degree 
in solid tumors; however, because MDSC limit the infiltration of T cells into the tumor 
microenvironment, and condition the tumor microenvironment to an IL-10/TGFβ-rich milieu, T 
cells that do eventually traffic into the tumor risk being polarized toward a tolerogenic phenotype. 
Another method that also uses host T cells, to eradicate tumors is the CART cell therapy method 
[98]. Unlike ACT, Chimeric antigen receptor (CAR)-T cell therapy uses modified host T cells. 
These CART cells are artificially modified to contain “super active” TCRs specific to the tumor 
antigen [119]. These TCRs often have costimulatory activation domains attached directly to the 
TCR ζ chain (Fig. 1-15). This method induces extreme activity in the modified T cells, which act 
directly to eliminate the tumor cells, while limiting damage to other cells. The downside to this 
treatment is that activation of so many cytotoxic T cells results in a cytokine storm, producing 
extremely high fever and sepsis-like symptoms in patients treatment recipients [119]. This method 
is thought to be capable of overcoming MDSC-mediated inhibition because of its ability to 
powerfully induce a substantial inflammatory response capable of overcoming the anti-
inflammatory signals used by the MDSC. Other methods of immunotherapy include checkpoint 
blockade, whereby neutralizing antibodies toward receptors that induce T cell exhaustion are 
given to the patient. This method has been proven to be very effective with less severe side effects 
including formation of necrotic tissue at the tumor site [119]. Checkpoint blockade functions by 
limiting the interactions between T cells and their inhibitory counter-receptors, thereby 
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prolonging the lifespan and activity of the anti-tumor T cells. Unfortunately, because MDSC limit 
T cell trafficking of the tumor infiltrating lymphocytes, and use additional methods of T cell 
inhibition, MDSC are able to overcome the immunotherapeutic effects of checkpoint blockade 
[98]. 
1.14.4.1 MDSC are co-opted by tumors to facilitate the immunosuppressive environment 
In addition to being a major obstacle in the battle against cancer, MDSC generation is also 
directly induced by tumors [64]. The process by which tumors create MDSC for their own 
support is called co-optation, or less formally “hijacking.” Tumor cells use the host-evolved 
protective response of MDSC generation not to limit immune function for the purpose of turning 
down inflammation, but instead for the pathogenic function of supporting tumor growth and 
survival. In fact, tumors can directly stimulate the creation of these cells through secretion of 
growth factors and cytokines, and/or through stimulation of cytokine/growth factor expression 
from surrounding fibroblasts [64]. These secreted factors not only work to condition the 
microenvironment to become generally immunosuppressive, but also skew hematopoiesis away 
from the steady-state, and toward a demand-adapted phenotype. By artificially inducing an 
emergency inflammatory response the tumor is able to shift leukocyte production away from the 
steady-state, and toward the emergency hematopoiesis program. Although the exact mechanism 
of this induction is unknown, some proposed factors that may act to drive the hematopoietic shift 
from a healthy to an altered state are IL-6, GM-CSF, and G-CSF, as these cytokine have been 
shown to induce MDSC generation in vitro [64]. Upon generation, the newly formed MDSC are 
recruited into the tumor microenvironment, where the M-MDSC rapidly mature into M2 
macrophages and TAMs. Once in the microenvironment, MDSC operate as a shield to protect the 
tumor from detection by T cells, and support tumor growth and development through secretion of 
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pro-tumor cytokines and growth factors. For these reasons, MDSC are extremely important to the 
maintenance of the tumor microenvironment, and limiting MDSC generation during 
tumorigenesis decreases the ability for tumor cells to persist within the tissue. Many inhibitors of 
MDSC have been developed for use in cancer treatment, and are primarily concerned with 
reducing the suppressive nature of these cells. Additional methods seek to inhibit generation and 
recruitment of MDSC to the tumor site. Many of these drugs, however are not specifically 
designed to inhibit MDSC, but have been developed for other targets, and many of the 
mechanisms of action are still unknown. Therefore, understanding the precise mechanisms govern 
generation of MDSC will allow us to produce better inhibitors of these powerfully 
immunosuppressive cells. 
2 MATERIALS & METHODS 
2.1 Mice & Disease Models 
C57BL/6 mice (6-10 weeks old, 18-20g) originally obtained from The Jackson Laboratory 
(Bar Harbor, ME) were bred and housed in a specific pathogen-free facility with free access to 
food and water. Georgia State University’s Institutional Animal Care and Use Committee 
(IACUC) approved all experimental procedures performed in the mice. To induce colitis in mice, 
2% dextran sulfate sodium (DSS, MP Biomedicals) was freshly dissolved into pure drinking 
water. Mice were treated with DSS for 9 consecutive days, followed by up to 21 days of untreated 
drinking water to allow for colitis recovery and tissue repair. Mice were examined daily to assess 
the level of stress, onset of colitis-associated symptoms, and recovery from inflammation. Body 
weight, stool consistency, and rectal bleeding were monitored daily to determine the disease 
activity index (DAI) of each animal. DAI was calculated using an average of three criteria: 1) 
percentage body weight loss (0, none; 1, 1-5%; 2, 5-10%; 3, 10-15%; 4, >15%), 2) stool 
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consistency (0, solid stool; 2, loose stool; 4, diarrhea), and 3) presence of blood in stool (0, 
negative; 2, positive; 4, gross bleeding) as shown in previous colitis studies [120] . Stool was also 
collected daily and tested for the concentration of fecal lipocalin-2 by ELISA. Mice were 
euthanized at three day time points (0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30) during DSS treatment 
and recovery. Serum, spleen, colon, and bone marrow tissues were collected from the euthanized 
mice and analyzed for inflammatory markers (Fig. 2-1). 
 
Figure 2-1 Treatment model of DSS colitis and collection of tissues for analysis. 
C57BL/6 mice are treated with 2% DSS via drinking water for 9 days. DSS is removed from drinking water at day 9, and mice are 
allowed to recover from colitis. Tissues were collected at 3 day intervals and analyzed. 
 
2.2 Measurement of Serum Cytokines 
Whole blood was collected from mice without the use of anti-coagulation additives, and 
centrifuged at low speed to isolate the serum fraction. Isolated serum was assayed for cytokines 
using standard sandwich ELISA technique. Briefly, a 96-well flat-bottom ELISA plate was coated 
with purified antibodies against IL-6, IL-17,and GM-CSF. Following washing, serum samples 
collected from mice were incubated in the antibody-coated wells, each sample in duplicate. 
Following incubation, the wells were washed with 0.005% Tween-20 PBS, and biotinylated and 
HRP-conjugated streptavidin antibodies were added to each well. Finally, the HRP substrate, o-
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phenylenediamine dihydrochloride (OPD, Sigma) was added to each well, and color change was 
detected at wavelength 450nm. Purified and biotinylated antibodies against all cytokines were 
purchased from BD Biosciences and BioLegend. Recombinant cytokines used for standards were 
purchased from PeproTech. Data was analyzed using SoftMax Pro microplate data software. 
2.3 Measurement of Fecal LCN2 
Control, and mice treated with DSS were removed from cage mates using isolation 
collection chambers. Fecal pellets were collected from isolation chambers daily for 30 days. Once 
collected, fecal pellets were weighed and homogenized at a concentration of 100mg/ml in 0.1% 
Tween-20 PBS. Following homogenization, fecal suspensions were vortexed vigorously for 20 
minutes, followed by centrifugation at 12,000 rpm, 4°C for 10 minutes. Supernatants were 
collected and stored at -20°C before analysis. Fecal lipocalin-2 levels were determined using the 
commercial LCN2/NGAL ELISA DuoSet (R&D Systems). Samples were diluted (1:20 for 
untreated and 1:200 for DSS treated mice) using 1% BSA PBS, and evaluated using standard 
sandwich ELISA technique. Each sample was prepared in duplicate. HRP-conjugated streptavidin 
in conjunction with OPD were used for color development at wavelength 450nm. Results were 
recorded using SoftMax Pro microplate data software. 
2.4 Measurement of Bone Marrow Cell Populations 
Bone marrow cells were harvested from the femora and tibiae of each mouse by flushing 
the bone cavities with Hank’s Balanced Salt Solution without Ca2+ or Mg2+ (HBSS-, Corning). 
Following RBC lysis, cells were loaded onto a discontinuous Percoll® density gradient (40%, 
50%, 60% and 70% Percoll® concentrations) and centrifuged at 1,500 RPM at 18°C for 45 
minutes. Following centrifugation, cells aggregated at the interface of each Percoll® density layer, 
resulting in four discrete bands. Each band of cells was collected using a syringe. Cells were 
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centrifuged and washed three times using HBSS- to remove residual Percoll®. Cells were counted 
using a Nexcelom Cellometer Auto 2000 (Lawrence, MA). The sum of all fractions was used to 
calculate the total number of isolated BM cells. Each cell fraction was divided by the total number 
of isolated cells to determine the percentage contribution of each fraction to the total. 
2.5 Measurement of Chemokine Receptors 
Following Percoll® fractionation, fraction 3 and 4 BM cells were labeled with 
fluorophore-conjugated anti-mouse Ly6C, Ly6G, and CXCR2, CXCR4 chemokine receptor 
antibodies, followed by washing. Stained cells were analyzed by FACS (LSR Fortessa, BD 
Biosciences) to determine changes in surface receptor expression. All antibodies were obtained 
from BioLegend. FACS analysis was performed using FlowJo software. 
 
2.6 FACS Analysis of Splenocytes  
Whole spleens were excised from euthanized mice, and emulsified in RBC lysis buffer 
(0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA). After RBC lysis, the purified splenocytes 
were suspended in PBS and labeled with two combinations of fluorescence-conjugated antibodies 
(anti-mouse CD4 and CD8, or CD11b, Ly6C, and Ly6G) and analyzed by flow cytometry (LSR 
Fortessa, BD Biosciences). All antibodies were obtained from BioLegend. FACS analysis was 
performed using FlowJo software. 
2.7 T cell Proliferation Assay 
Isolated splenocytes were labeled by incubation with carboxyfluorescein succinimidyl ester 
(CFSE) followed by several washes, and then resuspended in complete RPMI (1% glutamine, 
10% heat inactivated FBS, 0.1% β-mercaptoethanol) cell culture media. A 96 well cell culture 
plate was coated with anti-CD3e antibodies (BioLegend), followed by washing. Splenocytes were 
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loaded into each coated well. For co-culture experiments MDSC were added to the splenocytes in 
each well at a ratio of 1:8. Soluble anti-CD28 (BioLegend) was added to each sample to induce  
 
Figure 2-2 T cell proliferation schematic. 
T splenocytes are labeled with CFSE, and activated with anti-CD3 and -CD28 ligation antibodies to induce activation. During 
proliferation, intracellular CFSE will become more dilute through each round of cell division. 
 
 
proliferation through T cell ligation. Cells were incubated at 37°C, 5% CO2 for 4 days. Cells were 
collected and labeled with fluorescent anti-CD4, and -CD8 antibodies (BioLegend) and analyzed 
by flow cytometry. As T cell proliferated, total CFSE per cell decreases, therefore low CFSE 
levels in T cells isolated from the final day of the experiment indicates strong proliferation, while 
high levels of CFSE per T cells indicates little to no proliferation (Fig. 2-2). Percent proliferation 
was measured using FlowJo analysis software. 
 
3 RESULTS 
Because the specific mechanisms governing transition from the onset to the resolution phase 
of inflammation remain undefined by immunologists, and because understanding these elusive 
mechanisms will contribute greatly to the understanding of inflammatory regulation, our study 
endeavored to determine the mechanisms governing this transition. Because MDSC are potent 
suppressors of the immune system, have been shown to coordinate the dramatic proliferation of 
tissue cells, and arise during chronic inflammation, we propose that immature myeloid cells 
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become transcriptionally reprogrammed to MDSC during the post-acute phase of colitis for the 
purpose of suppressing the overstimulated immune response. 
3.1 Establishing a Colitis Model to Assess Wound Healing  
We first needed to establish a mouse model to evaluate the changes in the myeloid 
compartments during inflammation and resolution phases of colitis. To accomplish this, we used 
the already established murine dextran sulfate sodium (DSS) colitis model to develop 
inflammation to the post-acute phase, followed by removal of the chemical insult to establish  
 
Figure 3-1 Establishment of inflammation and recovery during DSS-induced colitis.  
A) Model of DSS treatment used to induce colitis and recovery. B) Percent body weight loss in DSS-treated colitis and control 
mice. C) Disease activity index was calculated in colitis mice. Disease score represents the average of three disease scoring 
criteria: body weight loss, stool consistency, and bloody stool. D) Colon length was assessed at various time points during colitis 
progression. Colon length was dramatically shortened from 3d-12d, followed by an increase in length after stopping DSS 
treatment. All averages represent n=5 mice/group ± SEM. E) Representative colon length comparisons of colons taken from mice 
at each time point during DSS+ water administration cycle. While colon length returned to baseline untreated levels by day 18, 
colon diameter remained dilated through 12d.  Images are representative of at least 3 independent experiments.  
***p < 0.0001, ** p < 0.01 versus non-treated control mice. 
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inflammation recovery. Mice were treated for 9 days with 2% DSS administrated in drinking 
water, after which the DSS water was replaced with untreated water, as seen in the schematic in 
figure 3-1A. All animals were monitored for percentage body weight loss, disease activity, colon 
tissue loss, and fecal lipocalin-2 during treatment. Mice were sacrificed at three day time points 
and key organs, including spleen, serum, bone marrow, and colon tissue were harvested and 
analyzed for symptoms of inflammation as well as to determine changes within the myeloid and 
lymphoid compartments. As seen in figure 3-1B, mice treated with DSS rapidly lost weight from 
day 6 through day 9, however steadily recovered from this weight loss after stopping DSS 
treatment (days 12-18), and returned to the baseline value by day 18. Disease activity index was 
also determined during the treatment and recovery phases of DSS administration (Fig. 3-1C). As 
seen in the body weight curve, mice treated with DSS showed increased disease activity scores 
starting at day 6 and peaking between days 9-10, after which the mice recovered through day 18. 
Other criteria used to determine the relative disease condition of the DSS-treated mice included 
colon length and fecal LCN-2, a marker of intestinal inflammation [79] (Figs. 3-1 D&E and 3-
2A). Significant loss of colon tissue length coupled with maximum weight loss and DAI scores, 
indicated that mice reached peak inflammation 1-2 days post removal of DSS from drinking  
water. It should also be noted that loose and bloody stool can be seen during peak colitis at day 12 
(Fig. 3-1D&E), illustrating the severe tissue damage acquired during onset and progression of the 
inflammatory response. Recovery following this phase of persistent inflammation was gradual, 
and colon tissue did not return to the pre-inflammatory state until nearly 21-24 days after stopping 
DSS treatment (Fig.3-1E). Although all common, observable indicators of active inflammation 
returned to baseline levels by day 18, fecal LCN-2 peaked at day 17, and is slow to return to 
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baseline levels demonstrating that the inflammatory process continues beyond the day 18 (Fig. 3-
2A). Because LCN-2 is factor that is secreted first by degranulating neutrophils during active 
inflammation, and second by epithelial cells during tissue repair, we believe that the 
overwhelming increase in LCN-2 at day 17 is due to the initiation of the resolution phase of 
inflammation.  
 
Figure 3-2 LCN-2 increases during colitis resolution.  
A) ELISA of fecal lipocalin-2 (LCN2), a marker of inflammation in DSS-treated and control mice. LCN-2 produces a biphasic 
expression pattern, peaking at day 17. Data represents average fecal LCN-2 ± SEM 5 mice/group. B) Immunofluorescent staining 
of colon tissue; red, SMA; green, LCN-2. Co-expression of SMA and LCN-2 in colon tissue at day 18 indicates LCN-2 is 
produced during the tissue repair process. Images are representative of tissue sections taken from 3 independent experiments. 
 
 
LCN-2 has previously been reported to control the immune response during inflammation 
by inducing the polarization of macrophages toward the tissue repair-supportive M2 phenotype. 
To determine if the initiation of the tissue repair process correlates with increased expression of 
LCN-2 at day 17, we performed immunofluorescent staining of colonic epithelium harvested at 
this time point. Smooth muscle actin (SMA), a marker of the tissue repair process, was stained in 
conjunction with LCN-2 to illustrate that LCN-2 is released from colonic epithelium as a function 
of the tissue repair process (Fig. 3-2B).  
As seen in figure 3-2A, colonic epithelial LCN-2 increases during a period of active 
inflammation recovery starting at days 12-13 and peaking at day 17. Taken together these data 
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confirm the establishment of a DSS-induced colitis and inflammation recovery model to be used 
for determining changes to the immune system during inflammation recovery. With this model, 
we will determine the dynamic changes in the myeloid compartments, to define the role of 
myeloid cells in the coordinating the transition to the resolution phase of inflammation. 
3.2 IL-17 Drives Expansion of MDSC in the Bone Marrow 
MDSC are present during chronic inflammation and are potent suppressors of the immune 
response. Furthermore, prevailing conditions during cancer directly induce the generation of 
MDSC. MDSC populations have been demonstrated to expand during chronic inflammation and 
are known to acquire at least two defining functions. To determine when during the inflammatory 
process this population of cells expand, and to determine when IMC acquire additional functions, 
thus defining them as MDSC, we examined changes in the dynamic regulation of hematopoiesis 
during chronic inflammation. To achieve this, we examined the myeloid cell populations within 
the bone marrow and spleens of mice during our recovery and treatment model. We asked three 
questions: 1) when during the inflammatory process do IMC expand, 2) when do IMC acquire 
migratory function, and 3) when do IMC become functionally reprogrammed to become fully 
suppressive MDSC? 
  
Figure 3-3 IL-17 increases during colitis. 
ELISA of proinflammatory cytokines from serum from mice treated with colitis recovery model of DSS administration. IL-17 
increases steadily during DSS treatment, and slowly returns to baseline levels by 30d. No significant increases seen in IL-6 of GM-
CSF serum levels. Data represents the mean ± SEM of 5 mice/group. 
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To address when IMC populations expand, whole bone marrow populations were collected 
at each time point during the inflammation and recovery model. To specifically determine 
changes within the BM myeloid populations, we applied a novel density gradient centrifugation  
technique using Percoll®. This technique allowed for the simultaneous separation of IMC from  
Table 3-1 Dynamic changes in BM populations during colitis. 
 
Treatment 
Day 
(n) 
Bone Marrow Fractions 
(Percoll interface) 
(% total BM cells isolated ± SEM) 
Fraction 1 
(0-40%) Fraction 2 (40-50%) Fraction 3 (50-60%) Fraction 4 (60-70%) 
0 
(n=5) 16.79 ± 1.33% 8.00 ± 1.41% 37.52 ± 2.69% 37.71 ± 0.96% 
3 
(n=6) 22.88 ± 0.95% 6.58 ± 0.94% 39.60 ± 1.74% 30.74 ± 1.73% 
6 
(n=5) 27.86 ± 4.12%  8.55 ± 1.03% 40.70 ± 5.78% 23.00 ± 4.47% 
9 
(n=5) 16.35 ± 1.90 % 11.41 ± 0.89% 61.61 ± 4.24% 10.61 ± 2.29% 
12 
(n=5) 11.01 ± 1.52% 10.18 ± 2.03% 67.59 ± 1.75% 11.23 ± 1.14% 
15  
(n=5) 8.36 ± 0.90% 4.66 ± 0.79% 68.33 ± 1.66% 18.66 ± 2.33% 
18 
(n=5) 11.88 ± 1.767% 5.84 ± 1.7-% 40.71 ± 6.35% 41.46 ± 7.43% 
21 
(n=5) 10.40 ± 0.98% 4.70 ± 0.41% 37.90 ± 4.23% 46.57 ± 4.48% 
24 
(n=6) 9.45 ± 1.60% 5.07 ± 0.97% 51.29 ± 4.78% 34.30 ± 5.29% 
27 
(n=5) 15.21 ± 1.47% 5.33 ± 0.77% 39.19 ± 2.93% 40.24 ± 3.38% 
30 
(n=5) 12.95 ± 1.307 7.59 ± 1.21% 42.88 ± 2.94% 36.46 ± 4.28% 
 
mature myeloid cells and other bone marrow cell types. Separation of whole bone marrow using 
this density gradient technique resulted in the formation of four density fractions. Through flow 
cytometry analysis, we defined fraction 1 as stromal cells, fraction 2 as mostly B cells, with ~15% 
myeloid cells, fraction 3 as a heterogeneous population of CD11b+ myeloid cells, and fraction 4 
as mature PMN (data not shown). Dynamic changes occurred in all fractions over though course 
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of colitis and recovery; however, the most dramatic changes were seen in fractions 3 and 4, which 
were the myeloid-saturated fractions. Figure 3-8A illustrates positive fractionation of whole bone 
marrow. Low density CD11b+ IMC were enriched in the third fraction, specifically at the 50-60% 
Percoll® interface, whereas mature myeloid cells (CD11b+, Gr-1high) were enriched in the fourth 
fraction (the 60-70% Percoll® interface). Tracking the dynamic changes within the bone marrow 
over the course of inflammation and recovery revealed that the bone marrow IMC population 
(fraction 3) expands beginning 9 days into the inflammatory process, and continues to expand 
after the removal of the inflammatory stimulus, peaking at day 15, followed by reduction at day 
18 (Tbl. 3-1). This population of cells stabilized to the baseline healthy levels at the late stages of 
the colitis model. Contrastingly, mature myeloid cell populations (fraction 4) steadily declined 
over the course of inflammation. This steady decrease is due to recruitment of PMN to the site of 
active inflammation, a phenomenon characterized by our lab in previous studies. The decrease in 
BM IMC at the post acute phase of colitis suggests one of two possibilities, either a decrease in 
IMC production, or as with the mature leukocytes, recruitment into circulation. Furthermore, the 
percentage perceived “decrease” in fraction 3 cells may also be due to the increase of other cell 
populations within the bone marrow. 
To determine if the decrease in bone marrow myeloid cells at day 18 was due to the 
acquisition of migratory capabilities, we assessed changes to the myeloid cell populations within 
the spleen. Changes to both the myeloid and lymphoid splenocyte populations were tracked over 
the course of the inflammatory process. Interestingly, CD11b+ myeloid splenocytes increased 
slightly during active inflammation as days 3-9 exhibited only a minimal increase (11.33 to 
13.35%), but increased dramatically from days 12-21, peaking at day 18 (Fig. 3-4 and Tbl. 3-2). 
Because the increase in myeloid splenocytes occurs at the time point corresponding with the 
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sudden decrease in IMC populations observed within the bone marrow, and because MDSC have 
previously been shown to acquire migratory function, this data suggests that IMC first expand in 
the bone marrow, and then acquire migratory function during inflammation resolution at day 18, 
where they are released into circulation and accumulate in the spleen. 
In an effort to identify soluble factors that drive the dynamic changes in hematopoiesis 
during inflammation and resolution, we measured serum cytokine levels at each time point during 
treatment. As previously reported by our lab and others, IL-17 is the primary cytokine 
upregulated during colitis, and our model recapitulates this finding. Within our model, we 
observed baseline healthy serum IL-17 levels at 40ng/ml, however this cytokine increased nearly 
3 fold at the peak of colitis (days 9-12, Fig. 3-3). Interestingly, cytokines known to directly drive 
the generation of MDSC, IL-6 and GM-CSF, were not observed at significantly enhanced levels 
within the serum during colitis, remaining in the low pg/ml range. Although these cytokines were 
not significantly elevated in the serum, they may indeed play a role in the expansion of IMC 
during inflammation. Because IL-17 is known to stimulate production of both IL-6 and GM-CSF 
in macrophages, systemic upregulation of IL-17 may induce local bone marrow macrophages to 
produce these cytokines, thereby driving changes to hematopoiesis locally, rather than 
systemically. 
In our colitis inflammation and recovery model, serum IL-17 steadily increased during 
active colitis, peaking at day 9. After removal of the inflammatory stimulus, IL-17 remained 
elevated in the serum. Additionally, the height of IL-17 production directly preceded the peak of 
IMC expansion in the bone marrow. This data, coupled with the ability for IL-17 to drive IL-6  
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Table 3-2 Inverse relationship between myeloid and T splenocytes during colitis. 
 
Treatment 
Day Percentage Splenocytes 
CD4
+ CD8+ CD11b+ 
0 10.72 ± 1.31% 
(n=4) 6.89 ± 0.26% (n=2) 11.63 ± 0.58% (n=6) 
3 6.82 ± 1.75% 
(n=4) 7.92 ± 0.49% (n=4) 11.33 ± 1.31% (n=4) 
6  7.61 ± 0.11% 
(n=2) 8.34 ± 1.89% (n=2) 14.04 ± 0.92% (n=5) 
9 8.62 ± 0.36% 
(n=4) 9.64 ± 0.40% (n=5) 13.35 ± 1.07% (n=4) 
12  4.70 ± 0.98% 
(n=3) 5.13 ± 0.94% (n=3) 15.98 ± 2.03% (n=3) 
15  5.36 ± 0.14% 
(n=5) 5.67 ± 0.42% (n=5) 15.75 ± 1.24% (n=5) 
18 4.17 ± 0.38% 
(n=4) 4.29 ± 0.25% (n=4) 29.73 ± 4.42% (n=3) 
21 3.06 ± 0.38% 
(n=6) 4.50 ± 0.42% (n=6) 27.73 ± 5.11% (n=4) 
24 7.91 ± 0.57 
(n=3) 7.04 ± 0.67% (n=4) 27.56 ± 2.62% (n=5) 
27 6.89 ± 1.33% 
(n=4) 6.67 ± 0.982% (n=5) 22.55 ± 3.36% (n=4) 
30 8.06 ± 1.50% 
(n=3) 6.83 ± 1.09% (n=3) 19.86 ± 4.44% (n=5) 
 
and GM-CSF production, and the known associations between IL-17, chronic inflammation and 
MDSC suggests that IL-17 drives expansion of IMC during inflammation. 
3.3 Myeloid Cells Deplete T Cells in the Spleen During Inflammation Resolution 
From the gradient density experiments, we observed that the immature, low density myeloid 
cell population was dramatically expanded during the post-acute phase of colitis, particularly at 
the early stages of inflammation resolution through a process likely coordinated by enhanced 
systemic IL-17. In addition to characterizing the dynamic regulation of hematopoiesis during 
colitis inflammation and recovery, we also attempted to further define the nature of the 
accumulated myeloid splenocytes. To achieve this goal, FACS was used to determine if myeloid 
cells accumulating in the spleen tissues represented known characteristics of MDSC, including 
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heterogeneity and T cell suppressive qualities. Using specific monocyte and granulocyte cell type 
markers Ly6C and Ly6G respectively, it was observed that the enhanced population of CD11b+ 
myeloid cells found within the spleens during inflammation were composed of a heterogeneous 
 
Figure 3-4 Myeloid cells accumulate in spleens of colitis mice.  
A) FACS of whole spleens from DSS-treated colitis mice. Percentage of myeloid cells significantly increases in the spleen during 
inflammation resolution time points, most dramatically at day 21. Quantification of CD11b+ splenocyte populations n=4 mice/time 
point. FACS scatter plots representative of at least 4 individual experiments.  
 
mixture of monocyte- and granulocyte-like cells (Fig. 3-5). This observation supported the notion 
that the enhanced myeloid population seen in the spleen during inflammation were likely MDSC, 
as these cells are characteristically composed of a mixed population of monocytic and 
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granulocytic subpopulations. As seen in figure 3-5, both subpopulations of myeloid cells were 
increased over the course of colitis treatment and recovery, peaking at days 18-21. 
 
To further characterize the physiological purpose of the myeloid cell accumulation in the 
spleen, we evaluated the T lymphocyte populations within the spleen during inflammation and 
recovery. Because MDSC are known to potently suppress T cell proliferation, we examined both 
CD4+ and CD8+ splenocyte populations over the course of inflammation and colitis recovery. We 
 
Figure 3-5 Expanded CD11b+ splenocytes represent a heterogeneous population. 
A) FACS of CD11b+ myeloid splenocyte subpopulations taken from whole spleens of colitis mice. Ly6C and Ly6G were used 
markers of monocyte-like and granulocyte-like cells, respectively. FACS scatter plots representative of at least 4 individual 
experiments. B) Quantification of individual myeloid splenocyte subpopulations. Both myeloid subpopulations increase during 
inflammation recovery. Data represented as the mean ± SEM 
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anticipated that IMC were undergoing a functional reprogramming event to MDSC during 
inflammation, and that observed accumulation of myeloid cells within the spleen was functioning 
to inhibit the immune response during inflammation by dampening T cell activation and 
proliferation. Supporting this theory, we found myeloid and T splenocyte populations exhibited 
an inverse relationship during the inflammatory process (Fig. 3-6). As spleen myeloid populations 
increased over the course of inflammation from days 3-21, both CD4+ and CD8+ T splenocyte 
populations correspondingly decreased (Fig. 3-6, and Tbl. 3-1). Furthermore, this inverse 
relationship reached its climax at the 18 day time point. Here, it was observed that  
 
Figure 3-6 Inverse relationship between myeloid and T splenocytes. 
As CD11b+ myeloid splenocytes increase, CD4+ and CD8+ splenocytes decrease during the post-acute phase of colitis, peaking at 
days 18-21. 
 
myeloid cells constituted a staggering 29.73% of the total spleen cells, while at the same point the 
total CD4+ and CD8+ T splenocyte percentages decreased to 4.17 and 4.29% respectively; levels 
nearly half those of their healthy counterparts. At later time points however, as the myeloid 
splenocyte population waned (days 27-30) the T cell populations steadily recovered to healthy 
levels (Table 3-2). From these data, it was observed that accumulated myeloid cells in the spleens 
of colitis mice were of a heterogeneous nature, representing both monocytic and granulocytic 
subpopulations, and that accumulation of these cells in the spleens of treated mice was inversely 
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proportionate to the T splenocyte populations. These data suggest that increased, heterogeneous 
myeloid cell populations within the spleen exhibited T cell suppressive capability, and that these 
characteristics are congruent with characteristics describing MDSC. Therefore, we proposed that 
IMC expand in the bone marrow during persistent inflammation, acquire suppressive function, 
and are recruited to the T cell-rich spleen for the purpose of dampening the immune response in 
favor of the resolution of inflammation and promotion of tissue repair. 
 
 
Figure 3-7 T splenocytes decrease during colitis.  
FACS of CD4+ and CD8+ T splenocytes. T cell populations decrease as the myeloid population increases within the spleen. FACS 
scatter plots representative of at least 4 individual experiments. 
 
3.4 Increased CXCR2 Expression Allows MDSC to Enter Circulation 
To determine the mechanism responsible for driving the acquisition of migratory function 
in MDSC, we evaluated surface expression of the chemokine receptor CXCR2 using FACS. 
Observation of increased CXCR2 chemokine receptors present in the IMC fraction confirmed that 
IMC gain migratory functional capability during the post-acute phase of colitis. Interestingly, M-
MDSC did not increase CXCR2 expression, but the G-MDSC subpopulation did exhibit increased 
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CXCR2 surface expression (Fig. 3-8). Observation of enhanced expression of CXCR2 over the 
course of colitis substantiates our claim that the decrease in BM IMC seen at day 18 is, in part due  
 
Figure 3-8 Increased expression of CXCR2 in MDSC. 
M-MDSC do not show any increased CXCR2 expression over the course of colitis, however, G-MDSC increase CXCR2 surface 
expression most evidently at the post-acute phase of colitis, but do not reach maximum levels of CXCR2 expression as seen in 
mature PMN. 
 
to the acquisition of migratory function, and not because of decreased generation of these cells. 
Because both M-MDSC and G-MDSC subpopulations increase within the spleen during colitis, 
further investigation is needed to determine the chemokine receptor that is responsible for 
coordinating the migration of M-MDSC. As with mature inflammatory leukocytes (PMN), this 
method of acquired migratory capability appears to be the major mechanism governing the entry 
of IMC into circulation. Enhanced CXCR2 in IMC allows these cells to respond to the major 
inflammatory recruitment chemokine IL-8 that is dramatically upregulated in inflamed tissue. 
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Although not explicitly determined in this study, it is easy to imagine that recruitment of IMC into 
circulation via the IL-8-CXCR2 axis not only results in accumulation of IMC in the spleen, but 
also at the site of inflammation. 
3.5 Immature Myeloid Cells Become Functionally Reprogrammed to Suppress T cell 
Proliferation 
We have demonstrated that during active inflammation, and the early phases of resolution, 
the immature myeloid cell compartment expands in the bone marrow, and these cells are recruited 
to the T cell-rich environment of the spleen, where they accumulate in large numbers. 
Additionally, as the myeloid cell population increases in the spleen, the T splenocyte population 
correspondingly decreases. To verify that within our model of inflammation and resolution, 
myeloid cells do, in fact acquire T cell suppressive capability, and that spleen myeloid cells 
inhibit the activation and proliferation of T cells leading to a reduction of T splenocyte 
populations, we assessed T cell inhibitory capability using an in vitro T cell proliferation model.  
To measure the suppressive activities of these cells, IMC were isolated from the bone 
marrow during inflammation and recovery, and were subjected to co-culture with activated T 
splenocytes at a ratio of 1:8 (IMC:splenocytes). Following incubation, CD4+ and CD8+ T cells 
were analyzed for proliferation via FACS. As shown in figure 3-8B immature myeloid cells 
isolated from the bone marrow began to inhibit T cell proliferation as early as 3 days into DSS 
treatment, and became more potently suppressive of T cell proliferation during the resolution 
phase of experimental colitis. IMC isolated during early inflammation resolution time points 
(days 9-18) exerted the most significant T cell suppressive function (Fig. 3-8B) where T cell 
proliferation was almost undetectable for both CD4+ and CD8+ T cells. Remarkably, the immature 
myeloid cells isolated from days 12-18 exhibited the most potent T cell suppression in vitro; a 
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quality that recapitulates the inverse relationship between myeloid and T splenocytes gathered 
from the in vivo data. These data support the hypothesis that T splenocyte depletion 
corresponding with myeloid cell accumulation is due to active suppression of T cell proliferation 
by MDSC in vivo. This data supports the notion that IMC are functionally reprogrammed to 
MDSC during the late phase of inflammation and may support the transition to the early phases of 
inflammation resolution. 
 
Figure 3-9 MDSC inhibit T cell proliferation.  
Immature myeloid cells from inflammation recovery time points inhibit T cell proliferation. A) Example of discontinuous Percoll 
gradient following separation of whole BM. Four resulting fractions, F1-4. B) Assessment of immature myeloid cells (F3) 
inhibitory function using T cell proliferation assay. Fraction 3 myeloid cells were co-cultured with healthy activated, CFSE-loaded 
T splenocytes at a ratio of 1:8. Proliferation was determined by FACS for both CD4+ and CD8+ T cells. T cells cultured with F3 
from untreated mice exhibited no reduction in T cell proliferation when compared to the positive control.  T cell proliferation was 
greatly inhibited in all DSS-treated mice, but most notably at the inflammation recovery time points. BM immature myeloid cells 
acquire T cell suppressive function during inflammation recovery. Histograms are representative of three independent experiments 
performed in duplicate.  
 
 
4 DISCUSSION 
As discussed previously, MDSC are potent suppressors of the immune response that have 
been established in many models, including chronic inflammation, and cancer. Additionally, these 
cells have been shown to have non-pathogenic, protective functions during allograft 
transplantation and pregnancy. In previous studies using models of post-acute/chronic 
inflammation in our lab, we determined functional changes to inflammatory leukocytes, which 
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resulted in the potentiation of inflammatory function, specifically in PMN [121]. This study 
characterized additional functional changes within the myeloid cell compartment; however, these 
changes did not support the inflammatory response, instead the changes we observed were 
suppressive, and functioned to counteract the inflammatory response in favor of resolution and 
tissue repair. Our findings defined a non-pathogenic role for MDSC in the coordination of 
inflammation resolution, and support the growing idea that soluble factors secreted as a result of 
post-acute inflammation induce functional reprogramming of the myeloid compartment, which 
further regulates the inflammatory response. 
4.1 DSS Colitis is a Useful Model for Studying Inflammation Resolution 
DSS-induced colitis has been a long-used, predictable, easily-administered model of 
inflammation; however, until now, DSS was used mainly as a method to examine the mechanisms 
responsible for the onset of inflammation, and the individual relationships between cells of the 
immune system and affected tissue cells. A tremendous amount of extremely useful information 
about the immune system and inflammatory response has been gleaned from DSS colitis studies; 
although, our study went a step further, and sought to use the DSS-induced colitis model to 
examine the resolution of inflammation, and the onset of immunomodulatory functions within the 
effector immune cells. In addition to the commonly measured markers of disease activity such as 
body weight loss, bloody stool, and colon tissue loss, our study also examined the non-lethal 
disease activity index measurement of fecal LCN-2. LCN-2, a prevailing clinical marker of 
inflammation was found to be associated with both weight loss and disease activity index curves, 
all demonstrating a steady onset of colitis activity from days 1-9 post initial DSS administration, 
followed by a steady decrease to basal levels. Astonishingly, unlike the weight loss and disease 
activity indexes, LCN-2 levels remained significantly elevated through day 30, reaching 3 fold 
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induction compared to their untreated counterparts. This novel characterization of the DSS-
induced colitis model suggests that although animals visibly seem to return to a basal level of 
health, as if inflammation had never been induced, these animals are far from completely 
recovered. LCN-2 levels confirm our other findings, which collectively determine that DSS-
treated mice continue to undergo inflammatory processes long after they return to healthy body 
weight and disease activity index. This data is consistent with the previously described notion that 
the inflammatory response has three functions: 1) removal of pathogen, 2) removal of 
damaged/alien tissue cells, and 3) initiation of the tissue repair process. Often in inflammation 
research, the third function of the inflammatory response is ignored, but we can see from our 
study, that tissue repair is a persistent, long-lived function of the inflammatory response that 
deserves as much, if not more attention from researchers, as tissue repair induces significant 
changes within the immune system, and these changes can be mimicked, or co-opted by tumor 
cells to support their own functions. 
4.2 LCN-2 Participates in Coordinating Resolution of Inflammation 
LCN-2, secreted first by inflammatory PMN, and second by epithelial tissue cells and 
MΦ, has previously been demonstrated as a modulator of the inflammatory response, capable of 
reducing generation of inflammatory mediators through conversion of MΦ to the M2-like 
phenotype [84]. A study conducted by Warszawska et al. found that LCN2-/- macrophages 
produced significantly more proinflammatory mediators including IL-8, IL-6, and TNF-α than 
unaltered MΦ, in response to activation with S. pneumoniae.  Furthermore, it was discovered that 
these MΦ also produced significantly more IL-10 that WT MΦ. In this study, researchers were 
able to reduce proinflammatory mediator secretion and rescue IL-10 secretion in activated LCN2 
knockout MΦ by supplementing media with recombinant LCN-2 [84]. 
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As previously reported by others, our study found that LCN-2 is induced during infection 
and during periods of persistent inflammation. Additionally, in vitro analyses of the role of LCN-
2 during inflammation have confirmed an immunomodulatory role for this protein; however, an 
exact mechanism for LCN-2 immunomodulatory regulation has yet to be described. In the 
previously described study, it was found that LCN-2 potently inhibits bacterial clearance by 
alveolar MΦ through an IL-10-dependent mechanism. When discussed in the context of this 
study, our data appears to confirm a role for LCN-2 in transforming the insulted 
microenvironment toward a more suppressive state, perhaps through the conversion of 
inflammatory M1 MΦ toward an M2-like polarization. This immunomodulatory function of 
LCN-2 may help to establish a protective response during times of extreme inflammation to limit 
tissue damage acquired by the constant influx of inflammatory leukocytes. Our study also 
confirms that LCN-2 and augmented production of smooth muscle actin (SMA) occur 
concurrently within the insulted colon tissue, establishing that the second wave of LCN-2 
production by epithelial cells is tightly associated with the onset of tissue repair. This data, taken 
with the known immunomodulatory function of LCN-2 previously established by Warsawska et 
al. suggests that LCN-2 likely plays a role in orchestrating the transition from active inflammation 
to inflammation resolution and tissue repair. 
Our study recapitulates the previously reported immunomodulatory function of LCN-2 
and illustrates the tight association between LCN-2 production and onset of the tissue repair 
process during colitis, confirming in vivo that LCN-2 likely aides the establishment of 
immunosuppression during tissue repair. 
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4.3 MDSC Arise as a Result of Persistent Colitis 
Our study identified significant expansion of the BM IMC population during colitis. 
Expansion of these cells began early on in the inflammatory process (9d) and continued to expand 
even after removal of the inflammatory stimulus (DSS). The immature, low density myeloid cell 
population reached a maximum level of expansion at day 15, which was followed by a sudden, 
dramatic decrease of these cells at day 18. We believe that this sudden decrease was due to the 
acquisition of migratory function in the IMC, leading to egress from the bone marrow, and 
entrance into circulation. Using this model of post-acute DSS-induced colitis, we were able to 
show that colitis stimulates the generation of expanded IMC in the bone marrow. These data 
illustrate that hematopoiesis is dynamically regulated by inflammatory processes occurring in 
distant tissues. Previous data from another study by our lab illustrated a similar phenomenon, 
whereby many models of persistent inflammation, including STZ-induced diabetes, LPS-induces 
bronchitis, and DSS-induced colitis resulted in functional changes in bone marrow-derived PMN 
[121]. Furthermore, many studies have collectively suggested cytokine-driven emergency 
hematopoiesis is a powerful method of dynamically changing the types of effector immune cells 
produced in the bone marrow to suit the needs of the host during conditions of chronic infection. 
These findings led us to hypothesize that soluble factors (cytokines and growth factors) secreted 
at the site of colitis, travel through circulation to induce changes to hematopoiesis in the distant 
bone marrow, and that these changes either potentiate or diminish the inflammatory capabilities 
of bone marrow-derived immune cells to suit the need of the host.  
Our study found that indeed, additional changes occur within the bone marrow myeloid 
compartment as a result of persistent colitis inflammation. We determined that in addition to 
potentiating PMN inflammatory activity during inflammation, IMC expand and acquire at least 
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two additional functions: migratory capability and T cell suppression. The acquisition of these 
two additional functions in the heterogeneous population of IMC were consistent with previous 
reports describing MDSC. Furthermore, our study establishes a role for MDSC in the 
coordination of the resolution of persistent inflammation. As in our previous study, we 
determined that IL-17, the major cytokine upregulated during the post-acute stage of colitis 
corresponded with the expansion and acquisition of new functions in development of MDSC. 
4.3.1  IL-17 Drives MDSC Expansion 
By treating mice with a chemical inducer of colitis (DSS) to the post-acute phase of 
inflammation, we were able to demonstrate significant, systemic upregulation of the cytokine IL-
17. Consistent with our earlier studies and others, we identified IL-17 as the most prominently 
enhanced serum cytokine during colitis. Furthermore, we found that enhanced IL-17 serum 
expression was associated with the expansion of IMC in the bone marrow. This finding was not 
surprising, as other have reported that IL-17 plays a significant role in hematopoiesis, and is a 
well-characterized hallmark of chronic inflammation in many autoimmune maladies [122, 123]. 
Additionally, pilot studies in our lab confirmed the expansion of IMC by direct i.v. injection of 
IL-17 (data not shown). This experiment confirmed that IL-17 dramatically increases production 
of myeloid-derived cells within 24 hours of injection. In a previous study by our lab, we reported 
that IL-17 produced as a result of post-acute inflammation induced functional changes in mature 
PMN, potentiating their inflammatory functions. Specifically, we showed that IL-17 enhanced 
respiratory burst and phagocytosis capacity, and accelerated PMN migratory capabilities [121]. 
Because many studies have defined roles for IL-17 in hematopoiesis and myeloid cell functional 
alteration, it is not surprising that our study suggests a role for IL-17 in MDSC generation during 
colitis inflammation. 
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Previous studies seeking to determine a mechanism for IL-17-driven enhanced 
hematopoiesis discovered that IL-17 is only able to increase hematopoiesis in the presence of 
bone marrow fibroblasts [124], but not in the absence of these cells. This finding suggests that IL-
17 alters hematopoiesis through an indirect mechanism, whereby IL-17 acts on the fibroblast 
intermediaries, which in turn, secrete additional cytokines and growth factors that promote 
hematopoiesis. Because IL-17 has been demonstrated to enhance myelopoiesis, and has been 
shown to alter the function of PMN at the post-acute/chronic stage of inflammation, and because 
IL-17 expression directly correlates with the acquisition of immunosuppressive capabilities by 
IMC, we believe IL-17 is also responsible for driving the generation of MDSC during the post-
acute phase of colitis. In a previous study by Lechner et al., and confirmed by our lab, in vitro 
generation of MDSC was achieved by adding IL-6 and GM-CSF to an in vitro culture of whole 
bone marrow [95]. In our current study, we did not observe any significant increase of either IL-6 
or GM-CSF in the serum of colitis mice; however we did observe extreme enhanced systemic IL-
17 levels. Because IL-17 induces increased myelopoiesis through fibroblast intermediaries, and 
IL-17 has been shown to induce expression of both IL-6 and GM-CSF, we believe IL-17 drives 
MDSC generation by stimulating bone marrow fibroblasts and bone marrow macrophages to 
produce IL-6 and GM-CSF locally within the bone marrow milieu. 
Although incompletely understood, STAT3 is the major characteristic transcription factor 
associated with MDSC. STAT3 activation promotes the transcriptional induction of many of the 
genes that confer suppressive capabilities specifically within the M-MDSC population, including 
arg1, inos, and cxcr2. IL-6 is a powerful inducer of STAT3, therefore it is no surprise that IL-6 
has been defined as a factor that induces the generation of MDSC; however, GM-CSF is an 
activator of STAT5, a potent suppressor of STAT3 activity. The finding that GM-CSF is 
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necessary to promote in vitro generation of MDSC is somewhat unexpected. In fact, Cohen et al 
demonstrated that absence of GM-CSF is necessary to elicit STAT3-dependent myeloid 
differentiation [104]. It remains unclear exactly how these two factors drive transcriptional 
alteration during MDSC generation, however it appears that activation of the STAT3 
transcriptional program is indispensible for the activation of suppressive genes that define the 
suppressive MDSC phenotype. 
4.4 MDSC Accumulate in the Spleen to Inhibit T Cell Proliferation 
Our data illustrated that immature myeloid cells expanded in the bone marrow until day 
15, after which this population of cells sharply decreased. We hypothesized that this drastic 
reduction in bone marrow IMC was the result of two possible mechanisms: the first, was through 
the dramatic decrease in production of IMC, and the second was through the acquisition of 
migratory function. If the drastic reduction in bone marrow IMC was due to decreased 
production, we would expect the kinetics of this depletion to more gradual than sudden. 
Additionally, if loss of IMC was due to promotion of maturation of monocytes and granulocytes, 
we would expect the mature monocyte/granulocyte population to increase accordingly; however, 
we do not see this phenomenon. Instead, we postulated that the sudden, sharp decrease in bone 
marrow IMC was due to the acquisition of migratory capability in the IMC. As the IMC become 
recruited into circulation by inflammatory signals produced within the inflamed colon, IMC at 
day 18 are able to respond to the call from the wound site, and enter the circulation, much like the 
mature inflammatory leukocytes. 
4.4.1 MDSC Develop Migratory Function 
MDSC did not acquire migratory function until the post-acute stage of inflammation. As 
mentioned previously, unlike the pattern of steady mature PMN mobilization from the bone 
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marrow, onset of migratory capability in IMC was observed as a more sudden pattern of acquired 
function. We observed that bone marrow IMC populations expanded as a result of inflammation 
in the colon, and sharply decreased at day 18. Furthermore, we determined that the expanded IMC 
spleen population was likely due to release from the BM. This accumulation of myeloid cells in 
the spleen peaked at days 18-21. Although acquisition of migratory function has been established 
as a defining characteristic of MDSC, most studies investigating the functional capabilities of 
MDSC have been performed in tumor models, and as a result, have determined that MDSC 
develop migratory function for the purpose of migrating into tumor tissue. Our study, for the first 
time, establishes a different migratory location for MDSC, the spleen. By homing to the spleen 
during persistent inflammation, we propose that MDSC are limiting the expansion of activated T 
cells for the purpose of inhibiting the immune response. 
Although it is unclear what mechanisms specifically drive acquisition migratory function, 
using tumor models, other studies have proposed that MDSC increase expression of chemokine 
receptor CXCR2, which enables them to respond to mobilization signals from the site of 
inflammation, or tumor. Specifically, Katoh et al. found that CXCR2 knockout MDSC are unable 
to promote colitis-associated tumorigenesis [125]. To determine if MDSC generated under 
inflammatory conditions exhibited similar mobilization mechanisms, we tested the expression of 
CXCR2 on fraction 3 IMC from bone marrow samples. This data revealed steady upregulation of 
surface expression of CXCR2 peaking at day 18, but not before this time point. This data 
confirms that functional changes are acquired within the bone marrow, before the cell enters 
circulation, and that increased expression of CXCR2 is likely one mechanism explaining 
acquisition of IMC migratory capability, at least in G-MDSC. More studies must be carried out to 
investigate how M-MDSC may enter circulation. 
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Furthermore, it has been shown in previous studies that CXCR2 is subject to expression 
under STAT3 regulation [126], a pathway that has been shown to be dominantly activated during 
the generation of MDSC in tumor models [101]. This pathway is inducible by many factors 
produced during persistent inflammation, including IL-6 and G-CSF, two cytokines upregulated 
by bone marrow macrophages in the presence of IL-17 [124]. This information, along with the 
discovery that IL-17 drives the expansion of IMC during persistent colitis raises the obvious 
question: does IL-17 drive both the expansion and functional alteration of IMC to MDSC, 
specifically promoting the acquisition of migratory function? Although our study does not 
specifically answer this question, IL-17 appears to play a key role in regulating at least the 
expansion of IMC, and therefore further examination of this hypothesis certainly has merit. 
4.4.2  MDSC Inhibit T Cell Function in the Spleen 
One consequence of the acquisition of migratory capability in MDSC was the observed 
accumulation of MDSC in the spleens of mice at the post-acute phase of inflammation. Therefore, 
we examined if accumulation of MDSC in the T cell-rich spleen environment contributed to the 
loss of T splenocytes in vivo. Indeed, our study confirmed that myeloid cells that accumulated in 
the spleens of mice during the post-acute phase of colitis corresponded with the depletion of both 
CD4+ and CD8+ T splenocyte populations. Although a trend diplaying an inverse relationship 
between myeloid and T splenocyte populations was established, the decline of T splenocytes 
slightly predated the expansion of myeloid splenocytes. We believe this may be due to parallel 
inhibitory functional acquisition by the extramedullary myeloid cells within the spleen, and that 
this function change occurs in a similar fashion to the functional changes in the myeloid 
population of the BM. Because both maximum myeloid cells accumulation and T splenocyte 
depletion peak at days 18-21, we believe the total myeloid cell population exerts maximum 
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inhibitory function over T splenocytes at these time points. These time points are also consistent 
with the BM IMC exhibiting very inhibitory profiles. From these data, we proposed that 
collection of MDSC in the spleens of colitis mice suppressed the proliferation of activated T 
splenocytes, and that this inhibition of T cell response directly contributed to the resolution of 
inflammation in the colon. We therefore, assessed the suppressive functions of bone marrow-
derived IMC at all time points during colitis in vitro to ensure that the MDSC were directly 
responsible for depleting T splenocyte populations. 
4.4.3 MDSC From Inflammation Resolution Phase Potently Inhibit T Cell Proliferation  
To further ensure that MDSC directly developed T cell inhibitory properties as a result of 
persistent inflammation, we assessed IMC isolated from the bone marrow of colitis mice and 
subjected them to co-culture with activated healthy T splenocytes. As seen from our data, IMC 
developed T cell inhibitory properties as early as 3d, and the effectiveness of acquired inhibitory 
function steadily increased through the entire inflammatory DSS treatment, peaking at the early 
phase of inflammation resolution. Perhaps, most striking was the complete T cell proliferation 
suppression in the artificial-activation system mediated entirely by MDSC isolation from 
inflammation recovery time points (12d-21d). This suppression was seen for both CD4+ and CD8+ 
T cells, and mirrors the in vivo data, demonstrating most significant T cell suppression during the 
same time points. These data confirms that T splenocyte populations are indeed being reduced as 
a direct function of MDSC accumulation in vivo, and that MDSC are most potent inhibitors of T 
cell function during the tissue repair process. Taken together, these data supports the 
immunomodulatory role for MDSC at the adaptive immune effector cell level. 
T cell inhibitory function within the spleen can be seen from our in vivo FACS data, which 
shows as MDSC collect in the spleen, T splenocyte populations dramatically decrease. 
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Interestingly, MDSC formation begins very early during the inflammatory response, before the 
insult moves to the post-acute phase of colitis; however, these suppressive MDSC are unable to 
mobilize into the circulation. Thus, the immunosuppressive capabilities of MDSC are reserved for 
times of truly persistent, unresolving inflammation. This system allows the immune system to 
develop a suppressive subtype of myeloid cells, which are only able to exert their suppressive 
function during times of persistent inflammatory activation, but not during acute, resolving 
inflammatory conditions. If inflammatory signals subside quickly, MDSC are not able to migrate 
out into circulation, and thus are unable to inhibit the immune response; however, if inflammatory 
signals persist to a point where potently suppressive myeloid cells are required to modulate 
immune function for the protection of the host, then suppressive myeloid cells gain the ability to 
enter circulation and carry out suppression of the immune response. 
4.5 MDSC Function as Inhibitors of the Inflammatory Response During Chronic 
Inflammation 
In the past, MDSC have been discussed primarily as a harmful, immunosuppressive 
subtype of cells responsible for enabling tumor immune escape. As seen from our study, we 
determined a suppressive, non-pathogenic role for MDSC during colitis. As described in our 
study, we determined that MDSC first acquire T cell suppressive functions that peak at the post-
acute stage of colitis inflammation, and that these cells remain sequestered away from T cells in 
the bone marrow until inflammation persists to the post-acute phase. Our study, in conjunction 
with other studies, demonstrated that soluble factors produced at the site of inflammation drive 
these functional changes within the bone marrow. Additionally, previous studies by our lab have 
described a role for IL-17 in the potentiation of PMN function. In this study, we propose IL-17 
also functions to induce the generation of an immunosuppressive subtype of IMC which function 
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to coordinate resolution of persistent colitis inflammation by inhibiting the expansion of activated 
T cells. Our model describes a non-pathogenic evolutionary function of MDSC for the control of 
hyperactivation of the inflammatory response.  
Since their discovery in tumor-bearing hosts, MDSC have primarily been studied in the 
context of cancer models that predominantly examine the specific methods MDSC use to induce 
immunosuppression, but these studies tend to neglect the naturally-evolved, non-pathogenic role 
of MDSC; however, expanded MDSC populations have also been reported as essential for the 
control of immune clearance of foreign tissue during allograft transplantation and pregnancy. 
During allograft transplantation, MDSC colonize the transplanted tissue and induce tolerance of 
the allograft, leading to decreased risk of rejection by the immune system of the recipient [127]. 
Similarly, during pregnancy, MDSC protect the “non-self” fetal tissue from clearance by the type 
I immune response by inducing tolerance, and helping to generate regulatory T cells [101]. Using 
the limited information regarding the non-pathogenic functions of MDSC during necessary 
immune suppression, we proposed that MDSC develop suppressive capabilities as a result of 
prolonged inflammation as a protective immune inhibitory feedback mechanism. As in 
pregnancy, MDSC-mediated non-pathogenic inhibition of the immune response is meant to 
protect the inflamed tissue from additional damage brought on by continuous activation of the 
inflammatory response. As mentioned in the introduction, recruitment of mature inflammatory 
effector leukocytes to the site of inflammation results in secretion of many toxic, cell-damaging 
factors. The infiltration of PMN during inflammation secretes these cytotoxic factors in an effort 
to eliminate pathogen from sites of non-sterile injury, however these functions are non-specific to 
pathogen and result in the accumulation of damaged cells within the tissue. During progression to 
the post-acute phase of colitis, the accumulation of epithelial cell damage results in loss of gut 
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barrier function, which induces more inflammation that is unable to resolve in the tissue. In this 
system, inhibition of the type I immune response to pathogen is essential for the resolution of 
inflammation. Generation of anti-inflammatory, immunosuppressive myeloid cells function to 
inhibit the inflammatory response to stop the recruitment of tissue-damaging leukocytes, and to 
promote the transition toward inflammation resolution and tissue repair 
4.6 Generation of MDSC Promotes Survival of Tumor Cells 
Since their initial discovery, MDSC have been shown to enhance tumor cell survival, even 
functioning as a clinical marker of cancer severity. Many studies have been performed to 
elucidate the intricate mechanisms MDSC use to promote tumor survival. As previously discussed 
many of these mechanisms inhibit T cell immune functions, limiting the ability for T cells to 
identify and eliminate transformed, pre-tumor cells. Furthermore, these studies have also 
uncovered the ability for tumors to directly induce MDSC generation through the secretion of 
cytokines. Our study confirms that the process of altering hematopoiesis through production of 
secretion of cytokines is a mechanism evolved by the host to combat the overstimulation of the 
immune response. Under tumor conditions, this protective mechanism for inhibiting excessive 
tissue damage due to an advanced inflammatory process is co-opted to support the tumor. Indeed, 
many tumors have demonstrated the ability to either directly increase secretion of cytokines, or to 
stimulate surrounding fibroblast tissue to perform this function. As a result, hematopoiesis is 
altered in such a way that mimics the response to advanced inflammation. Bone marrow cells 
respond to cytokine signals produced by the tumor to develop expanded, suppressive MDSC, 
which are recruited to the tumor. Once in the tumor tissue, MDCS create a “shield” around the 
tumor cells, which limits the surveillance of tumor cells by T cells. By inactivating and/or 
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suppressing any approaching T cells, MDSC circumvent many immunotherapeutic approaches to 
 
Figure 4-1 MDSC arise during chronic inflammation through increased production of IL-
17.  
Model of in vivo MDSC generation during DSS-induced colitis and recovery. Post-acute colitis results in the upregulation of IL-17 
from Th17 cells and other subsets of immune cells. High levels of IL-17 enter circulation, where it acts on BM MΦ, inducing the 
localized increased expression of IL-6 and GM-CSF. These cytokines induce changes to the transcriptional programming during 
emergency hematopoiesis leading to generation and expansion of suppressive MDSC. MDSC develop increased CXCR2 
expression, which reaches a critical threshold at day 18, resulting in release of MDSC into circulation. After entry into circulation, 
MDSC collect in the T cell-rich environment of the spleen, and presumably at the site of inflammation, where they function to 
suppress T cell activation and proliferation, thereby limiting the immune response in favor of tissue repair. Generated using Blood 
and Immunology” and “Tissues” licensed under CC BY 3.0. 
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cancer treatment, which focus on bolstering the effectiveness of tumor recognition and clearance 
by immune cells.  
Once in the tumor tissue, MDSC continue to drive the conversion of the 
microenvironment toward an immunosuppressive phenotype, driving polarization of local 
immune cells toward suppressive phenotypes, and limiting activation of T cells by inhibiting DC 
maturation. Although these functions likely occur during MDSC-mediated transition of 
inflammation toward tissue repair, our data did not investigate the suppressive functions of 
MDSC on any other immune cells except T cells. In addition to shielding the tumor from 
detection by the immune system, MDSC also directly promote tumor growth by stimulating 
secretion of growth and angiogenic factors. We believe, that MDSC that arise from chronic 
inflammatory conditions promote transition from active inflammation to tissue repair and 
resolution through a similar mechanism, whereby MDSC inhibit proinflammatory functions of the 
immune system in favor of tissue repair functions, including reepithelialization and establishment 
of new blood vessels. MDSC are generated by both chronic inflammation and cancer conditions, 
and our study demonstrates that MDSC arise during the post-acute phase of inflammation to 
restrain the immune system from causing further damage to the inflamed tissue. Therefore, it is 
easy to imagine that MDSC arise during periods of persistent, damaging inflammation, and that 
inhibition of T cell immune surveillance by MDSC protects any transformed, neoplastic tissue 
cells from clearance. We believe that this is a possible mechanism of action responsible for the 
observed tight correlation between chronic inflammation and cancer. 
4.7 Targeting MDSC to Control the Immune Response 
MDSC have major significance as a therapeutic target for treatment of both autoimmune 
disease and cancer. As discussed previously, MDSC have been demonstrated as indispensible 
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cells for inducing necessary immune suppression during pregnancy, and high numbers of MDSC 
have been shown to correlate with the successful tolerance of transplanted allograft tissue. 
Furthermore, our study and others illustrate that MDSC, arising during both chronic inflammation 
and cancer, coordinate immunosuppression. This ability appears to contribute to promotion of 
inflammatory resolution during persistent inflammation, and drives immune escape of tumor cells 
during cancer. For these reasons, control of MDSC generation and function present unique 
therapeutic opportunities for the treatment of both autoimmune disorders and cancer treatment. 
By developing therapies that target augmentation of generation of MDSC, scientists can 
hope to alleviate autoimmune-acquired tissue damage due to overstimulation of the inflammatory 
response. Rheumatoid arthritis and IBD are two specific disorders that may be improved by 
selective augmentation of MDSC generation. 
Although future therapies that target augmentation of MDSC generation could potentially 
work to assuage autoimmune disease symptoms, these therapies must be applied carefully, as 
uncontrolled generation of MDSC has the potential to induce neoplastic cell immune escape. In 
this case, limitation of MDSC generation would benefit the host. 
 
4.8 Current Perspective for MDSC: The Role of Immunotherapeutics in Treatment of 
Autoimmune Diseases and Cancer 
Currently, many obstacles exist in the treatment strategies of many autoimmune diseases 
and cancer. These two types of human clinical ailments represent two sides of the same coin, that 
is overactivation of the immune response leads to conditions of autoimmunity, whereas 
overinhibition of the same immune effector functions result in failure to clear neoplastic cells. In 
an effort to correct dysfunction of the immune response, often treatment of one ailment results in 
  139 
pressure on the immune system to swing too far the other direction. For this reason, it is essential 
that further studies be conducted with the purpose of understanding the intricate mechanisms that 
govern each specific immune dysregulation, so that more targeted therapies can be produced, with 
less risk further compromising the immune responses. 
One example of this can be seen in the current treatment strategies of autoimmune 
inflammatory disorders RA, psoriasis, and IBD. Currently, two major categories of inhibitory 
antibody therapies have been developed: anti-TNFα and anti-IL-17. While anti-TNFα strategies 
have been a very successful treatment strategy across all of these disorders, anti-IL-17 has only 
been successful in RA and psoriasis, but not in IBD. In fact, neutralization of IL-17 has been 
shown to worsen clinical symptoms of IBD; however no studies have determined why IL-17 
promotes inflammation in RA and psoriasis, but is necessary for stabilizing the system in IBD. 
Through our study, we revealed that IL-17 may play a central role in establishing a feedback 
mechanism that inhibits continuation of the inflammatory response in the bowel through 
promoting MDSC generation, however more studies must be conducted to confirm our theory. If 
IL-17 does coordinate acquisition of inhibitory immune function as our study suggests, then this 
information would certainly why treatment of IBD patients with anti-IL-17 worsens the clinical 
presentation.  
Treatment with biologic neutralization antibodies, while very promising treatments for 
limiting the detrimental effects of the immune response, also drastically increase the patients’ risk 
for developing cancers and increasing susceptibility to infections. Such broad inhibition of major 
pro-inflammatory cytokines has powerful ramifications, which for limited treatment may be 
necessary, but must be used with caution as overuse of these biologics severely limit many 
aspects of the immune response. 
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On a cautiously optimistic note, it seems that overcoming MDSC-mediated immune cell 
inhibition in conjunction with treatments that boost T cell function is a promising avenue for 
clinical application in the removal of cancer cells for those tumors that are unable to be removed 
surgically. Furthermore, as more information about MDSC generation is gathered, it may become 
possible to manage when MDSC are produced. One such example of this type of treatment 
strategy is for treatment of cancer. Following surgical or radiological removal of cancer cells, the 
risk for developing a more aggressive relapsing cancer is always a concern for clinicians. Because 
MDSC likely coordinate the growth of new tumor cells, immediate treatment with MDSC 
inhibitors may significantly reduce the risk for relapse, thereby improving survival in these 
patients.  
In conclusion, the more information that is gained from studies on MDSC generation 
during many different conditions will contribute significantly to new therapeutic approaches for 
treatment of many diseases of the immune system. Targeting these very special cells either for the 
promotion of immune inhibition, or for limitation of immune inhibition may hold the key for 
tailoring immune function, although we must do so cautiously.  
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